WO2024057190A2 - Targeted compositions - Google Patents
Targeted compositions Download PDFInfo
- Publication number
- WO2024057190A2 WO2024057190A2 PCT/IB2023/059008 IB2023059008W WO2024057190A2 WO 2024057190 A2 WO2024057190 A2 WO 2024057190A2 IB 2023059008 W IB2023059008 W IB 2023059008W WO 2024057190 A2 WO2024057190 A2 WO 2024057190A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- group
- salt
- independently
- alkyl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 15
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract description 36
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 31
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims abstract description 29
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims abstract description 26
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims abstract description 24
- 238000011282 treatment Methods 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims abstract description 12
- 206010023421 Kidney fibrosis Diseases 0.000 claims abstract description 9
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims abstract description 8
- 208000006265 Renal cell carcinoma Diseases 0.000 claims abstract description 8
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims abstract description 8
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 162
- 238000000034 method Methods 0.000 claims description 137
- 239000003446 ligand Substances 0.000 claims description 121
- 210000004027 cell Anatomy 0.000 claims description 107
- 150000003839 salts Chemical class 0.000 claims description 107
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 101
- 108020004459 Small interfering RNA Proteins 0.000 claims description 100
- -1 3- formylphenyl Chemical group 0.000 claims description 84
- 229920000642 polymer Polymers 0.000 claims description 84
- 230000008569 process Effects 0.000 claims description 84
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 73
- 239000000178 monomer Substances 0.000 claims description 69
- 229920001184 polypeptide Polymers 0.000 claims description 66
- 125000005647 linker group Chemical group 0.000 claims description 60
- 108091034117 Oligonucleotide Proteins 0.000 claims description 51
- 125000000217 alkyl group Chemical group 0.000 claims description 49
- 125000004432 carbon atom Chemical group C* 0.000 claims description 46
- 125000000623 heterocyclic group Chemical group 0.000 claims description 44
- 210000004024 hepatic stellate cell Anatomy 0.000 claims description 41
- 125000001072 heteroaryl group Chemical group 0.000 claims description 39
- 230000008685 targeting Effects 0.000 claims description 34
- 108091008606 PDGF receptors Proteins 0.000 claims description 32
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims description 32
- 125000004122 cyclic group Chemical group 0.000 claims description 31
- 229920006395 saturated elastomer Polymers 0.000 claims description 30
- 125000001424 substituent group Chemical group 0.000 claims description 25
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 24
- 241001465754 Metazoa Species 0.000 claims description 24
- 150000003254 radicals Chemical class 0.000 claims description 24
- 125000005843 halogen group Chemical group 0.000 claims description 23
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 21
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 125000004043 oxo group Chemical group O=* 0.000 claims description 19
- 125000006239 protecting group Chemical group 0.000 claims description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 17
- 125000000524 functional group Chemical group 0.000 claims description 17
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 16
- 125000001153 fluoro group Chemical group F* 0.000 claims description 16
- 229920001223 polyethylene glycol Polymers 0.000 claims description 16
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 15
- 239000012986 chain transfer agent Substances 0.000 claims description 15
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 11
- 125000002252 acyl group Chemical group 0.000 claims description 11
- SOGAXMICEFXMKE-UHFFFAOYSA-N alpha-Methyl-n-butyl acrylate Natural products CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 claims description 11
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 102000001189 Cyclic Peptides Human genes 0.000 claims description 10
- 108010069514 Cyclic Peptides Proteins 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims description 9
- 125000004423 acyloxy group Chemical group 0.000 claims description 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 9
- 238000002372 labelling Methods 0.000 claims description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- ZHNSYNYLKYUVAH-GTPODGLVSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-methylprop-2-enoate Chemical compound C1C=C2C[C@@H](OC(=O)C(C)=C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 ZHNSYNYLKYUVAH-GTPODGLVSA-N 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- HEBDGRTWECSNNT-UHFFFAOYSA-N 2-methylidenepentanoic acid Chemical group CCCC(=C)C(O)=O HEBDGRTWECSNNT-UHFFFAOYSA-N 0.000 claims description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 5
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims description 4
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 claims description 4
- 101710164680 Platelet-derived growth factor receptor beta Proteins 0.000 claims description 4
- 125000003172 aldehyde group Chemical group 0.000 claims description 4
- 125000002355 alkine group Chemical group 0.000 claims description 4
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 4
- 210000002950 fibroblast Anatomy 0.000 claims description 4
- 125000000468 ketone group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 125000001425 triazolyl group Chemical group 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000002889 endothelial cell Anatomy 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 5
- 125000003544 oxime group Chemical group 0.000 claims 3
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 abstract description 5
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 abstract 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 125
- 239000004055 small Interfering RNA Substances 0.000 description 93
- 229940104302 cytosine Drugs 0.000 description 56
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 53
- 229930024421 Adenine Natural products 0.000 description 47
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 47
- 229960000643 adenine Drugs 0.000 description 47
- 230000015572 biosynthetic process Effects 0.000 description 44
- 238000003786 synthesis reaction Methods 0.000 description 42
- 108090000623 proteins and genes Proteins 0.000 description 41
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 33
- 230000014509 gene expression Effects 0.000 description 29
- 125000004429 atom Chemical group 0.000 description 28
- 239000000872 buffer Substances 0.000 description 25
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 24
- 239000000047 product Substances 0.000 description 21
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 20
- 125000000539 amino acid group Chemical group 0.000 description 20
- 238000003556 assay Methods 0.000 description 20
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- 230000030279 gene silencing Effects 0.000 description 18
- 150000002430 hydrocarbons Chemical group 0.000 description 18
- 230000027455 binding Effects 0.000 description 17
- 229920001400 block copolymer Polymers 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 210000001163 endosome Anatomy 0.000 description 16
- 238000012226 gene silencing method Methods 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 108010090804 Streptavidin Proteins 0.000 description 15
- 230000021615 conjugation Effects 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 15
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 13
- 230000009368 gene silencing by RNA Effects 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 230000000670 limiting effect Effects 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 150000002923 oximes Chemical group 0.000 description 13
- 238000006116 polymerization reaction Methods 0.000 description 13
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 10
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 10
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 10
- 230000003213 activating effect Effects 0.000 description 10
- 229960002685 biotin Drugs 0.000 description 10
- 235000020958 biotin Nutrition 0.000 description 10
- 239000011616 biotin Substances 0.000 description 10
- 238000003818 flash chromatography Methods 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 238000010168 coupling process Methods 0.000 description 9
- 231100000673 dose–response relationship Toxicity 0.000 description 9
- 238000000684 flow cytometry Methods 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 229920005604 random copolymer Polymers 0.000 description 9
- 238000012712 reversible addition−fragmentation chain-transfer polymerization Methods 0.000 description 9
- 101150018337 Serpinh1 gene Proteins 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 7
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 125000006413 ring segment Chemical group 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 238000000265 homogenisation Methods 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 5
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 5
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 108091081021 Sense strand Proteins 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000004761 fibrosis Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 125000004430 oxygen atom Chemical group O* 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 229940035893 uracil Drugs 0.000 description 5
- VCQURUZYYSOUHP-UHFFFAOYSA-N (2,3,4,5,6-pentafluorophenyl) 2,2,2-trifluoroacetate Chemical compound FC1=C(F)C(F)=C(OC(=O)C(F)(F)F)C(F)=C1F VCQURUZYYSOUHP-UHFFFAOYSA-N 0.000 description 4
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 4
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 4
- 101150112014 Gapdh gene Proteins 0.000 description 4
- 101000611202 Homo sapiens Peptidyl-prolyl cis-trans isomerase B Proteins 0.000 description 4
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 4
- 239000012124 Opti-MEM Substances 0.000 description 4
- 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000005754 cellular signaling Effects 0.000 description 4
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 4
- 229960003677 chloroquine Drugs 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 125000002652 ribonucleotide group Chemical group 0.000 description 4
- 238000007363 ring formation reaction Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 150000003852 triazoles Chemical group 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 108010067770 Endopeptidase K Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 101100013786 Mus musculus Gapdh gene Proteins 0.000 description 3
- 101100533280 Mus musculus Serpinh1 gene Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 108091028664 Ribonucleotide Proteins 0.000 description 3
- KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 150000003935 benzaldehydes Chemical class 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 239000001679 citrus red 2 Substances 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 3
- 229940125900 compound 59 Drugs 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 229920000359 diblock copolymer Polymers 0.000 description 3
- 230000012202 endocytosis Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000037440 gene silencing effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000007758 minimum essential medium Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000002151 riboflavin Substances 0.000 description 3
- 239000002336 ribonucleotide Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- QBXODCKYUZNZCY-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]oxyacetic acid Chemical compound CC(C)(C)OC(=O)NOCC(O)=O QBXODCKYUZNZCY-UHFFFAOYSA-N 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
- AISZNMCRXZWVAT-UHFFFAOYSA-N 2-ethylsulfanylcarbothioylsulfanyl-2-methylpropanenitrile Chemical compound CCSC(=S)SC(C)(C)C#N AISZNMCRXZWVAT-UHFFFAOYSA-N 0.000 description 2
- CKOQSKSHQSFICH-UHFFFAOYSA-N 3-(1,3-dioxolan-2-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C2OCCO2)=C1 CKOQSKSHQSFICH-UHFFFAOYSA-N 0.000 description 2
- VFXXTYGQYWRHJP-UHFFFAOYSA-N 4,4'-azobis(4-cyanopentanoic acid) Chemical compound OC(=O)CCC(C)(C#N)N=NC(C)(CCC(O)=O)C#N VFXXTYGQYWRHJP-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 description 2
- HRZSNESBRSONNG-UHFFFAOYSA-N 4-di(propan-2-yl)phosphanylbutyl-di(propan-2-yl)phosphane Chemical compound CC(C)P(C(C)C)CCCCP(C(C)C)C(C)C HRZSNESBRSONNG-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical compound [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 101000986595 Homo sapiens Ornithine transcarbamylase, mitochondrial Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 208000000599 Ornithine Carbamoyltransferase Deficiency Disease Diseases 0.000 description 2
- 206010052450 Ornithine transcarbamoylase deficiency Diseases 0.000 description 2
- 208000035903 Ornithine transcarbamylase deficiency Diseases 0.000 description 2
- 102100028200 Ornithine transcarbamylase, mitochondrial Human genes 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000012987 RAFT agent Substances 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 108010006523 asialoglycoprotein receptor Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 231100000012 chronic liver injury Toxicity 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000009088 enzymatic function Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- JGJLWPGRMCADHB-UHFFFAOYSA-N hypobromite Chemical compound Br[O-] JGJLWPGRMCADHB-UHFFFAOYSA-N 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 238000010550 living polymerization reaction Methods 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 201000011278 ornithine carbamoyltransferase deficiency Diseases 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- 238000012247 phenotypical assay Methods 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- XOKSLPVRUOBDEW-UHFFFAOYSA-N pinane Chemical compound CC1CCC2C(C)(C)C1C2 XOKSLPVRUOBDEW-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 101150105899 ppiB gene Proteins 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000010526 radical polymerization reaction Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- PSVXZQVXSXSQRO-UHFFFAOYSA-N undecaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO PSVXZQVXSXSQRO-UHFFFAOYSA-N 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- JNYWVERKQKRXSL-PHDIDXHHSA-N (1r,4r)-2-oxa-5-azabicyclo[2.2.2]octane Chemical compound C1C[C@]2([H])CN[C@@]1([H])CO2 JNYWVERKQKRXSL-PHDIDXHHSA-N 0.000 description 1
- CJQNJRRDTPULTL-KNVOCYPGSA-N (1r,5s)-3-azabicyclo[3.2.1]octane Chemical compound C1[C@@]2([H])CC[C@]1([H])CNC2 CJQNJRRDTPULTL-KNVOCYPGSA-N 0.000 description 1
- JKHVDAUOODACDU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCN1C(=O)C=CC1=O JKHVDAUOODACDU-UHFFFAOYSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- YGZJTYCCONJJGZ-UHFFFAOYSA-N (3,5-dimethoxyphenyl)methanamine Chemical compound COC1=CC(CN)=CC(OC)=C1 YGZJTYCCONJJGZ-UHFFFAOYSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- 125000006651 (C3-C20) cycloalkyl group Chemical group 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- QRZUPJILJVGUFF-UHFFFAOYSA-N 2,8-dibenzylcyclooctan-1-one Chemical compound C1CCCCC(CC=2C=CC=CC=2)C(=O)C1CC1=CC=CC=C1 QRZUPJILJVGUFF-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- QPEJAHMNOVMSOZ-UHFFFAOYSA-N 2-azaspiro[3.3]heptane Chemical compound C1CCC21CNC2 QPEJAHMNOVMSOZ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 239000004229 Alkannin Substances 0.000 description 1
- DJHGAFSJWGLOIV-UHFFFAOYSA-K Arsenate3- Chemical compound [O-][As]([O-])([O-])=O DJHGAFSJWGLOIV-UHFFFAOYSA-K 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000012988 Dithioester Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004230 Fast Yellow AB Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 229910002567 K2S2O8 Inorganic materials 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 102100020870 La-related protein 6 Human genes 0.000 description 1
- 108050008265 La-related protein 6 Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 101100490446 Penicillium chrysogenum PCBAB gene Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- IOEJYZSZYUROLN-UHFFFAOYSA-M Sodium diethyldithiocarbamate Chemical compound [Na+].CCN(CC)C([S-])=S IOEJYZSZYUROLN-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 101150057615 Syn gene Proteins 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 1
- 239000004234 Yellow 2G Substances 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 229940000489 arsenate Drugs 0.000 description 1
- AQLMHYSWFMLWBS-UHFFFAOYSA-N arsenite(1-) Chemical compound O[As](O)[O-] AQLMHYSWFMLWBS-UHFFFAOYSA-N 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 239000004176 azorubin Substances 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- JXWABCYGGVHAHB-UHFFFAOYSA-N benzyl n-(3-aminopropyl)carbamate Chemical compound NCCCNC(=O)OCC1=CC=CC=C1 JXWABCYGGVHAHB-UHFFFAOYSA-N 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Chemical group 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000004106 carminic acid Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910001919 chlorite Inorganic materials 0.000 description 1
- 229910052619 chlorite group Inorganic materials 0.000 description 1
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000010968 computed tomography angiography Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 108010048032 cyclophilin B Proteins 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 108010004073 cysteinylcysteine Proteins 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- SOCTUWSJJQCPFX-UHFFFAOYSA-N dichromate(2-) Chemical compound [O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O SOCTUWSJJQCPFX-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012990 dithiocarbamate Substances 0.000 description 1
- 150000004659 dithiocarbamates Chemical class 0.000 description 1
- 125000005022 dithioester group Chemical group 0.000 description 1
- 229950004394 ditiocarb Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000001094 effect on targets Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical class N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N itaconic acid Chemical compound OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000004767 nitrides Chemical class 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N phthalic anhydride Chemical compound C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 229930006728 pinane Natural products 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 125000006684 polyhaloalkyl group Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 235000019394 potassium persulphate Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 239000004172 quinoline yellow Substances 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000004173 sunset yellow FCF Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000004149 tartrazine Substances 0.000 description 1
- QEQPZKCBLSKCJH-UHFFFAOYSA-N tert-butyl 3-[2-[2-(2-methylsulfonyloxyethoxy)ethoxy]ethoxy]propanoate Chemical compound CC(C)(C)OC(=O)CCOCCOCCOCCOS(C)(=O)=O QEQPZKCBLSKCJH-UHFFFAOYSA-N 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- UIERETOOQGIECD-ONEGZZNKSA-N tiglic acid Chemical compound C\C=C(/C)C(O)=O UIERETOOQGIECD-ONEGZZNKSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 239000012989 trithiocarbonate Substances 0.000 description 1
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical compound C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 description 1
- 229930004006 tropane Natural products 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000012991 xanthate Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2/00—Processes of polymerisation
- C08F2/38—Polymerisation using regulators, e.g. chain terminating agents, e.g. telomerisation
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
- C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2438/00—Living radical polymerisation
- C08F2438/03—Use of a di- or tri-thiocarbonylthio compound, e.g. di- or tri-thioester, di- or tri-thiocarbamate, or a xanthate as chain transfer agent, e.g . Reversible Addition Fragmentation chain Transfer [RAFT] or Macromolecular Design via Interchange of Xanthates [MADIX]
Definitions
- HSCs hepatic stellate cells
- Targeted delivery of therapeutic agents to HSCs may be important for the successful treatment of diseases of the liver and/or diseases of the kidney (e.g., liver fibrosis, non-alcoholic steatohepatitis (NASH), kidney fibrosis, or alcoholic steatohepatitis (ASH)). Accordingly, means of delivering therapeutics to HSCs are needed.
- diseases of the liver and/or diseases of the kidney e.g., liver fibrosis, non-alcoholic steatohepatitis (NASH), kidney fibrosis, or alcoholic steatohepatitis (ASH)
- NASH non-alcoholic steatohepatitis
- the invention provides compounds, compositions and methods that can be used to target oligonucleotides to platelet derived growth factor receptor (PDGFR) expressing cells.
- PDGFR platelet derived growth factor receptor
- this invention provides a compound of formula (I)
- L is a linking group; y is 1, 2, 3, 4 or 5; and each R 2 is independently an oligonucleotide, a label (e.g., a label derivable from fluorescein isothiocyanate (FITC) or Cy5), a phenyl group that is substituted with a formyl (-CHO) group, or a group of formula:
- the invention provides a process for preparation of a diblock polymer of the following formula (X): [Block A] - [Block B] (X) comprising: a) contacting a compound of structure Va, Vb, Vc, or Vd wherein R 27 is (Ci-Ci2)alkyl, wherein R 28 is (Ci-Ci2)alkyl, wherein R 25 and R 26 are independently H, (Ci-Ci2)alkyl, aryl, or heteroaryl, with one or more A monomers selected from the group consisting of: a polyethyleneglycol methacrylate with 2-20 ethylene glycol units (PEGMA); a (C4-Cis)alkyl-methacrylate; a (C4-Cis)branched alkyl-methacrylate; a cholesteryl methacrylate; a (C4-Cis)alkyl-methacrylate substituted with one or more fluorine atoms; and a (C4-C
- Block A comprises one or more residues of A monomers and has a molecular weight of from about 1 kDa to about 25 kDa;
- Block B comprises one or more residues of monomers Bl, B2, and B3 and has a molecular weight of from about 1 kDa to about 25 kDa.
- Li is a linking moiety
- Z is a functional group that is optionally protected with a protecting group and is capable of reacting with Y of a compound of formula (XII):
- T is a ligand (optionally targeting ligand);
- Y is a functional group that is capable of reacting with Z to form a conjugate; and L2 is absent or is a linking moiety.
- the invention provides a compound of formula (I) (R 1 ) x — L— (R 2 ) y
- each R 1 is independently a targeting ligand, which is selected from a) a cyclic polypeptide depicted by SEQ ID NO: 1 :C*SRNLIDC* (SEQ ID NO: 1), wherein * denotes a disulfide bond linking the two C residues to thereby form the cyclic polypeptide, b) any cyclic polypeptide having at least 80 % sequence identity (e.g., at least 85%; e.g., at least 87.5%; e.g., at least 90%; e.g., at least 95%; e.g., at least 99% sequence identity) with the polypeptide depicted by SEQ ID NO: 1, under the proviso that both C* residues are present, and wherein * denotes a disulfide bond linking the two C residues to thereby form the cyclic polypeptide;
- L is a linking group; and y is 1, 2, 3, 4 or 5; and each R 2 is independently an endosomal release polymer.
- the invention also provides synthetic intermediates and methods disclosed herein that are useful to prepare compounds of the formula I and formula XI.
- Figure 2 Uptake of monovalent or trivalent pPB ligand-biotin-AF488-streptavidin complex by HSC-T6 and NIH3T3 cells as analyzed by flow cytometry.
- Figure 7 In vitro gene silencing by TripPB siRNA conjugates and pPB-ERP in pHHSC.
- Figure 8 In vivo gene silencing by TripPB siRNA conjugates and pPB-ERP in mouse liver fibrosis model.
- Figure 9. Dose response of pPB-ERP when co-treated with TripPB-siRNA conjugate in mouse liver fibrosis model.
- Figure 10 In vivo gene silencing by DipPB and TripPB siRNA conjugates and pPB-ERP in mouse liver fibrosis model.
- an oligonucleotide can be, but is not limited to, a double stranded siRNA molecule.
- GalN Ac-conjugated short interfering RNA’s are a modality for mediating RNA interference (RNAi) in hepatocytes. They comprise two important components; a GalNAc targeting ligand, which binds to the asialoglycoprotein receptor (ASGPr) found on the surface of hepatocytes to mediate uptake, and the siRNA oligonucleotide, that once delivered to the cytoplasm of hepatocytes can mediate destruction of specific mRNA sequences (determined by the sequence of the siRNA) to reduce expression of the associated protein product.
- RNAi RNA interference
- siRNA delivery to hepatocytes has been demonstrated with this class of therapeutics, successful application to other cell types has been more problematic. Suitable receptors must be identified, which are expressed relatively selectively on the target cell surface and in sufficient numbers. Then, appropriate ligands must be identified that bind with high specificity and affinity to the target receptor. A significant third hurdle is endosomal escape; when bound to a receptor, the ligand conjugate is taken up by the cell and entrapped in an endosome, from which it must escape to reach the cytoplasm. Despite lacking an active endosomal escape mechanism, GalNAc conjugates appear to mediate activity regardless, possibly because the receptor is so abundantly expressed and quickly recycled ( ⁇ 15 minutes) following uptake. The sheer number of conjugate molecules taken up by hepatocytes may obviate the need for an active endosomal escape. This has not been true for other ligand-based siRNA conjugate systems.
- Hepatic stellate cells play a key role in the progression of fibrosis: In response to chronic liver damage, they become activated, and are largely responsible for collagen deposition and scarring of the liver.
- RNAi strategies include RNAi strategies.
- siRNA conjugates have been synthesized to target HSC via platelet-derived growth factor receptor (PDGFR) using a cyclic octapeptide motif.
- PDGFR platelet-derived growth factor receptor
- trivalent presentation of a pPB ligand outperforms monovalent presentation for binding and uptake.
- Gene silencing experiments also demonstrated that trivalent ligand structures are particularly effective, e.g., when compared to mono and divalent conjugates.
- the invention also provides pPB conjugates of an endosome release polymer (ERP), the conjugate also being referred to as pPB-ERP.
- ERP endosome release polymer
- ERT endosome release polymer
- diblock polymer are used interchangeably herein.
- the specific ERT as provided by the present invention optionally characterized by presence of a functional group Z or alternatively by presence of a moiety T-L2-Y’-X’ as described herein, is obtainable by the process according to the present invention.
- the ERT according to the present invention is conjugated to a specific ligand T, such as e.g. specific targeting ligand, as described herein.
- the inventors designed a new process for preparing respectively conjugated ERP, i.e. pPB-ERP. Design of the new process became necessary since previously known processes for preparing ERP, such as with other ligands including N-acetyl glucosamine, proved to be neither resource friendly nor technically applicable to ligands such as pPB.
- pPB as well as certain other ligands described herein, such as other polypeptides, whether cyclic or not, are as such not tolerant or inert to RAFT polymerization as used in the prior art.
- the process according to the present invention is significantly more cost-effective for expensive ligands such as polypeptides, including pPB and derivatives thereof, as a result of the ligand being conjugated in the last step of the process.
- the present invention also provides methods for using one or more pPB conjugates of the present invention, such as pPB-siRNA according to the invention, pPB-ERP according to the invention, alone and/or in combination, in the treatment of one or more diseases of a human or an animal, preferably a human.
- the disease is a liver disease.
- the disease is a kidney disease.
- the disease is liver fibrosis.
- the disease is non-alcoholic steatohepatitis (NASH)
- the disease is kidney fibrosis.
- the disease is clear cell renal cell carcinoma.
- the disease is alcoholic steatohepatitis (ASH)
- HSC hepatic stellate cell
- HSCs hepatic stellate cells
- Targeted delivery of therapeutic agents to HSCs may be important for the successful treatment of liver fibrosis.
- a number of protein markers have been found to be overexpressed in activated HSCs, and their ligands have been used to specifically deliver various antifibrotic agents, (see, e.g., Chen et al., Journal of Pharmacology and Experimental Therapeutics, 2019, 370 (3) 695-702).
- delivery of therapeutics using other systems is needed as other means for delivering therapeutic agents to HSCs.
- Liver fibrosis is caused by the formation of an abnormally large amount of scar tissue in the liver. Liver fibrosis occurs when the liver attempts to repair and replace damaged cells. Various disorders and drugs can damage the liver and cause fibrosis.
- Nonalcoholic fatty liver disease is a condition in which triglycerides accumulate in the liver.
- Nonalcoholic steatohepatitis is a type of NAFLD.
- NASH is associated with inflammatory changes and liver cell damage. NASH is a leading cause of liver disease and often progresses to liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC).
- Non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH) have a similar pathogenesis and histopathology but a different etiology and epidemiology.
- NASH and ASH are advanced stages of non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD).
- Alcoholic steatohepatitis is a chronic, progressive liver disease characterized by fibrosis of the liver as well as possible necrosis of the liver tissue, brought on by excessive, prolonged alcohol use. Women are more susceptible to the disease because alcohol metabolism is lower in women than in men.
- Liver fibrosis is an important underlying cause of liver dysfunction and predicts mortality. Progression to cirrhosis and HCC leads to ultimate liver failure and thus liver transplantation is required.
- the current US prevalence of NASH-related fibrosis (F2 and later) is about 3.8 million patients. Doctors typically recommend weight loss to treat NAFLD and NASH. While weight loss can reduce fat in the liver, inflammation, and fibrosis, no medicines have been approved to treat NAFLD and NASH. Specifically, no medicines have been approved to treat liver fibrosis. (Clin Liver Dis. 2008 Nov;12(4):733-46, N Engl J Med. 2017 Nov 23;377(21):2063-2072, J Hepatol. 2017 Dec;67(6): 1265-127) Accordingly, new therapeutic treatment options, including delivery options, are needed for the treatment of liver fibrosis, e.g., in the context of NASH or ASH.
- conjugate includes compounds of formula (I) that comprise an oligonucleotide (e.g., an siRNA molecule) linked to a targeting ligand.
- oligonucleotide e.g., an siRNA molecule
- conjugate may be used herein interchangeably.
- small -interfering RNA or “siRNA” as used herein refers to double stranded
- RNA i.e., duplex RNA
- the siRNA may have substantial or complete identity to the target gene or sequence, or may comprise a region of mismatch (i.e., a mismatch motif).
- the siRNAs may be about 19-25 (duplex) nucleotides in length, and are preferably about 20-24, 21-22, or 21-23 (duplex) nucleotides in length.
- siRNA duplexes may comprise 3’ overhangs of about 1 to about 5 nucleotides or about 2 to about 3 nucleotides and 5’ phosphate termini.
- siRNA include, without limitation, a double-stranded polynucleotide molecule assembled from two separate stranded molecules, wherein one strand is the sense strand and the other is the complementary antisense strand.
- the 5' and/or 3' overhang on one or both strands of the siRNA comprises 1-5 (e.g., 1, 2, 3, 4 or 5) modified and/or unmodified deoxythymidine (t or dT) nucleotides, 1-5 (e.g., 1, 2, 3, 4 or 5) modified (e.g., 2'0Me) and/or unmodified uridine (U) ribonucleotides, and/or 1-5 (e.g., 1, 2, 3, 4 or 5) modified (e.g., 2'0Me) and/or unmodified ribonucleotides or deoxyribonucleotides having complementarity to the target sequence (e.g., 3'overhang in the antisense strand) or the complementary strand thereof (e.g., 3' overhang in the sense strand).
- 1-5 e.g., 1, 2, 3, 4 or 5
- siRNAs are chemically synthesized.
- siRNA can also be generated by cleavage of longer dsRNA (e.g., dsRNA greater than about 25 nucleotides in length) with the E. coll RNase III or Dicer. These enzymes process the dsRNA into biologically active siRNA (see, e.g., Yang et al. , Proc. Natl. Acad. Sci. USA, 99:9942-9947 (2002); Calegari et al. , Proc. Natl. Acad. Sci.
- dsRNAs are at least 50 nucleotides to about 100, 200, 300, 400, or 500 nucleotides in length.
- a dsRNA may be as long as 1000, 1500, 2000, 5000 nucleotides in length, or longer.
- the dsRNA can encode for an entire gene transcript or a partial gene transcript.
- siRNA may be encoded by a plasmid (e.g., transcribed as sequences that automatically fold into duplexes with hairpin loops).
- the phrase “inhibiting expression of a target gene” refers to the ability of a siRNA of the invention to silence, reduce, or inhibit the expression of a target gene.
- a test sample e.g., a biological sample from an organism of interest expressing the target gene or a sample of cells in culture expressing the target gene
- a siRNA that silences, reduces, or inhibits expression of the target gene.
- Expression of the target gene in the test sample is compared to expression of the target gene in a control sample (e.g., a biological sample from an organism of interest expressing the target gene or a sample of cells in culture expressing the target gene) that is not contacted with the siRNA.
- Control samples may be assigned a value of 100%.
- silencing, inhibition, or reduction of expression of a target gene is achieved when the value of the test sample relative to the control sample (e.g., buffer only, an siRNA sequence that targets a different gene, a scrambled siRNA sequence, etc. ⁇ is about 100%, 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or 0%.
- Suitable assays include, without limitation, examination of protein or mRNA levels using techniques known to those of skill in the art, such as, e.g., dot blots, Northern blots, in situ hybridization, ELISA, immunoprecipitation, enzyme function, as well as phenotypic assays known to those of skill in the art.
- synthetic activating group refers to a group that can be attached to an atom to activate that atom to allow it to form a covalent bond with another reactive group. It is understood that the nature of the synthetic activating group may depend on the atom that it is activating. For example, when the synthetic activating group is attached to an oxygen atom, the synthetic activating group is a group that will activate that oxygen atom to form a bond (e.g. an ester, carbamate, or ether bond) with another reactive group. Such synthetic activating groups are known. Examples of synthetic activating groups that can be attached to an oxygen atom include, but are not limited to, acetate, succinate, triflate, and mesylate.
- the synthetic activating group When the synthetic activating group is attached to an oxygen atom of a carboxylic acid, the synthetic activating group can be a group that is derivable from a known coupling reagent (e.g. a known amide coupling reagent). Such coupling reagents are known.
- a known coupling reagent e.g. a known amide coupling reagent
- an “effective amount” or “therapeutically effective amount” of a therapeutic nucleic acid such as siRNA is an amount sufficient to produce the desired effect, e.g., an inhibition of expression of a target sequence in comparison to the normal expression level detected in the absence of a siRNA.
- inhibition of expression of a target gene or target sequence is achieved when the value obtained with a siRNA relative to the control (e.g., buffer only, an siRNA sequence that targets a different gene, a scrambled siRNA sequence, etc.
- Suitable assays for measuring the expression of a target gene or target sequence include, but are not limited to, examination of protein or mRNA levels using techniques known to those of skill in the art, such as, e.g., dot blots, Northern blots, in situ hybridization, ELISA, immunoprecipitation, enzyme function, as well as phenotypic assays known to those of skill in the art.
- nucleic acid refers to a polymer containing at least two nucleotides (/. ⁇ ., deoxyribonucleotides or ribonucleotides) in either single- or double-stranded form and includes DNA and RNA.
- Nucleotides contain a sugar deoxyribose (DNA) or ribose (RNA), a base, and a phosphate group. Nucleotides are linked together through the phosphate groups.
- Bases include purines and pyrimidines, which further include natural compounds adenine, thymine, guanine, cytosine, uracil, inosine, and natural analogs, and synthetic derivatives of purines and pyrimidines, which include, but are not limited to, modifications which place new reactive groups such as, but not limited to, amines, alcohols, thiols, carboxylates, and alkylhalides.
- Nucleic acids include nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, and which have similar binding properties as the reference nucleic acid.
- nucleic acids can include one or more UNA moieties.
- oligonucleotide includes nucleotides containing up to about 60 nucleotides.
- a deoxyribooligonucleotide consists of a 5-carbon sugar called deoxyribose joined covalently to phosphate at the 5’ and 3’ carbons of this sugar to form an alternating, unbranched polymer.
- a ribooligonucleotide consists of a similar repeating structure where the 5-carbon sugar is ribose.
- RNA may be in the form, for example, of small interfering RNA (siRNA), Dicer-substrate dsRNA, small hairpin RNA (shRNA), small activating RNA (saRNA), asymmetrical interfering RNA (aiRNA), microRNA (miRNA), tRNA, rRNA, tRNA, viral RNA (vRNA).
- siRNA small interfering RNA
- Dicer-substrate dsRNA small hairpin RNA
- saRNA small activating RNA
- aiRNA asymmetrical interfering RNA
- miRNA microRNA
- tRNA tRNA
- rRNA tRNA
- viral RNA viral RNA
- oligonucleotide refers to a polymer or oligomer of nucleotide or nucleoside monomers consisting of naturally-occurring bases, sugars and intersugar (backbone) linkages.
- oligonucleotide also includes polymers or
- modified or substituted oligonucleotides may have properties, for example, of enhanced cellular uptake, reduced immunogenicity and/or increased stability in the presence of nucleases.
- gene refers to a nucleic acid e.g., DNA or RNA) sequence that comprises partial length or entire length coding sequences necessary for the production of a polypeptide or precursor polypeptide.
- Gene product refers to a product of a gene such as an RNA transcript or a polypeptide.
- label includes groups that enable the compound to be detected in vitro or in vivo.
- labeling agent is used interchangeably with the term label.
- a label may be selected from the group comprising a fluorophore, a chromophore, and a radionucleotide.
- the label can be detected by spectroscopy.
- the label can be detected by fluorescence spectroscopy.
- the label is a group that is derivable from fluorescein isothiocyanate (FITC) or Cy5.
- FITC fluorescein isothiocyanate
- a label can be detected by an apparatus suitable for detecting any one or more of alpha, beta particles, gamma rays, and x rays.
- alkyl by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain hydrocarbon radical, having the number of carbon atoms designated (i.e., Ci-s means one to eight carbons).
- alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n-pentyl, n-hexyl, n- heptyl, n-octyl, and the like.
- alkenyl refers to an unsaturated alkyl radical having one or more double bonds.
- alkynyl refers to an unsaturated alkyl radical having one or more triple bonds.
- unsaturated alkyl groups include vinyl, 2- propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(l,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers.
- alkylene by itself or as part of another substituent means a divalent radical derived from an alkane (including straight and branched alkanes), as exemplified by -CH2CH2CH2CH2- and -CH(CH 3 )CH 2 CH2-.
- cycloalkyl refers to hydrocarbon ringsystem having 3 to 20 overall number of ring atoms (e.g., 3-20 membered cycloalkyl is a cycloalkyl with 3 to 20 ring atoms, or C3-20 cycloalkyl is a cycloalkyl with 3-20 carbon ring atoms) and for a 3-5 membered cycloalkyl being fully saturated or having no more than one double bond between ring vertices and for a 6 membered cycloalkyl or larger being fully saturated or having no more than two double bonds between ring vertices.
- cycloalkyl As used herein, "cycloalkyl,” “carbocyclic,” or “carbocycle” is also meant to refer to bicyclic, polycyclic and spirocyclic hydrocarbon ring systems, such as, for example, bicyclo[2.2.1]heptane, pinane, bicyclo[2.2.2]octane, adamantane, norbornene, spirocyclic C5-12 alkane, etc.
- alkenyl “alkynyl,” “cycloalkyl,”, “carbocycle,” and “carbocyclic” are meant to include mono and polyhalogenated variants thereof.
- heterocycloalkyl refers to a saturated or partially unsaturated ring system radical having from 3-20 ring atoms (e.g., 3-20 membered heterocycloalkyl is a heterocycloalkyl radical with 3-20 ring atoms, a C2-19 heterocycloalkyl is a heterocycloalkyl having 3-10 ring atoms with between 2-19 ring atoms being carbon) that contain from one to ten heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, nitrogen atom(s) are optionally quaternized, as ring atoms.
- a “heterocycloalkyl,” “heterocyclic,” or “heterocycle” ring can be a monocyclic, a bicyclic, spirocyclic or a polycylic ring system.
- heterocycloalkyl examples include pyrrolidine, piperidine, N- methylpiperidine, imidazolidine, pyrazolidine, butyrolactam, valerolactam, imidazolidinone, hydantoin, dioxolane, phthalimide, piperidine, pyrimidine-2,4(lH,3H)-dione, 1,4-di oxane, morpholine, thiomorpholine, thiomorpholine-S-oxide, thiomorpholine-S,S-oxide, piperazine, pyran, pyridone, 3 -pyrroline, thiopyran, pyrone, tetrahydrofuran, tetrhydrothiophene, quinuclidine, tropane, 2-azaspiro[3.3]heptane, (lR,5S)-3-aza
- alkoxy and “alkylthio”, are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom (“oxy”) or thio grou, and further include mono- and poly -halogenated variants thereof.
- halo or halogen
- (halo)alkyl is meant to include both a “alkyl” and “haloalkyl” substituent.
- haloalkyl is meant to include monohaloalkyl and polyhaloalkyl.
- Ci-4 haloalkyl is mean to include trifluoromethyl, 2,2,2-trifluoroethyl, 4 -chlorobutyl, 3 -bromopropyl, difluoromethyl, and the like.
- aryl means a carbocyclic aromatic group having 6-14 carbon atoms, whether or not fused to one or more groups.
- aryl groups include phenyl, naphthyl, biphenyl and the like unless otherwise stated.
- heteroaryl refers to aryl ring(s) that contain from one to five heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized.
- a heteroaryl group can be attached to the remainder of the molecule through a heteroatom.
- heteroaryl groups include pyridyl, pyridazinyl, pyrazinyl, pyrimindinyl, triazinyl, quinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalaziniyl, benzotriazinyl, purinyl, benzimidazolyl, benzopyrazolyl, benzotriazolyl, benzisoxazolyl, isobenzofuryl, isoindolyl, indolizinyl, benzotriazinyl, thienopyridinyl, thienopyrimidinyl, pyrazolopyrimidinyl, imidazopyridines, benzothiaxolyl, benzofuranyl, benzothienyl, indolyl, quinolyl, isoquinolyl, isothiazolyl, pyrazolyl, indazolyl, pteri
- animal includes mammalian species, such as a human, mouse, rat, dog, cat, hamster, guinea pig, rabbit, livestock, and the like.
- alkylamino includes a group of formula -N(H)R, wherein R is an alkyl as defined herein.
- dialkylamino includes a group of formula -NR2, wherein each R is independently an alkyl as defined herein.
- salts includes any anionic and cationic complex, such as the complex formed between a cationic lipid and one or more anions.
- anions include inorganic and organic anions, e.g., hydride, fluoride, chloride, bromide, iodide, oxalate (e.g., hemioxalate), phosphate, phosphonate, hydrogen phosphate, dihydrogen phosphate, oxide, carbonate, bicarbonate, nitrate, nitrite, nitride, bisulfite, sulfide, sulfite, bisulfate, sulfate, thiosulfate, hydrogen sulfate, borate, formate, acetate, benzoate, citrate, tartrate, lactate, acrylate, polyacrylate, fumarate, maleate, itaconate, glycolate, gluconate, malate, mandelate, tiglate, ascorbate,
- acyl includes any alkyl, alkenyl, or alkynyl wherein the carbon at the point of attachment is substituted with an oxo group, as defined below.
- the atom to which the bond is attached includes all stereochemical possibilities.
- a bond in a compound formula herein is drawn in a defined stereochemical manner (e.g. bold, bold-wedge, dashed or dashed-wedge)
- a bond in a compound formula herein is drawn in a defined stereochemical manner (e.g. bold, bold-wedge, dashed or dashed-wedge)
- the atom to which the stereochemical bond is attached is enriched in the absolute stereoisomer depicted.
- the compound may be at least 51% the absolute stereoisomer depicted.
- the compound may be at least 60% the absolute stereoisomer depicted.
- the compound may be at least 80% the absolute stereoisomer depicted.
- the compound may be at least 90% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 95 the absolute stereoisomer depicted. In another embodiment, the compound may be at least 99% the absolute stereoisomer depicted.
- peptide as used herein comprises oligo- and polypeptides and refers to substances comprising two or more, preferably 3 or more, preferably 4 or more, preferably 6 or more, such as 8 or more amino acids joined covalently by peptide bonds.
- a peptide may include natural amino acids and non-natural amino acids, such as D-amino acids.
- a peptide merely includes natural amino acids.
- all amino acids in a peptide are L-amino acids.
- a peptide consisting of amino acids may also be referred to as “polypeptide”, e.g. a polypeptide having 6 to 10 amino acid residues, such as 7 to 9 amino acid residues, and preferably about 8 amino acid residues,
- a "cyclic peptide” or “cyclized peptide” refers to a peptide or polypeptide chain which forms a ring, preferably to a peptide or polypeptide having an intramolecular bond between two non-adjacent amino acids within a peptide.
- the intramolecular bond may be selected without limitation from the group consisting of (i) backbone to backbone (i.e. peptide bond), (ii) side-chain to backbone and (iii) side-chain to side-chain cycle formation.
- a cyclic peptide of the invention may comprise a linking group resulting from any of the foregoing, such as e.g.
- a peptide bond in case of backbone to backbone cyclization and e.g. disulfide bonds resulting from two residues containing thiol groups, such as cysteines which can form intramolecular disulfide bridges giving cyclic peptides.
- percentage identity refers to a percentage of amino acid residues which are identical between the two sequences to be compared, obtained after the best alignment of two sequences over their entire length. Sequence comparisons, for purposes of determining the percentage of sequence identity, between two amino acid sequences are typically carried out by comparing these sequences after having aligned them optimally, said comparison being carried out by segment or by "window of comparison” in order to identify and compare local regions of sequence similarity.
- the optimal alignment of the sequences for comparison may be produced by means of the local homology algorithm of Smith and Waterman, 1981, Ads App. Math. 2, 482, by means of the local homology algorithm of Needleman and Wunsch, 1970, J. Mol. Biol.
- siRNA can be provided in several forms including, e.g., as one or more isolated smallinterfering RNA (siRNA) duplexes, as longer double-stranded RNA (dsRNA), or as siRNA or dsRNA transcribed from a transcriptional cassette in a DNA plasmid.
- siRNA may be produced enzymatically or by partial/total organic synthesis, and modified ribonucleotides can be introduced by in vitro enzymatic or organic synthesis.
- each strand is prepared chemically. Methods of synthesizing RNA molecules are known in the art, e.g., the chemical synthesis methods as described in Verma and Eckstein (1998) or as described herein.
- RNA, synthesizing RNA, hybridizing nucleic acids, making and screening cDNA libraries, and performing PCR are well known in the art (see, e.g., Gubler and Hoffman, Gene, 25:263-269 (1983); Sambrook et al., supra, Ausubel et al., supra), as are PCR methods (see, U.S. Patent Nos. 4,683,195 and 4,683,202; PCR Protocols: A Guide to Methods and Applications (Innis et al., eds, 1990)).
- Expression libraries are also well known to those of skill in the art.
- siRNAs are chemically synthesized.
- the oligonucleotides that comprise the siRNA molecules of the invention can be synthesized using any of a variety of techniques known in the art, such as those described in Usman et al., J. Am. Chem. Soc., 109:7845 (1987); Scaringe et al., Nucl. Acids Res., 18:5433 (1990); Wincott et al., Nucl. Acids Res., 23:2677-2684 (1995); and Wincott et al., Methods Mol. Bio., 74:59 (1997).
- oligonucleotides makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5 ’-end and phosphoramidites at the 3 ’-end.
- small scale syntheses can be conducted on an Applied Biosystems synthesizer using a 0.2 pmol scale protocol.
- syntheses at the 0.2 pmol scale can be performed on a 96-well plate synthesizer from Protogene (Palo Alto, CA).
- Protogene Protogene
- siRNA molecules can be assembled from two distinct oligonucleotides, wherein one oligonucleotide comprises the sense strand and the other comprises the antisense strand of the siRNA.
- each strand can be synthesized separately and joined together by hybridization or ligation following synthesis and/or deprotection.
- the linking group can be variable provided the targeting conjugate functions as described herein.
- the linking group can vary in length and atom composition and for example can be branched or non-branched or cyclic or a combination thereof.
- the linking group may also modulate the properties of the targeted conjugate such as but not limited to solubility, stability and aggregation.
- the linker comprises about 3-5000 atoms. In one embodiment the linker comprises about 3-4000 atoms. In one embodiment the linker comprises about 3-2000 atoms. In one embodiment the linker comprises about 3-1000 atoms. In one embodiment the linker comprises about 3-750 atoms. In one embodiment the linker comprises about 3-500 atoms. In one embodiment the linker comprises about 3-250 atoms. In one embodiment the linker comprises about 3-100 atoms. In one embodiment the linker comprises about 3-50 atoms. In one embodiment the linker comprises about 3-25 atoms.
- the linker comprises about 10-5000 atoms. In one embodiment the linker comprises about 10-4000 atoms. In one embodiment the linker comprises about 10-2000 atoms. In one embodiment the linker comprises about 10-1000 atoms. In one embodiment the linker comprises about 10-750 atoms. In one embodiment the linker comprises about 10-500 atoms. In one embodiment the linker comprises about 10-250 atoms. In one embodiment the linker comprises about 10-100 atoms. In one embodiment the linker comprises about 10-50 atoms. In one embodiment the linker comprises about 10-25 atoms.
- the linker L comprises atoms selected from H, C, N, S and O.
- the linker L comprises atoms selected from H, C, N, S, P and O.
- the linker L comprises a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to 1000 (or 1-750, 1-500, 1-250, 1-100, 1- 50, 1-25, 1-10, 1-5, 5-1000, 5-750, 5-500, 5-250, 5-100, 5-50, 5-25, 5-10 or 2-5 carbon atoms) wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(R a )-, 3-7 membered heterocycle, 5-6-membered heteroaryl or carbocycle and wherein each chain, 3-7 membered heterocycle, 5-6-membered heteroaryl or carbocycle is optionally and independently substituted with one or more (e.g.
- the linker comprises a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to 1000 (or 1- 750, 1-500, 1-250, 1-100, 1-50, 1-25, 1-10, 1-5, 5-1000, 5-750, 5-500, 5-250, 5-100, 5-50, 5-25, 5-10 or 2-5 carbon atoms) wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(R a )-, wherein each R a is independently H or (Ci-Ce)alkyl.
- the linker L comprises a polyethylene glycol. In one embodiment the linker comprises a polyethylene glycol linked to the remainder of the targeted conjugate by a carbonyl group. In one embodiment the polyethylene glycol comprises about 1 to about 500 or about 5 to about 500 or about 3 to about 100 repeat (e.g., -CH2CH2O-) units (Greenwald, R.B., et al., Poly (ethylene glycol) Prodrugs: Altered Pharmacokinetics and Pharmacodynamics, Chapter, 2.3.1., 283-338; Filpula, D., et al., Releasable PEGylation of proteins with customized linkers, Advanced Drug Delivery, 60, 2008, 29-49; Zhao, H., et al., Drug Conjugates with Poly(Ethylene Glycol), Drug Delivery in Oncology, 2012, 627-656).
- -CH2CH2O- repeat
- the linker L is -(CEbCEEO ⁇ CEECEbC ⁇ O)-.
- the linker L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 500 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(R a )-, 3-20 membered heterocycle, 3-20 membered heteroaryl or 3-20 membered carbocycle and wherein each chain, 3-20 membered heterocycle, 3-20 membered heteroaryl and 3-20 membered carbocycle is optionally and independently substituted with one or more (e.g.
- the linker L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 100 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(R a )-, 3-20 membered heterocycle, 3-20 membered heteroaryl or 3-20 membered carbocycle and wherein each chain, 3-20 membered heterocycle, 3-20 membered heteroaryl and 3-20 membered carbocycle is optionally and independently substituted with one or more (e.g.
- the linker L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 50 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(R a )-, 3-20 membered heterocycle, 3-20 membered heteroaryl or 3-20 membered carbocycle and wherein each chain, 3-20 membered heterocycle, 3-20 membered heteroaryl and 3-20 membered carbocycle is optionally and independently substituted with one or more (e.g.
- the linker L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 50 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(R a )-, or R b , wherein each chain and R b is optionally and independently substituted with one or more (e.g.
- each R b is independently H or (Ci-Ce)alkyl; and each R b is independently selected from the group consisting of:
- the linker L comprises phen-l,3-diyl or phenl-l,3,5-triyl.
- each R 1 is linked to L through a carbonyl group of L.
- each R 2 is linked to L through a carbon-carbon bond.
- the linker L is selected from the group consisting of:
- the linker is comprised of a moiety of formula L2-Y’Z’-LI, wherein each of L2, Y’Z’, and Li are as defined herein.
- Y and Z are selected such that Y’Z’ together comprise an oxime functionality.
- Y and Z are selected such that Y’Z’ together comprise a triazole ring.
- One aspect of the invention is a compound of formula I, as set forth about in the Summary of the Invention, or a salt thereof.
- each R 1 is independently a targeting ligand, which is selected from: a) a cyclic polypeptide depicted by SEQ ID NO: 1 :C*SRNLIDC* (SEQ ID NO: 1), wherein * denotes a disulfide bond linking the two C residues to thereby form the cyclic polypeptide, and b) any cyclic polypeptide having at least 80 % sequence identity (e.g., at least 85%; e.g., at least 87.5%; e.g., at least 90%; e.g., at least 95%; e.g., at least 99% sequence identity) with the polypeptide depicted by SEQ ID NO: 1, under the proviso that both C* residues are present, and wherein * denotes a disulfide bond linking the two C residues to thereby form the cyclic polypeptide;
- L is a linking group; y is 1, 2, 3, 4 or 5; and each R 2 is independently an oligonucleotide, a label (e.g., a label derivable from fluorescein isothiocyanate (FITC) or Cy5), a phenyl group that is substituted with a formyl (-CHO) group, or a group of formula:
- Ri is a polypeptide, preferably a cyclic polypeptide, having 6 to 10 amino acid residues, such as 7 to 9 amino acid residues, and preferably about 8 amino acid residues.
- the polypeptide defined in b) is identical to the polypeptide defined in a), except that exactly one of the eight amino acid residues is being exchanged for another amino acid, and thus nonidentical.
- the polypeptide of b), as described herein has 87.5 % sequence identity with the polypeptide defined in a).
- the polypeptide has 7 to 10 amino acid residues, and preferably about 8 or 9 amino acid residues, most preferably 8 amino acid residues.
- Ri can be described as a polypeptide having 7 to 10 amino acid residues, and preferably about 8 or 9 amino acid residues, most preferably 8 amino acid residues, wherein the polypeptide has an amino acid sequence as defined by SEQ ID NO: 1, except that one or more amino acid residues are inserted, deleted or exchanged.
- amino acid residues are inserted, deleted or exchanged.
- one to three amino acid residues are inserted, deleted or exchanged, more preferably two or less amino acid residues are inserted, deleted or exchanged, and most preferably one amino acid residue is inserted, deleted or exchanged.
- Said polypeptide has at least two functional groups capable of forming a bond with each other, such as thiol groups of e.g.
- cysteine residues which are capable of forming a disulfide bond, thereby forming a cyclic polypeptide.
- the functional groups capable of forming a bond with each other are preferably located at or near the N- terminus and C-terminus, respectively.
- Ri is a polypeptide having a core as defined in a) or b) above, and in addition to that an extension of the polypeptide sequence at either the N-terminus and/or the C- terminus of the polypeptide defined above, such that Ri overall is a longer polypeptide which comprises Ri but which is not limited to Ri.
- cyclization results from the formation of disulfide bridges between cysteine residues of the peptide such as between the amino acids at positions 1 and 8 of the amino acid sequences described herein, particularly in a) and b) above.
- an intramolecular bond may be formed in a peptide described herein by a cyclization which is different from a Cys-Cys cyclization.
- the present invention also contemplates peptides, wherein one or both of the Cysteine moieties in the peptide described herein are replaced by a moiety other than Cys.
- one or both of the Cys residues at the first and last position (such as positions 1 and 8) of the amino acid sequences described herein may be replaced by (an) amino acid(s) which is (are) able to form an intramolecular bond in the peptide.
- said bond is formed between the amino acids at the first and last position (such as positions 1 and 8) of the amino acid sequences described herein.
- E3 The compound or salt of El, wherein x is 3.
- E4 The compound or salt of any one of E1-E3, wherein each R 1 is covalently bound to L (i) through the N terminus of the polypeptide or (ii) through the C terminus of the polypeptide or (iii) through the side chain of an amino acid of the polypeptide.
- E5 The compound or salt of any one of E1-E3, wherein each R 1 is covalently bound to L through the N terminus of the polypeptide.
- E7 The compound or salt of any one of E1-E6, wherein each R 2 is independently an oligonucleotide.
- E8 The compound or salt of any one of E1-E6, wherein each R 2 is independently an siRNA.
- Such compound is particularly advantageous (for a non-limiting and illustrative embodiment, see e.g. Example 12)
- El 2 The compound or salt of any one of El -El 1, wherein L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 500 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -0-, -S, -N(R a )-, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, or 3-20 membered carbocycle and wherein each chain, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, and 3-20 membered carbocycle is optionally and independently substituted with one or more (e.g.
- El 3 The compound or salt of any one of El -El 1, wherein L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 100 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(R a )-, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, or 3-20 membered carbocycle and wherein each chain, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, and 3-20 membered carbocycle is optionally and independently substituted with one or more (e.g.
- L is a branched or unbranched
- El 5 The compound or salt of any one of El -El 1, wherein L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 50 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(R a )-, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, or 3-20 membered carbocycle and wherein each chain, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, and 3-20 membered carbocycle is optionally and independently substituted with one or more (e.g.
- each R b is independently H or (Ci-Ce)alkyl; and each R b is independently selected from the group consisting of:
- E19 The compound or salt of any one of El-El 1, wherein L comprises phen-l,3-diyl or phenl-l,3,5-triyl.
- E20 The compound or salt of any one of El -El 1, wherein L comprises: E21.
- E22 The compound or salt of any one of E1-E20, wherein each R 2 is linked to L through a carbon-carbon bond.
- E23 The compound or salt of any one of El -El 1, wherein L is selected from the group consisting of: E24.
- R 2 is not an oligonucleotide.
- R 2 is not an oligonucleotide.
- E24 is selected to be 1.
- the invention provides a process for preparation of a diblock polymer of the following formula (X): [Block A] - [Block B] (X) comprising: a) contacting a compound of structure Va, Vb, Vc, or Vd wherein R 27 is (Ci-Ci2)alkyl, wherein R 28 is (Ci-Ci2)alkyl, wherein R 25 and R 26 are independently H, (Ci-Ci2)alkyl, aryl, or heteroaryl, with one or more A monomers selected from the group consisting of: i) a polyethyleneglycol methacrylate with 2-20 ethylene glycol units
- M 2 is a methacrylate, which is optionally selected among a (C4-Cis)alkyl-methacrylate; a (C4-Cis)branched alkyl-methacrylate; a cholesteryl methacrylate; a (C4-Cis)alkyl-methacrylate substituted with one or more fluorine atoms; and a (C4-Cis)branched alkyl-methacrylate substituted with one or more fluorine atoms; in the presence of a free radical to provide a first product; b) contacting the first product with one or more B mon omers of formulae B 1, B2 and B3
- Block A comprises one or more residues of A monomers and has a molecular weight of from about 1 kDa to about 25 kDa;
- Block B comprises one or more residues of monomers Bl, B2, and B3 and has a molecular weight of from about 1 kDa to about 25 kDa.
- Li is a linking moiety
- Z is a functional group that is optionally protected with a protecting group and is capable of reacting with Y of a compound of formula (XII):
- T is a ligand (optionally targeting ligand);
- Y is a functional group that is capable of reacting with Z to form a conjugate
- L2 is absent or is a linking moiety.
- a “free radical source” as used herein is not particularly limited. Suitable free radical sources include without limitation Azobisisobutyronitrile (AIBN), 1,1- Azobis(cyanocyclohexane) (ACHN/VAZO-88), 4,4'-azobis(4-cyanovaleric acid) (ACVA), Potassium persulfate (K2S2O8).
- CTA chain transfer agent
- Typical CTAs suitable in the present invention are, in non-limiting examples, thiocarb onylthio compounds (or similar..
- a CTA is also sometimes referred to as “RAFT agent” in the art.
- RAFT agent RAFT agent
- step c) is optional, it is preferred that the process of the present invention actually comprises step c) as well.
- the result of a process comprising step c) is the compound of formula (I), which is devoid of a CTA moiety.
- step c) is not present, the resulting polymer still comprises a moiety derived from the CTA, while otherwise identical to the compound of formula (I).
- T moiety is conjugated to the polymer obtained by the above process in a step of post-polymerization conjugation:
- T is selected to be an oligonucleotide or a peptide, such as the cyclic peptide as described herein.
- the process according to the present invention is characterized in that T is conjugated to the polymer after the polymerization reaction (also referred to as RAFT polymerization).
- the process according to the present invention can also be referred to as post-polymerization conjugation.
- the inventors made endosome release polymer (ERP) characterized by such T moieties available through the present invention.
- the present invention provides a process for making endosome release polymer (ERP), wherein the ERP obtainable by such process is characterized in comprising a ligand which is optionally an oligonucleotide or a peptide. Even though oligonucleotides and peptides, among other ligands, are not susceptible to RAFT polymerization, the present invention makes ERP with such ligands available.
- the process of the present invention is also an economic process for making ERP comprising a relatively expensive or valuable ligand, optionally selected among an oligonucleotide and a peptide.
- the second product i.e. the product resulting from step b
- the contacting of the second product with one or more free radicals provides the diblock polymer of formula (X).
- the free radical removes this group and changes the terminal group of the polymer to a proton.
- the contacting of the second product with one or more free radicals occurs under protic conditions. This is advantageous for changing polymer end group, to substitute the RAFT agent by a proton.
- RAFT Reversible Addition- Fragmentation chain Transfer
- RAFT is used in synthesizing ethylenic backbone polymers of this invention.
- RAFT is a living polymerization process.
- RAFT comprises a free radical degenerative chain transfer process.
- RAFT procedures for preparing a polymer described herein employs thiocarbonylthio compounds such as, without limitation, dithioesters, dithiocarbamates, trithiocarbonates and xanthates to mediate polymerization by a reversible chain transfer mechanism.
- the low concentration of active radicals at any particular time limits normal termination reactions.
- polymers of the present invention have a low poly dispersity index (PDI or DI) or differences in chain length.
- Poly dispersity index can be determined in any suitable manner, e.g., by dividing the weight average molecular weight of the polymer chains by their number average molecular weight. The number average molecule weight is sum of individual chain molecular weights divided by the number of chains. The weight average molecular weight is proportional to the square of the molecular weight divided by the number of molecules of that molecular weight. Since the weight average molecular weight is always greater than the number average molecular weight, poly dispersity is always greater than or equal to one.
- poly dispersity values approaching one are achievable using radical living polymerization.
- Methods of determining poly dispersity such as, but not limited to, size exclusion chromatography, dynamic light scattering, matrix-assisted laser desorption/ionization chromatography and electrospray mass chromatography are well known in the art.
- the polymers e.g., membrane destabilizing polymers
- the polymers have a poly dispersity index (PDI) of less than 2.0, or less than 1.8, or less than 1.6, or less than 1.5, or less than 1.4, or less than 1.3, or less than 1.2.
- the polymer is a block copolymer (e.g., endosome release copolymer) comprising a hydrophilic block and a hydrophobic block and having a poly dispersity index (PDI) of less than 2.0, or less than 1.8, or less than 1.6, or less than 1.5, or less than 1.4, or less than 1.3, or less than 1.2.
- Suitable solvents include water, alcohol (e.g., methanol, ethanol, n-propanol, isopropanol, butanol), tetrahydrofuran (THF) dimethyl] sulfoxide (DMSO), dimethylformamide (DMF), acetone, acetonitrile, hexamethylphosphoramide, acetic acid, formic acid, hexane, cyclohexane, benzene, toluene, dioxane, methylene chloride, ether (e.g., diethyl ether), chloroform, and ethyl acetate.
- the solvent includes water, and mixtures of water and water-miscible organic solvents such as DMF.
- the A monomers are selected from the group consisting of monomers of formulae Al and A2.
- Rounded brackets denote the monomer moieties. Squared brackets denote Blocks A and B, respectively, of the diblock polymer. Stoichiometry (m and n; q, r and s) and molecular weights (v and w) are as defined in E25. E27. The process of E25 or E26 wherein Z is a functional group that is protected with a protecting group, wherein the process further comprises removing the protecting group from Z.
- this process yields the endosome release polymer described in E49 and any of its embodiments.
- the conjugate is a conjugate of formula (XIII):
- Rounded brackets denote the monomer moieties.
- Squared brackets denote Blocks A and B, respectively, of the diblock polymer.
- Block A has a molecular weight of from about 1 kDa to about 25 kDa; and Block B has a molecular weight of from about 1 kDa to about 25 kDa.
- PEGMA is polyethyleneglycol methacrylate residue with 2-20 ethylene glycol units
- M 2 is a methacrylate residue selected from the group consisting of a (C4-Cis)alkyl-methacrylate residue; a (C4-Cis)branched alkyl- methacrylate residue; a cholesteryl methacrylate residue; a (C4-Cis)alkyl-methacrylate residue substituted with one or more fluorine atoms; and a (C4-Cis)branched alkyl-methacrylate residue substituted with one or more fluorine atoms; and v is 1 to 25 kDa; and wherein Block B has formula:
- BMA is butyl methacrylate residue
- PAA is propyl acrylic acid residue
- Rounded brackets denote the monomer moieties.
- Squared brackets denote Blocks A and B, respectively, of the diblock polymer.
- E32 The process of any one of E25-E31, wherein Z and Y are selected so that Y’Z’ comprises an oxime functionality.
- E33 The process of any one of E25-E31, wherein Z and Y are selected so that Y’Z’ comprises a triazole ring.
- E34 The process of any one of E25-E27 and E29-E32, wherein Z comprises an aminooxy group that is protected, and the protecting group is on the nitrogen of the aminooxy group.
- E35 The process of any one of E29-E32, wherein Z comprises an aminooxy group, Y comprises a ketone group or an aldehyde group, and Y’Z’ comprises an oxime functional group.
- E36 The process of any one of E29-E32, wherein Z comprises a ketone group or an aldehyde group, Y comprises an aminooxy group, and Y’Z’ comprises an oxime functional group.
- E37 The process of E29 or E33, wherein Z comprises an alkyne group, Y comprises an azide group, and Y’Z’ comprises a triazole ring.
- E38 The process of E29 or E33, wherein Z comprises an azide group, Y comprises an alkyne group, and Y’Z’ comprises a triazole ring.
- E39 The process of any one of any one of E29-E38, wherein T is a targeting ligand or a labeling agent.
- E40 The process of any one of E29-E38, wherein the targeting ligand is selected from the group of an oligonucleotide, a peptide, a saccharide, and a small molecule.
- E42 The process of any one of E29-E38, wherein the targeting ligand comprises a cyclic peptide as described in El.
- E44 The process of any one of E29-E38, wherein the labeling agent is selected from the group consisting of a fluorophore, a chromophore, and a radionucleotide.
- E45 The process of any one of E29-E38, wherein the labeling agent is derivable from fluorescein isothiocyanate (FITC) or Cy5.
- FITC fluorescein isothiocyanate
- Cy5 Cy5
- E46 A product prepared by the process of any one of E25-E45.
- E47 A conjugate prepared by the process of any one of E29-E45.
- E49 The composition of E48, wherein at least one of the conjugates comprises a labelling agent.
- each R 1 is independently a targeting ligand, which is selected from a) a cyclic polypeptide depicted by SEQ ID NO: 1 :C*SRNLIDC* (SEQ ID NO: 1), wherein * denotes a disulfide bond linking the two C residues to thereby form the cyclic polypeptide, b) any cyclic polypeptide having at least 80 % sequence identity (e.g., at least 85%; e.g., at least 87.5%; e.g., at least 90%; e.g., at least 95%; e.g., at least 99% sequence identity) with the polypeptide depicted by SEQ ID NO: 1, under the proviso that both C* residues are present, and wherein * denotes a disulfide bond linking the two C residues to thereby form the cyclic polypeptide;
- L is a linking group; and y is 1, 2, 3, 4 or 5; and each R 2 is independently an endosomal release polymer.
- the compound or salt of E50 is available by the process of E29 and any of its embodiments.
- E51 The compound or salt of E50, wherein the endosomal release polymer comprises a diblock polymer comprising Block A and Block B having the following formula:
- Block A comprises one or more residues of monomers Al and A2 as described in E25 and has a molecular weight of from about 1 kDa to about 25 kDa;
- Block B comprises one or more residues of monomers Bl, B2, and B3 as described in E25 and has a molecular weight of from about 1 kDa to about 25 kDa.
- said compound of Formula (I) is obtainable by a process as described herein.
- PEGMA is polyethyleneglycol methacrylate residue with 2-20 ethylene glycol units
- M 2 is a methacrylate residue selected from the group consisting of a (C4-Cis)alkyl-methacrylate residue; a (C4-Cis)branched alkyl- methacrylate residue; a cholesteryl methacrylate residue; a (C4-Cis)alkyl-methacrylate residue substituted with one or more fluorine atoms; and a (C4-Cis)branched alkyl-methacrylate residue substituted with one or more fluorine atoms;
- BMA is butyl methacrylate residue
- PAA is propyl acrylic acid residue
- a pharmaceutical composition comprising a compound as described in any one of E1-E24 and E50-E53 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- a pharmaceutical composition comprising a first compound as described in any one of E1-E24 or a pharmaceutically acceptable salt thereof, wherein each R 2 is independently an oligonucleotide and a second compound as described in any one of E50-E53 or a pharmaceutically acceptable salt thereof.
- E56 A method to deliver an oligonucleotide to an animal comprising administering a compound as described in any one of E1-E24 or a pharmaceutically acceptable salt thereof, to the animal.
- E57 A method to deliver an oligonucleotide to cells that express platelet-derived growth factor receptor (PDGFR) in an animal comprising administering a compound as described in any one of E1-E24 or a pharmaceutically acceptable salt thereof, to the animal.
- PDGFR platelet-derived growth factor receptor
- E58 The method of E57, wherein the platelet-derived growth factor receptor (PDGFR) is platelet-derived growth factor receptor alpha (PDGFRa).
- PDGFR platelet-derived growth factor receptor alpha
- E59 The method of E57, wherein the platelet-derived growth factor receptor (PDGFR) is platelet-derived growth factor receptor beta (PDGFRP).
- PDGFR platelet-derived growth factor receptor
- PDGFRP platelet-derived growth factor receptor beta
- E60 The method of E57, wherein the cells that express PDGFR are hepatic stellate cells (HSC), endothelial cells, fibroblasts or tumor cells.
- HSC hepatic stellate cells
- endothelial cells fibroblasts or tumor cells.
- a method to treat a disease involving PDGFR expressing cells comprising administering a compound as described in any one of E1-E24 or a pharmaceutically acceptable salt thereof, to the animal.
- a disease involving PDGFR expressing cells e.g., liver fibrosis, non-alcoholic steatohepatitis (NASH), clear cell renal cell carcinoma, kidney fibrosis, or alcoholic steatohepatitis (ASH)
- NASH alcoholic steatohepatitis
- E62 A compound as described in any one of E1-E24 or a pharmaceutically acceptable salt thereof for delivering an oligonucleotide to an animal.
- E63 A compound as described in any one of E1-E24 or a pharmaceutically acceptable salt thereof for delivering an oligonucleotide to cells that express platelet-derived growth factor receptor (PDGFR).
- PDGFR platelet-derived growth factor receptor
- E64 A compound as described in any one of E1-E24 or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a disease involving PDGFR expressing cells (e.g., liver fibrosis, non-alcoholic steatohepatitis (NASH), clear cell renal cell carcinoma, kidney fibrosis, or alcoholic steatohepatitis (ASH)).
- a disease involving PDGFR expressing cells e.g., liver fibrosis, non-alcoholic steatohepatitis (NASH), clear cell renal cell carcinoma, kidney fibrosis, or alcoholic steatohepatitis (ASH)).
- E65 The use of a compound as described in any one of E1-E24 or a pharmaceutically acceptable salt thereof to prepare a medicament for delivering an oligonucleotide to an animal.
- E66 The use of a compound as described in any one of E1-E24 or a pharmaceutically acceptable salt thereof to prepare a medicament for delivering an oligonucleotide to cells that express platelet-derived growth factor receptor (PDGFR).
- PDGFR platelet-derived growth factor receptor
- E67 The use of a compound as described in any one of E1-E24 or a pharmaceutically acceptable salt thereof to prepare a medicament for treating a disease involving PDGFR expressing cells (e.g., liver fibrosis, non-alcoholic steatohepatitis (NASH), clear cell renal cell carcinoma, kidney fibrosis, or alcoholic steatohepatitis (ASH)).
- a disease involving PDGFR expressing cells e.g., liver fibrosis, non-alcoholic steatohepatitis (NASH), clear cell renal cell carcinoma, kidney fibrosis, or alcoholic steatohepatitis (ASH)).
- E68 The method, compound of use of any one of E56-E67, which comprises the combined use of a first compound as described in any one of E1-E24, wherein each R 2 is independently an oligonucleotide, with a second compound as described in any one of E50-E53.
- each R 1 is independently a targeting ligand of formula:
- L is a linking group; and y is 1, 2, 3, 4 or 5; and each R 2 is independently an oligonucleotide, a label (e.g., a label derivable from fluorescein isothiocyanate (FITC) or Cy5), a phenyl group that is substituted with a formyl (-CHO) group, or a group of formula: or y is 1, 2, 3, 4, or 5 and R 2 is an endosomal release agent including polymers and peptides or a salt thereof.
- FITC fluorescein isothiocyanate
- Cy5 a label derivable from fluorescein isothiocyanate
- a phenyl group that is substituted with a formyl (-CHO) group or a group of formula:
- y is 1, 2, 3, 4, or 5 and R 2 is an endosomal release agent including polymers and peptides or a salt thereof.
- E102-E122 Further embodiments (E102-E122) are described below.
- El 02. The compound or salt of E101, wherein each R 1 is independently a targeting ligand of formula: El 03.
- E108 The compound or salt of any one of E101-E107, wherein L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 500 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(R a )-, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, or 3-20 membered carbocycle and wherein each chain, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, and 3-20 membered carbocycle is optionally and independently substituted with one or more (e.g.
- L is a branched or un
- L is a branched or un
- El 12. The compound or salt of any one of El 01 -El 07, wherein L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 50 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(R a )-, or R b , wherein each chain and R b is optionally and independently substituted with one or more (e.g.
- each R b is independently H or (Ci-Ce)alkyl; and each R b is independently selected from the group consisting of:
- El 15 The compound or salt of any one of E101-E114, wherein L comprises phen-1,3- diyl or phen 1 - 1 , 3 , 5 -triyl .
- El 17 The compound or salt of any one of El 01 -El 16, wherein each R 1 is linked to L through a carbonyl group of L.
- El 18 The compound or salt of any one of El 01 -El 17, wherein each R 2 is linked to L through a carbon-carbon bond.
- E101 or E102 which is selected from the group consisting of:
- E121 The compound or salt of E101, wherein y is 1 and R 2 is an endosomal release polymer of formula XX:
- PEGMA is polyethyleneglycol methacrylate residue with 2-20 ethylene glycol units
- M 2 is a methacrylate residue selected from the group consisting of a (C4-Cis)alkyl-methacrylate residue; a (C4-Cis)branched alkyl- methacrylate residue; a cholesteryl methacrylate residue; a (C4-Cis)alkyl-methacrylate residue substituted with one or more fluorine atoms; and a (C4-Cis)branched alkyl-methacrylate residue substituted with one or more fluorine atoms;
- BMA is butyl methacrylate residue
- PAA is propyl acrylic acid residue
- E122 The compound or salt of E121, which is a compound of the following formula: or a salt thereof. Stoichiometry (m and n; q, r and s) and molecular weights (v and w) are as defined in E121.
- the invention provides a process for preparing a diblock polymer of formula (X):
- Prieve et al describe the synthesis of di -block polymers using RAFT polymerisation techniques, wherein the alpha end of the polymer features either a mannose or GalNac monosaccharide ligand. Details were limited, input and output amounts were not recorded, and no yields were given.
- the synthesis can require significant amounts of input starting material chain transfer agent (CTA) relative to the amount of output polymer. For example, in a synthesis using GalNAc CTA, 180g of input CTA was utilised to produce approximately 50 g of final polymer. This ratio of starting material to product seems to be consistent irrespective of the scale of the synthesis. In cases where ligands are relatively cheap and accessible, this material requirement is not necessarily an obstacle. However, in cases where the ligand may be significantly more expensive, this high input material requirement becomes prohibitive.
- RAFT polymerisation methodology is reported to be tolerant of a range of functional groups, it does not necessarily extend to all possible functional groups, including the functionality that may be present in a peptide where each amino acid residue may have a different potentially reactive group in its side chain. Incorporating protection group strategies to address the attendant complications would add significant technical complexity to the synthesis and likely further increase the material requirement and cost associated with trying to execute RAFT polymerisation on ligands more complicated than monosaccharides.
- oxime formation proceeded to an appreciable degree particularly in the presence of an acid catalyst, (e.g trifluoroacetic acid (TFA))
- an acid catalyst e.g trifluoroacetic acid (TFA)
- TFA trifluoroacetic acid
- oxime chemistry is particularly suitable for ligands (functional and protecting groups) that are not acid sensitive.
- GalNAc is conjugatable to polymer via processes known in the art, and would be less suitable to be conjugated in the new process according to the present invention because it might undergo acid catalyzed hydrolysis at the glycometric centre resulting in ligand elimination
- ligands such as those described herein including the peptides described herein, which are particularly suitable to be conjugated by the process according to the present invention, but cannot be conjugated to a satisfying degree by the processes previously known in the art.
- polymer synthesis is complicated by the lack of useful, non destructive, diagnostic techniques for reaction monitoring and determination of reaction completion.
- the processes of the invention enable accurate determination of reaction endpoint, confirmation of ligand attachment, and they provide an approach to reaction clean up that removes unwanted reagents from the reaction without the need for additional precipitation or dialysis that can significantly impact recovered yield of the final polymer.
- block copolymer refers to two or more homopolymer or copolymer subunits linked by covalent bonds. Block copolymers with two or three distinct blocks are called diblock copolymers and triblock copolymers, respectively.
- a schematic generalization of a diblock copolymer is represented by the formula [F;G,Hh. .
- each letter stands for a constitutional unit derived from polymerization of a corresponding monomer and wherein each subscript to a constitutional unit represents the mole fraction of that unit in the particular block, the three dots indicate that there may be more (there may also be fewer) constitutional units in each block and q and r indicate the molecular weight of each block in the diblock copolymer.
- the number and the nature of each constitutional unit is separately controlled for each block. The schematic is not meant and should not be construed to infer any relationship whatsoever between the number of constitutional units and the number of different types of constitutional units in each of the blocks.
- constitutional units may be disposed in a purely random, an alternating random, a regular alternating, a regular block or a random block configuration unless expressly stated to be otherwise.
- a purely random configuration may have the non -limiting form: f-f-g-h-f-g-g-h-g-h-h-h...
- An exemplary alternating random configuration may have the non-limiting form: f-g-f-h-g-f-g-h-g- f-h....
- an exemplary regular alternating configuration may have the non-limiting form: f-g- h-fg- h-f-g-h....
- An exemplary regular block configuration may have the following non-limiting configuration: ...f-f-f-g-g-g-h-h-h-f-f.
- an exemplary random block configuration may have the non-limiting configuration: f-f-f-h-h-f-f-g-g-g-h-h-f-f-h-h....
- a gradient polymer the content of one or more monomeric units increases or decreases in a gradient manner from the a-end of the polymer to the w-end.
- the brackets enclosing the constitutional units are not meant and are not to be construed to mean that the constitutional units themselves form blocks.
- the constitutional units within the square brackets may combine in any manner with the other constitutional units within the block, i.e., purely random, alternating random, regular alternating, regular block or random block configurations.
- the block copolymers described herein are, optionally, alternate, gradient or random block copolymers. Block copolymers and methods for their preparation are described in International Patent Application Publication Number W02015/017519, which is hereby incorporated herein by reference in its entirety.
- the ligand (such as e.g. targeting ligand), is not incorporated during polymerization such as contemplated in W02015/017519, e.g. by incorporating monomer A4 (comprising a targeting moiety T2) into block A of the polymer, but rather, according to the present invention, the ligand T (e.g. targeting ligand) is incorporated post polymerization.
- ligands which are not susceptible to RAFT polymerization such as in a non-limiting example oligonucleotides and peptides, such as the pPB peptide.
- one ligand (T), or one moiety bearing a natural number of targeting ligands (T) is being incorporated into every one polymer, i.e. according to the present invention a typical stoichiometry is 1, or a multiplicity thereof.
- the process of the present invention is thus differentiated over W02015/017519 at least in higher specificity of ligand incorporation and in allowing incorporating certain ligands that the process of W02015/017519 does not allow for.
- a further advantage of the present invention results from the fact that the ligand T is always placed on the hydrophilic end of the polymer, as opposed to incorporation at a random position as taught in W02015/017519.
- the ligand endosome release polymer (ERT) of the present invention which can be visualized by Formula (I ⁇ : (R 1 ) x — L— (R 2 ) y (I) wherein R 1 and R 2 and L are defined as specified herein, and wherein x is selected from an integer among 1, 2, 3, 4 or 5, and y is selected from an integer among 1, 2, 3, 4 or 5, provides for a defined stoichiometry between R 1 and R 2 .
- block copolymers according to the present invention include those where Block A is a first block that is a random copolymer formed from monomers of formulae Al, A2 and A3 as described herein. Additional examples of block copolymers include those where Block A is a first block that is a random copolymer formed from monomers comprising formulae Al and A2 as described above. Additional examples of block copolymers include those where A is a first block that is a polymer formed from monomer A2 as described above. Additional examples of block copolymers include those where Block A is a first block that is a random copolymer comprising residues of monomers of formula Al.
- block copolymers include those where Block A is a first block that is a random copolymer comprising residues of monomers of formula A2. Additional examples of block copolymers include those where Block A is a first block that is a random copolymer comprising residues of monomers of formula A3.
- block copolymers examples include those where Block B is a second block that is a random copolymer formed from monomers of formulae Bl, B2 and B3 as described herein. Additional examples of block copolymers include those where Block B is a second block that is a random copolymer comprising residues of monomers of formula Bl. Additional examples of block copolymers include those where Block B is a second block that is a random copolymer comprising residues of monomers of formula B2. Additional examples of block copolymers include those where Block B is a second block that is a random copolymer comprising residues of monomers of formula B3.
- Block A comprises residues derived from the polymerization of monomers of formulae Al and A2.
- the term “residue” means the portion of the monomer that remains in the polymer following polymerization.
- Block A comprises one or more residues of monomers Al and A2 and has a molecular weight of from about 1 kDa to about 25 kDa.
- Block A comprises one or more residues of monomers Al and A2 and has a molecular weight of from about 2 kDa to about 20 kDa.
- Block A comprises one or more residues of monomers Al and A2 and has a molecular weight of from about 2 kDa to about 15 kDa. In another embodiment, Block A comprises one or more residues of monomers Al and A2 and has a molecular weight of from about 2 kDa to about 10 kDa. In another embodiment, Block A comprises one or more residues of monomers Al and A2 and has a molecular weight of from about 2 kDa to about 5 kDa. In another embodiment, Block A comprises one or more residues of monomers Al and A2 and has a molecular weight of from about 5 kDa to about 20 kDa.
- Block A comprises one or more residues of monomers Al and A2 and has a molecular weight of from about 5 kDa to about 15 kDa. In another embodiment, Block A comprises one or more residues of monomers Al and A2 and has a molecular weight of from about 5 kDa to about 10 kDa. In another embodiment, Block A comprises one or more residues of monomers Al and A2 and has a molecular weight of from about 10 kDa to about 25 kDa. In another embodiment, Block A comprises one or more residues of monomers Al and A2 and has a molecular weight of from about 10 kDa to about 20 kDa. In another embodiment, Block A comprises one or more residues of monomers Al and A2 and has a molecular weight of from about 10 kDa to about 15 kDa.
- Block B comprises residues derived from the polymerization of monomers of formulae B 1, B2 and B3.
- the term “residue” means the portion of the monomer that remains in the polymer following polymerization.
- Block B comprises one or more residues of monomers Bl, B2 and B3 and has a molecular weight of from about 1 kDa to about 25 kDa.
- Block B comprises one or more residues of monomers Bl, B2 and B3 and has a molecular weight of from about 2 kDa to about 20 kDa.
- Block B comprises one or more residues of monomers B 1 , B2 and B3 and has a molecular weight of from about 2 kDa to about 15 kDa. In another embodiment, Block B comprises one or more residues of monomers Bl, B2 and B3 and has a molecular weight of from about 2 kDa to about 10 kDa. In another embodiment, Block B comprises one or more residues of monomers Bl, B2 and B3 and has a molecular weight of from about 2 kDa to about 5 kDa. In another embodiment, Block B comprises one or more residues of monomers B 1, B2 and B3 and has a molecular weight of from about 5 kDa to about 20 kDa.
- Block B comprises one or more residues of monomers Bl, B2 and B3 and has a molecular weight of from about 5 kDa to about 15 kDa. In another embodiment, Block B comprises one or more residues of monomers B 1, B2 and B3 and has a molecular weight of from about 5 kDa to about 10 kDa. In another embodiment, Block B comprises one or more residues of monomers Bl, B2 and B3 and has a molecular weight of from about 10 kDa to about 25 kDa. In another embodiment, Block B comprises one or more residues of monomers Bl, B2 and B3 and has a molecular weight of from about 10 kDa to about 20 kDa.
- Block B comprises one or more residues of monomers Bl, B2 and B3 and has a molecular weight of from about 10 kDa to about 15 kDa.
- Z and Y are selected so that Z in the diblock polymer of formula (X and XI) will react with Y in a compound of formula (XII):
- the conjugate is a conjugate of formula (XIII):
- the aminoxy of Z can react with an aldehyde (R”’is H) or with a ketone (R”’is C) of Y to provide the corresponding Z’Y’ oxime.
- the aminoxy of Y can react with an aldehyde (R”is H) or with a ketone (R”is C) of Z to provide the corresponding Z’Y’ oxime.
- a compound of formula (X) wherein Z is protected with a protecting group may be removed from Z prior to reaction with the compound of formula (XII). It may also be desirable to prepare a compound of formula (XII) wherein Y is protected with a protecting group. In such a case, the protecting group may be removed from Y prior to reaction with the compound of formula (X).
- a compound of formula (X) wherein Z is protected with a protecting group is a useful intermediate for preparing a conjugate of the invention (e.g., a conjugate of formula (XIII)).
- Such a protected compound of formula (X) is an embodiment of the invention.
- a compound of formula (XII) wherein Y is protected with a protecting group is a useful intermediate for preparing a conjugate of the invention (e.g., a conjugate of formula (XIII)).
- Such a protected compound of formula (XIII) is an embodiment of the invention.
- Nomenclature pPB (N- to C- terminus) H2N-CSNLIDC-C00H (disulphide between two Cys).
- Biotinylated versions of ligands were prepared for in vitro binding experiments, to gauge relative binding efficiencies (see Example 6, 7 and 8).
- the following biotinylated ligands were prepared using standard solid phase peptide synthesis (SPPS). Biotin was coupled using standard organic chemistry amide coupling techniques and the final ligands were purified with reverse phase HPLC. Product confirmation was achieved with mass spectrometry and product purity determined by RPLC techniques.
- SPPS solid phase peptide synthesis
- pPB monovalent Biotin Compound 1). MW: Calc 1260.56. Found 1260.2. Purity (HPLC) >90%
- Example 2 Synthesis of peptide conjugated PEG 12 benzaldehydes
- the following pPB benzaldehyde ligands (18a and 18b) were synthesized to allow for conjugation to the endosome release polymer (27) once RAFT polymerization was completed.
- 18a+b pPB benzaldehyde ligands
- the endosome release polymer was synthesized using RAFT polymerization and terminated with a protected aminooxy functional group to allow for subsequent oxime conjugation to benzaldehyde peptide ligands (18a and 18b). Part 1) Synthesis of chain transfer agent tert-butyl ((6-cyano-6-methyl-9,15-dioxo-4-thioxo-
- Step 1 Removal of BOC from endosomal release polymer 25 1 ,044g of polymer was taken up in DCM (4 ml) and TF A (3 ,3ml) was added. The reaction was stirred at RT for 2 hr. The reaction was concentrated in-vacuo for 60 mins. The residual TFA salt was used in the subsequent conjugation step without additional processing.
- Step 2. Oxime conjugation. The residual material from the previous step was taken up in DCM (5 mL), 0.55 stoichiometric equivalents of the appropriate peptide benzaldehyde (18 a or b) added and the reaction stirred at RT for 72 hrs.
- ligands and corresponding siRNA conjugates were synthesized to assess in vitro (Example 10) and in vivo activity (Example 11) in conjunction with a targeting endosome release polymer (Example 3).
- Peptide ligands were first synthesized using standard solid phase peptide synthesis protocols, then functionalized with an appropriate conjugation motif (e.g mal eimide or DBCO) to facilitate coupling to the 3’ end of the sense strand of an siRNA molecule.
- the phosphate at the 3’ end of the siRNA was also accordingly modified for coupling to the ligand (e.g 3’ C6 amino or 3’ C6 sulfhydryl).
- Step 1 Synthesis of tert-butyl 3-(2-(2-(2-((methylsulfonyl)oxy)ethoxy)ethoxy)- ethoxy)propanoate tert-Butyl-3- ⁇ 2-[2-(2-hydroxyethoxy)ethoxy]ethoxy ⁇ propanoate (25 g, 90 mmol) and TEA (16.0 mL, 113 mmol were stirred in DCM at 0°C. Methanesulfonyl chloride (11.3 g, 99 mmol) in DCM was added dropwise and the reaction stirred at RT for 1.5 hr.
- Step 5 Synthesis of tert-butyl 3- ⁇ 2-[2-(2- ⁇ 3-[2-(2- ⁇ 2-[3-(tert-butoxy)-3-oxopropoxy]- ethoxy ⁇ ethoxy)ethoxy]-5-[(l,3-dioxoisoindol-2-yl)methyl]phenoxy ⁇ ethoxy)ethoxy]ethoxy ⁇ - propanoate
- Step 6 Synthesis of tert-butyl 3-[2-(2- ⁇ 2-[3-(aminomethyl)-5-[2-(2- ⁇ 2-[3-(tert- butoxy)-3-oxopropoxy] ethoxy ⁇ ethoxy)ethoxy] phenoxy] ethoxy ⁇ ethoxy)ethoxy] propanoate .
- Step 7 Synthesis of tert-butyl 3- ⁇ 2-[2-(2- ⁇ 3-[2-(2- ⁇ 2-[3-(tert-butoxy)-3- oxopropoxy]ethoxy ⁇ ethoxy)ethoxy]-5- ⁇ [3-(2,5-dioxopyrrol-l- yl)propanamido]methyl ⁇ phenoxy ⁇ ethoxy)ethoxy]ethoxy ⁇ propanoate tert-Butyl-3-[2-(2- ⁇ 2-[3-(aminomethyl)-5-[2-(2- ⁇ 2-[3-(tert-butoxy)-3- oxopropoxy] ethoxy ⁇ ethoxy)ethoxy]phenoxy] ethoxy ⁇ ethoxy)ethoxy]propanoate (7.71 g, 11.7 mmol), 2,5-dioxopyrrolidin-l-yl 3-(2,5-dioxopyrrol-l-yl)propanoate (3.1 g, 1
- Step 8 Synthesis of 3-[2-(2- ⁇ 2-[3-(2- ⁇ 2-[2-(2-carboxyethoxy)ethoxy]ethoxy ⁇ ethoxy)- 5- ⁇ [3-(2,5-dioxopyrrolidin-l- yl)propanamido] methyl ⁇ phenoxy] ethoxy ⁇ ethoxy)ethoxy] propanoic acid tert-butyl 3- ⁇ 2-[2-(2- ⁇ 3-[2-(2- ⁇ 2-[3-(tert-butoxy)-3-oxopropoxy]ethoxy(ethoxy)ethoxy]- 5- ⁇ [3-(2,5-dioxopyrrolidin-l-yl)propanamido]methyl(phenoxy(ethoxy)ethoxy]- ethoxy ⁇ propanoate (9.0 g, 11.1 mmol) was stirred in formic acid at RT for 16 hr.
- Step 9 Synthesis of 2,5-dioxopyrrolidin-l-yl 3-(2- ⁇ 2-[2-(3- ⁇ [3-(2,5-dioxopyrrol-l- yl)propanamido] methyl ⁇ -5- ⁇ 2- [2- (2- ⁇ 3- [(2,5-dioxopyrrohdin- l-yl)oxy] -3- oxopr opoxy ⁇ ethoxy)ethoxy] ethoxy ⁇ phenoxy)ethoxy] ethoxy ⁇ ethoxy)propanoate
- Trimeric pPB (compound 58) can be prepared according to the procedure described in the scheme above.
- Trimeric scrambled pPB (compound 59) can be prepared using an analogous procedure to that described for compound 58.
- Trimeric C6 pPB (compound 63) Trimeric C6 pPB (compound 63) can be prepared according to the procedure described in the scheme above.
- Trimeric C6 scrambled pPB (compound 64) Trimeric C6 scrambled pPB (compound 64) can be prepared using an analogous procedure to that described for compound 63 pPB conjugation and siRNA synthesis were conducted as described elsewhere to give trimeric pPB (compound 58), trimeric scrambled pPB (compound 59), trimeric C6 pPB (compound 63) and trimeric C6 scrambled pPB (compound 64)
- siRNA-ligand conjugates as illustrated in Example 3, were prepared using automated oligonucleotide synthesis using standard procedures. Nucleotide deprotection and cleavage from the solid support, afforded the 3’ modified sense strand and the corresponding and complementary anti-sense strand. After purification by dual HPLC, the ligand conjugated siRNA duplex was formed by annealing. Table 1 lists siRNA sequences, ID’s and mass analysis.
- HSC-T6 is an immortalized rat hepatic stellate cell line and NIH3T3 is a murine embryonic fibroblast cell line. Both cell lines express the pPB target receptor PDGFRB with NIH3T3 cells exhibiting higher expression (Fig 1). Preparation of biotin-pPB/AF488-streptavidin complex
- Biotinylated monovalent or trivalent pPB ligand were reconstituted in DMSO and functionalized by incubating with Alexa Fluor 488-labelled streptavidin in Tyrode buffer (containing 10 mM HEPES, 5.6 mM glucose, 10 mM KC1, 35 mM NaCl, 0.4 mM MgCl, 1.0 mM CaC12 and 0.1% BSA, pH 7.3) at 4°C overnight at a molar ratio of 4.5:1 of biotinylated ligands to biotin binding sites.
- Tyrode buffer containing 10 mM HEPES, 5.6 mM glucose, 10 mM KC1, 35 mM NaCl, 0.4 mM MgCl, 1.0 mM CaC12 and 0.1% BSA, pH 7.3
- HSC-T6 cells were cultured in rat HSC medium (DMEM-High Glucose without Sodium Pyrvate containing 10% FBS and 2.5 mM L-Glutamine).
- NIH3T3 cells were cultured in MEM containing 10% FBS and 2.5 mM L-Glutamine.
- HSC-T6 or NIH3T3 cells were seeded into sterile 96 wells plates (20000/well) and cultured for 48 h at 37 °C.
- the previous prepared biotin-pPB/AF488-streptavidin complex was diluted to 2.22, 0.556, 0.136, 0.035 and 0.009 pM (based on streptavidin molar concentration) in Tyrode buffer and was kept on ice. Prior to complex incubation, the cells were washed three times with ice cold Tyrode buffer and functionalized streptavidin was added to each well which was incubated at 4 °C for 1.5 h.
- the cells were washed three times with ice-cold Tyrode buffer to remove any unbound ligand complex, before adding 37 °C preheated complete media and immediately incubating the cells in 37 °C for 1 h to allow endocytosis of receptor bound ligand-complexes. After incubation, the cells were washed once with DPBS and 50 pL of 0.25% Trypsin-EDTA was added to each well. After incubation at 37 °C for 3-4min, 100 pL of media was added to each well to inactivate the trypsin, and detachment of cells was accomplished with vigorous mixing.
- the cells were transferred to a V-bottom 96-well plate, spun at 1200 RPM for 5 min, and washed twice with DPBS before resuspension in DPBS containing Live/Dead Red stain. After 30 min at 4 °C, the cells were centrifuged, and the pellet resuspended in stain buffer prior to flow cytometry analysis.
- Analyses were performed on a FACS-Canto II using the software FACS Diva. As a marker for viability, cells were stained with Live/Dead Red. The forward scatter and side scatter gate were set to include all viable cells.
- MFI mean fluorescence intensity
- MFI mean fluorescence intensity
- Example 7 Uptake of divalent and trivalent pPB ligands by primary human hepatic stellate cells in vitro.
- Biotinylated divalent, trivalent pPB or scrambled trivalent pPB ligands were reconstituted in DMSO and functionalized by incubating with Alexa Fluor 488-labelled streptavidin in Tyrode buffer (containing 10 mM HEPES, 5.6 mM glucose, 10 mM KC1, 35 mM NaCl, 0.4 mM MgCl, 1.0 mM CaC12 and 0.1% BSA, pH 7.3) at 4°C overnight at a molar ratio of 4.5: 1 of biotinylated ligands to biotin binding sites.
- Tyrode buffer containing 10 mM HEPES, 5.6 mM glucose, 10 mM KC1, 35 mM NaCl, 0.4 mM MgCl, 1.0 mM CaC12 and 0.1% BSA, pH 7.3
- Cell culture pHHSC were cultured using a human hepatic stellate cell culture kit from ScienCell.
- the cells were washed three times with ice-cold Tyrode buffer to remove any unbound ligand complex, before adding 37 °C preheated complete media and immediately incubating the cells in 37 °C for 1 h to allow endocytosis of receptor bound ligand-complexes. After incubation, the cells were washed once with DPBS and 50 pL of 0.025% Trypsin-EDTA was added to each well. After incubation at 37 °C for 3-4min, 100 pL of Trypsin Neutralization Solution (TNS) was added to each well to inactivate the trypsin, and detachment of cells was accomplished with vigorous mixing.
- TMS Trypsin Neutralization Solution
- the cells were transferred to a V-bottom 96-well plate, spun at 1200 RPM for 5 min, and washed twice with stain buffer before resuspension in stain buffer containing DAPI (4’,6-diamidino-2-phenylindole) prior to flow cytometry analysis.
- LX-2 is an immortalized human hepatic stellate cell line and NIH3T3 is a murine embryonic fibroblast cell line. All 3 cell lines express the pPB target receptor PDGFRB with NH43T3 cells exhibited highest expression (Fig 4). Materials and Methods
- Biotinylated trivalent pPB ligand was reconstituted in DMSO and functionalized by incubating with Alex Fluor 488-labelled streptavidin in Tyrode buffer (containing 10 mM HEPES, 5.6 mM glucose, 10 mM KC1, 35 mM NaCl, 0.4 mM MgCl, 1.0 mM CaC12 and 0.1% BSA, pH 7.3) at 4°C overnight at a molar ratio of 4.5: 1 of biotinylated ligands to biotin binding sites.
- Tyrode buffer containing 10 mM HEPES, 5.6 mM glucose, 10 mM KC1, 35 mM NaCl, 0.4 mM MgCl, 1.0 mM CaC12 and 0.1% BSA, pH 7.3
- LX-2 cells were cultured in DMEM-High Glucose containing 10% FBS and 2.5 mM L- Glutamine.
- NIH3T3 cells were cultured in MEM with containing 10% FBS and 2.5 mM L- Glutamine.
- pHHSC were cultured using the human hepatic stellate cell culture kit from ScienCell.
- LX-2, NIH3T3 or pHHSC cells were seeded into sterile 96 wells plates (20000/well) and cultured for 48 h at 37 °C.
- the previous prepared biotin-pPB/AF488-streptavidin complex was diluted to 3, 1, 0.3, and 0.1 pM (based on streptavidin molar concentration) in Tyrode buffer and was kept on ice. Prior to complex incubation, the cells were washed three times with ice cold Tyrode buffer and functionalized streptavidin was added to each well which was incubated at 4 °C for 1.5 h.
- the cells were washed three times with ice-cold Tyrode buffer to remove any unbound ligand complex, before adding 37 °C preheated complete media and immediately incubating the cells in 37 °C for 1 h to allow endocytosis of receptor bound ligandcomplexes.
- the cells were washed once with DPBS and 50 pL of 0.25% Trypsin-EDTA was added to each well.
- 100 pL of media was added to each well to inactivate the trypsin, and detachment of cells was accomplished with vigorous mixing.
- the cells were transferred to a V-bottom 96-well plate, spun at 1200 RPM for 5 min, and washed twice with stain buffer before resuspension in stain buffer containing DAPI prior to flow cytometry analysis.
- Example 9 Trivalent pPB Conjugate siRNA Enabled Gene Silencing in NIH3T3 Cells in Vitro when Treated Together with Chloroquine.
- PPIB is a widely expressed protein coding gene and was used as a surrogate siRNA target in this study.
- NIH3T3 cells express high levels of PDGFRB and exhibited the best pPB ligand uptake efficiency in the previous experiments.
- NH43T3 cells were cultured in MEM with containing 10% FBS and 2.5 mM L- Glutamine. Treatment of siRNAs in NIH3T3 cells
- NIH3T3 cells were seeded into sterile 96 wells plates (10000/well) and cultured for 24 h at 37 °C. Cells were then washed with 100 pL OptiMEM and then incubated with 0.4, 0.1 or 0.025 pM of TripPB-siPPIB, Tri-Scr-pPB-siPPIB, unconjugated siPPIB or siLuc2 in OptiMEM for 4 h. The siRNAs or conjugates were then removed, and the cells were treated with 50 pM of chloroquine in complete culture medium for another 20 h. Culture medium were removed after treatment completion and the cells were lysed with QuantiGene Lysis Mixture for next step gene expression quantification.
- cell lysates collected after siRNA treatment were subject to QuantiGene branched DNA assay according to the manufacturer’s protocol.
- cell lysates were incubated with capture probes targeting mPpib (target gene) and mGapdh (endogenous control) at 55 °C for 18-20 h. After washing, the plates were incubated with preamplification probes and amplification probes to amplify the signal. The excess probes were washed off and assay substrates added to allow quantifying luminescence using a plate reader. Ppib signal was normalized to the signal from Gapdh.
- the polymer was dissolved in 10 mM phosphate/200mM sucrose PBS (pH 7), up to 40 mg/mL followed by successive filtration (3-4 times) through a 0.2-micron sterile filter.
- Cell culture pHHSC were cultured using the human hepatic stellate cell culture kit from ScienCell.
- pHHSC cells were seeded into sterile 96 wells plates (5000/well) and cultured for 24 h at 37 °C. Cells were then washed with 100 pL OptiMEM and then treated with 0.3 or 0.1 pM of TripPB-siPPIB or unconjugated siPPIB in OptiMEM for 4 h. GalNAc or pPB functionalized ERP were then added to the culture at the concentration of 30 ug/mL.
- cells were supplemented with 10% FBS. Culture medium were removed at 72 h post siRNA treatment and the cells were lysed with QuantiGene Lysis Mixture for next step gene expression quantification.
- cell lysates collected after siRNA treatment were subject to QuantiGene branched DNA assay according to manufacturer’s protocol.
- cell lysates were incubated with capture probes targeting human PPIB (target gene) and GAPDH (endogenous control) at 55 °C for 18-20 h. After washing, the plates were incubated with preamplification probes and amplification probes to amplify the signal. The excessive probes were then washed off and assay substrates were added to allow quantifying luminescence using a plate reader. The signal from PPIB was normalized to the signal from GAPDH.
- pPB-ERP Improves in vivo Gene Silencing by TripPB siRNA Conjugate in Mouse Liver Fibrosis Model.
- HSC specific gene Hsp47 was selected as the siRNA target to allow evaluation of RNAi activity in the targeted cell population.
- mice were injected subcutaneously (SQ) in the scapular region with a single dose of vehicle control (saline), pPB-ERP alone (40 mg/kg), TripPB- siHsp47 (10 mg/kg) with pPB-ERP (40 mg/kg), unconjugated siHsp47 (10 mg/kg) with pPB- ERP (40 mg/kg), using a volume of 5 mL/kg body weight.
- SQ subcutaneously
- RNAlater fixed liver tissue was homogenized in Epicentre lysis buffer containing 1% proteinase K using the FastPrep®-24 homogenization instrument (4.0 m/s, 3 x 15 second bursts, MP Biomedicals). Samples were kept on ice both before and after the homogenization to prevent degradation. The lysates were cleared by centrifugation at 16,000 x at 16°C for 5 min and diluted in lysis working buffer to ensure all values would be in the assay linear range of detection before being subjected to bDNA assay using the Affymetrix QuantiGene 2.0 assay kit, according to the manufacturer’s protocol. The bDNA probes were specifically designed to target mouse Hsp47 and mouse Gapdh. The signal from Hsp47 was normalized to the signal from Gapdh. Results
- HSC specific gene Hsp47 was selected as the siRNA target to allow evaluation of RNAi activity in the targeted cell population.
- One day post the last dose of CC14 animals were injected subcutaneously in the scapular region with a single dose of vehicle control (saline), TripPB-siHsp47 (3 mg/kg), pPB-ERP alone (40 mg/kg) or TripPB-siHsp47 (3 mg/kg) with pPB-ERP at 12, 20 or 40 mg/kg, using a volume of 5 mL/kg body weight.
- vehicle control saline
- TripPB-siHsp47 3 mg/kg
- pPB-ERP TripPB-siHsp47
- TripPB-siHsp47 TripPB-siHsp47
- RNAlater fixed liver tissue was homogenized in Epicentre lysis buffer containing 1% proteinase K using the FastPrep®-24 homogenization instrument (4.0 m/s, 3 x 15 second bursts, MP Biomedicals). Samples were kept on ice both before and after the homogenization to prevent degradation. The lysates were cleared by centrifugation at 16,000*g at 16°C for 5 min and diluted in lysis working buffer to ensure all values would be in the assay linear range of detection before being subjected to bDNA assay using the Affymetrix QuantiGene 2.0 assay kit, according to the manufacturer’s protocol.
- the bDNA probes were specifically designed to target mouse Hsp47 and mouse Gapdh. The signal from Hsp47 was normalized to the signal from Gapdh.
- Example 13 Divalent pPB-siRNA Conjugates Showed Comparable Activity to TripPB siRNA Conjugate in Mouse Liver Fibrosis Model.
- This example illustrates the in vivo gene silencing mediated by divalent and trivalent pPB conjugate siRNA together with pPB-ERP in a CC14 induced mouse liver fibrosis model.
- HSC specific gene Hsp47 was selected as the siRNA target to allow evaluation of RNAi activity in the targeted cell population.
- One day post the last dose of CC14 animals were injected subcutaneously (SQ) in the scapular region with a single dose of vehicle control (saline), DipPB-siHsp47 (3 mg/kg) with pPB-ERP (40 mg/kg), or TripPB -siHsp47 (3 mg/kg) with pPB-ERP (40 mg/kg), using a volume of 5 mL/kg body weight.
- the livers of treated animals were collected two days post siRNA and ERP treatment and fixed with RNAlater for a minimum of 16 h at 4 °C. RNAi activity of siRNA conjugates was assessed by quantifying target gene expression using Quantigene assay.
- RNAlater fixed liver tissue was homogenized in Epicentre lysis buffer containing 1% proteinase K using the FastPrep®-24 homogenization instrument (4.0 m/s, 3 x 15 second bursts, MP Biomedicals). Samples were kept on ice both before and after the homogenization to prevent degradation. The lysates were cleared by centrifugation at 16,000 xg at 16°C for 5 min and diluted in lysis working buffer to ensure all values would be in the assay linear range of detection before being subjected to bDNA assay using the Affymetrix QuantiGene 2.0 assay kit, according to the manufacturer’s protocol.
- the bDNA probes were specifically designed to target mouse Hsp47 and mouse Gapdh. The signal from Hsp47 was normalized to the signal from Gapdh.
- Endosome release polymers (Mannose-ERP 40 and GalNAc-ERP 41) were synthesized by Syngene International LTD using synthetic methodology analogous to that described in Prieve, M.G., Harvie, P., Monahan, S.D., Roy, D., Li, A.G., Blevins, T.L., Paschal, A.E., Waldheim, M., Bell, E.C., Galperin, A., Ella-Menye, J.R., et al. (2018). Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency. Mol Ther 26, 801-813.
- Mannose-ERP 40 and GalNAc-ERP 41 are presented below.
Abstract
The invention provides conjugates for the targeted delivery of therapeutic agents to PDGFR expressing cells for the treatment of a disease involving these cells (e.g., liver fibrosis, non-alcoholic steatohepatitis (NASH), clear cell renal cell carcinoma, kidney fibrosis, or alcoholic steatohepatitis (ASH)).
Description
TARGETED COMPOSITIONS
PRIORITY
This application claims priority to United States Provisional Application Number 63/405,697 that was filed on September 12, 2022. The entire content of the applications referenced above is hereby incorporated by reference herein.
BACKGROUND
Liver fibrosis is caused by excessive accumulation of extracellular matrix during chronic liver injuries. Activation of hepatic stellate cells (HSCs) is a key step during liver fibrogenesis. Targeted delivery of therapeutic agents to HSCs, e.g., activated HSCs, may be important for the successful treatment of diseases of the liver and/or diseases of the kidney (e.g., liver fibrosis, non-alcoholic steatohepatitis (NASH), kidney fibrosis, or alcoholic steatohepatitis (ASH)). Accordingly, means of delivering therapeutics to HSCs are needed.
BRIEF SUMMARY
The invention provides compounds, compositions and methods that can be used to target oligonucleotides to platelet derived growth factor receptor (PDGFR) expressing cells.
In one aspect this invention provides a compound of formula (I)
(R1)x - L— (R2)y
(I) or a salt thereof, wherein: x is 2, 3, 4 or 5; each R1 is independently a targeting ligand, which is selected from: a) a cyclic polypeptide depicted by SEQ ID NO: 1 :C*SRNLIDC* (SEQ ID NO: 1), wherein * denotes a disulfide bond linking the two C residues to thereby form the cyclic polypeptide, and b) any cyclic polypeptide having at least 80% sequence identity (e.g., at least 85%; e.g., at least 87.5%; e.g., at least 90%; e.g., at least 95%; e.g., at least 99% sequence identity) with the polypeptide depicted by SEQ ID NO: 1, under the proviso that both C* residues are present, and wherein * denotes a disulfide bond linking the two C residues to thereby form the cyclic polypeptide;
L is a linking group; y is 1, 2, 3, 4 or 5; and each R2 is independently an oligonucleotide, a label (e.g., a label derivable from fluorescein isothiocyanate (FITC) or Cy5), a phenyl group that is substituted with a formyl (-CHO) group, or a group of formula:
In another aspect, the invention provides a process for preparation of a diblock polymer of the following formula (X): [Block A] - [Block B]
(X) comprising: a) contacting a compound of structure Va, Vb, Vc, or Vd
wherein R27 is (Ci-Ci2)alkyl,
wherein R28 is (Ci-Ci2)alkyl,
wherein R25 and R26 are independently H, (Ci-Ci2)alkyl, aryl, or heteroaryl,
with one or more A monomers selected from the group consisting of: a polyethyleneglycol methacrylate with 2-20 ethylene glycol units (PEGMA); a (C4-Cis)alkyl-methacrylate; a (C4-Cis)branched alkyl-methacrylate; a cholesteryl methacrylate; a (C4-Cis)alkyl-methacrylate substituted with one or more fluorine atoms; and
a (C4-Cis)branched alkyl-methacrylate substituted with one or more fluorine atoms; in the presence of a free radical to provide a first product; b) contacting the first product with one or more B mon omers of formulae B 1, B2 and B3
in the presence of a free radical to provide a second product, and c) optionally contacting the second product with a free radical source (e.g.,
AIBN) to remove the chain transfer agent and provide the diblock polymer of formula (X); wherein:
Block A comprises one or more residues of A monomers and has a molecular weight of from about 1 kDa to about 25 kDa;
Block B comprises one or more residues of monomers Bl, B2, and B3 and has a molecular weight of from about 1 kDa to about 25 kDa.
Li is a linking moiety;
Z is a functional group that is optionally protected with a protecting group and is capable of reacting with Y of a compound of formula (XII):
T-L2-Y (XII) to form a conjugate wherein:
T is a ligand (optionally targeting ligand);
Y is a functional group that is capable of reacting with Z to form a conjugate; and L2 is absent or is a linking moiety.
In another aspect, the invention provides a compound of formula (I)
(R1)x— L— (R2)y
(I) or a salt thereof, wherein: x is 1, 2, 3, 4 or 5; each R1 is independently a targeting ligand, which is selected from a) a cyclic polypeptide depicted by SEQ ID NO: 1 :C*SRNLIDC* (SEQ ID NO: 1), wherein * denotes a disulfide bond linking the two C residues to thereby form the cyclic polypeptide, b) any cyclic polypeptide having at least 80 % sequence identity (e.g., at least 85%; e.g., at least 87.5%; e.g., at least 90%; e.g., at least 95%; e.g., at least 99% sequence identity) with the polypeptide depicted by SEQ ID NO: 1, under the proviso that both C* residues are present, and wherein * denotes a disulfide bond linking the two C residues to thereby form the cyclic polypeptide;
L is a linking group; and y is 1, 2, 3, 4 or 5; and each R2 is independently an endosomal release polymer.
The invention also provides synthetic intermediates and methods disclosed herein that are useful to prepare compounds of the formula I and formula XI.
Other objects, features, and advantages of the present invention will be apparent to one of skill in the art from the following detailed description and figures.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1. Western blot detection of PDGFRB expression in HSC-T6 and NH43T3 cells
Figure 2. Uptake of monovalent or trivalent pPB ligand-biotin-AF488-streptavidin complex by HSC-T6 and NIH3T3 cells as analyzed by flow cytometry.
Figure 3. Uptake of divalent or trivalent pPB ligand-biotin-AF488-streptavidin complex by pHHSCs as analyzed by flow cytometry.
Figure 4. Western blot detection of PDGFRB expression in LX-2, pHHSC and NIH3T3 cells
Figure 5. Uptake of trivalent pPB ligand-biotin-AF488-streptavidin complex by LX-2, NH43T3 and primary human HSC as analyzed by flow cytometry.
Figure 6. In vitro gene silencing by TripPB siRNA conjugates and chloroquine in NH43T3 cell.
Figure 7. In vitro gene silencing by TripPB siRNA conjugates and pPB-ERP in pHHSC.
Figure 8. In vivo gene silencing by TripPB siRNA conjugates and pPB-ERP in mouse liver fibrosis model.
Figure 9. Dose response of pPB-ERP when co-treated with TripPB-siRNA conjugate in mouse liver fibrosis model.
Figure 10. In vivo gene silencing by DipPB and TripPB siRNA conjugates and pPB-ERP in mouse liver fibrosis model.
In the application, including Figures, Examples and Schemes, it is to be understood that an oligonucleotide can be, but is not limited to, a double stranded siRNA molecule.
DETAILED DESCRIPTION
GalN Ac-conjugated short interfering RNA’s (siRNA) are a modality for mediating RNA interference (RNAi) in hepatocytes. They comprise two important components; a GalNAc targeting ligand, which binds to the asialoglycoprotein receptor (ASGPr) found on the surface of hepatocytes to mediate uptake, and the siRNA oligonucleotide, that once delivered to the cytoplasm of hepatocytes can mediate destruction of specific mRNA sequences (determined by the sequence of the siRNA) to reduce expression of the associated protein product.
While siRNA delivery to hepatocytes has been demonstrated with this class of therapeutics, successful application to other cell types has been more problematic. Suitable receptors must be identified, which are expressed relatively selectively on the target cell surface and in sufficient numbers. Then, appropriate ligands must be identified that bind with high specificity and affinity to the target receptor. A significant third hurdle is endosomal escape; when bound to a receptor, the ligand conjugate is taken up by the cell and entrapped in an endosome, from which it must escape to reach the cytoplasm. Despite lacking an active endosomal escape mechanism, GalNAc conjugates appear to mediate activity regardless, possibly because the receptor is so abundantly expressed and quickly recycled (~15 minutes) following uptake. The sheer number of conjugate molecules taken up by hepatocytes may obviate the need for an active endosomal escape. This has not been true for other ligand-based siRNA conjugate systems.
Hepatic stellate cells (HSC) play a key role in the progression of fibrosis: In response to chronic liver damage, they become activated, and are largely responsible for collagen deposition and scarring of the liver. A variety of genes are involved and are validated targets for treatment, including RNAi strategies. As described herein, siRNA conjugates have been synthesized to target HSC via platelet-derived growth factor receptor (PDGFR) using a cyclic octapeptide motif. In particular, as described herein, trivalent presentation of a pPB ligand outperforms monovalent presentation for binding and uptake. Gene silencing experiments also demonstrated that trivalent ligand structures are particularly effective, e.g., when compared to mono and divalent conjugates.
The invention also provides pPB conjugates of an endosome release polymer (ERP), the conjugate also being referred to as pPB-ERP. The inventors have found that for the pPB-ERP, monovalency is sufficient, i.e. one ERP moiety being bound to one pPB moiety, optionally via a linker. The terms “endosome release polymer” (ERT) and “diblock polymer” are used interchangeably herein. In particular embodiments, the specific ERT as provided by the present invention, optionally characterized by presence of a functional group Z or alternatively by presence of a moiety T-L2-Y’-X’ as described herein, is obtainable by the process according to the present invention. In particular embodiments, the ERT according to the present invention is conjugated to a specific ligand T, such as e.g. specific targeting ligand, as described herein.
The inventors designed a new process for preparing respectively conjugated ERP, i.e. pPB-ERP. Design of the new process became necessary since previously known processes for preparing ERP, such as with other ligands including N-acetyl glucosamine, proved to be neither resource friendly nor technically applicable to ligands such as pPB. pPB, as well as certain other ligands described herein, such as other polypeptides, whether cyclic or not, are as such not tolerant or inert to RAFT polymerization as used in the prior art. Also, the process according to the present invention is significantly more cost-effective for expensive ligands such as polypeptides, including pPB and derivatives thereof, as a result of the ligand being conjugated in the last step of the process.
The present invention also provides methods for using one or more pPB conjugates of the present invention, such as pPB-siRNA according to the invention, pPB-ERP according to the invention, alone and/or in combination, in the treatment of one or more diseases of a human or an animal, preferably a human.
In certain embodiments, the disease is a liver disease.
In certain embodiments, the disease is a kidney disease.
In certain embodiments, the disease is liver fibrosis.
In certain embodiments, the disease is non-alcoholic steatohepatitis (NASH)
In certain embodiments, the disease is kidney fibrosis.
In certain embodiments, the disease is clear cell renal cell carcinoma.
In certain embodiments, the disease is alcoholic steatohepatitis (ASH)
Also provided is a method of delivering a therapeutic agent to a hepatic stellate cell (HSC), in vivo or in vitro, comprising contacting the HSC with a conjugate as described herein.
Liver fibrosis is caused by excessive accumulation of extracellular matrix during chronic liver injuries. Activation of hepatic stellate cells (HSCs) is a key step during liver fibrogenesis. Targeted delivery of therapeutic agents to HSCs, e.g., activated HSCs, may be important for the successful treatment of liver fibrosis. A number of protein markers have been found to be
overexpressed in activated HSCs, and their ligands have been used to specifically deliver various antifibrotic agents, (see, e.g., Chen et al., Journal of Pharmacology and Experimental Therapeutics, 2019, 370 (3) 695-702). However, delivery of therapeutics using other systems is needed as other means for delivering therapeutic agents to HSCs.
Liver fibrosis is caused by the formation of an abnormally large amount of scar tissue in the liver. Liver fibrosis occurs when the liver attempts to repair and replace damaged cells. Various disorders and drugs can damage the liver and cause fibrosis.
Nonalcoholic fatty liver disease (NAFLD) is a condition in which triglycerides accumulate in the liver. Nonalcoholic steatohepatitis (NASH) is a type of NAFLD. NASH is associated with inflammatory changes and liver cell damage. NASH is a leading cause of liver disease and often progresses to liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC). Non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH) have a similar pathogenesis and histopathology but a different etiology and epidemiology. NASH and ASH are advanced stages of non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD). Alcoholic steatohepatitis (ASH) is a chronic, progressive liver disease characterized by fibrosis of the liver as well as possible necrosis of the liver tissue, brought on by excessive, prolonged alcohol use. Women are more susceptible to the disease because alcohol metabolism is lower in women than in men.
Liver fibrosis is an important underlying cause of liver dysfunction and predicts mortality. Progression to cirrhosis and HCC leads to ultimate liver failure and thus liver transplantation is required. The current US prevalence of NASH-related fibrosis (F2 and later) is about 3.8 million patients. Doctors typically recommend weight loss to treat NAFLD and NASH. While weight loss can reduce fat in the liver, inflammation, and fibrosis, no medicines have been approved to treat NAFLD and NASH. Specifically, no medicines have been approved to treat liver fibrosis. (Clin Liver Dis. 2008 Nov;12(4):733-46, N Engl J Med. 2017 Nov 23;377(21):2063-2072, J Hepatol. 2017 Dec;67(6): 1265-127) Accordingly, new therapeutic treatment options, including delivery options, are needed for the treatment of liver fibrosis, e.g., in the context of NASH or ASH.
As used herein, the following terms have the meanings ascribed to them unless specified otherwise.
The term “conjugate” as used herein includes compounds of formula (I) that comprise an oligonucleotide (e.g., an siRNA molecule) linked to a targeting ligand. Thus, the terms compound and conjugate may be used herein interchangeably.
The term “small -interfering RNA” or “siRNA” as used herein refers to double stranded
RNA (i.e., duplex RNA) that is capable of reducing or inhibiting the expression of a target gene
or sequence (e.g., by mediating the degradation or inhibiting the translation of mRNAs which are complementary to the siRNA sequence) when the siRNA is in the same cell as the target gene or sequence. The siRNA may have substantial or complete identity to the target gene or sequence, or may comprise a region of mismatch (i.e., a mismatch motif). In certain embodiments, the siRNAs may be about 19-25 (duplex) nucleotides in length, and are preferably about 20-24, 21-22, or 21-23 (duplex) nucleotides in length. siRNA duplexes may comprise 3’ overhangs of about 1 to about 5 nucleotides or about 2 to about 3 nucleotides and 5’ phosphate termini. Examples of siRNA include, without limitation, a double-stranded polynucleotide molecule assembled from two separate stranded molecules, wherein one strand is the sense strand and the other is the complementary antisense strand.
In certain embodiments, the 5' and/or 3' overhang on one or both strands of the siRNA comprises 1-5 (e.g., 1, 2, 3, 4 or 5) modified and/or unmodified deoxythymidine (t or dT) nucleotides, 1-5 (e.g., 1, 2, 3, 4 or 5) modified (e.g., 2'0Me) and/or unmodified uridine (U) ribonucleotides, and/or 1-5 (e.g., 1, 2, 3, 4 or 5) modified (e.g., 2'0Me) and/or unmodified ribonucleotides or deoxyribonucleotides having complementarity to the target sequence (e.g., 3'overhang in the antisense strand) or the complementary strand thereof (e.g., 3' overhang in the sense strand).
Preferably, siRNAs are chemically synthesized. siRNA can also be generated by cleavage of longer dsRNA (e.g., dsRNA greater than about 25 nucleotides in length) with the E. coll RNase III or Dicer. These enzymes process the dsRNA into biologically active siRNA (see, e.g., Yang et al. , Proc. Natl. Acad. Sci. USA, 99:9942-9947 (2002); Calegari et al. , Proc. Natl. Acad. Sci. USA, 99: 14236 (2002); Byrom et al., Ambion TechNotes, 10(l):4-6 (2003); Kawasaki et al., Nucleic Acids Res., 31 :981-987 (2003); Knight et al., Science, 293:2269-2271 (2001); and Robertson et al., J. Biol. Chem., 243:82 (1968)). Preferably, dsRNAs are at least 50 nucleotides to about 100, 200, 300, 400, or 500 nucleotides in length. A dsRNA may be as long as 1000, 1500, 2000, 5000 nucleotides in length, or longer. The dsRNA can encode for an entire gene transcript or a partial gene transcript. In certain instances, siRNA may be encoded by a plasmid (e.g., transcribed as sequences that automatically fold into duplexes with hairpin loops).
The phrase “inhibiting expression of a target gene” refers to the ability of a siRNA of the invention to silence, reduce, or inhibit the expression of a target gene. To examine the extent of gene silencing, a test sample (e.g., a biological sample from an organism of interest expressing the target gene or a sample of cells in culture expressing the target gene) is contacted with a siRNA that silences, reduces, or inhibits expression of the target gene. Expression of the target gene in the test sample is compared to expression of the target gene in a control sample (e.g., a biological sample from an organism of interest expressing the target gene or a sample of cells in
culture expressing the target gene) that is not contacted with the siRNA. Control samples (e.g., samples expressing the target gene) may be assigned a value of 100%. In particular embodiments, silencing, inhibition, or reduction of expression of a target gene is achieved when the value of the test sample relative to the control sample (e.g., buffer only, an siRNA sequence that targets a different gene, a scrambled siRNA sequence, etc.} is about 100%, 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or 0%. Suitable assays include, without limitation, examination of protein or mRNA levels using techniques known to those of skill in the art, such as, e.g., dot blots, Northern blots, in situ hybridization, ELISA, immunoprecipitation, enzyme function, as well as phenotypic assays known to those of skill in the art.
The term “synthetic activating group” refers to a group that can be attached to an atom to activate that atom to allow it to form a covalent bond with another reactive group. It is understood that the nature of the synthetic activating group may depend on the atom that it is activating. For example, when the synthetic activating group is attached to an oxygen atom, the synthetic activating group is a group that will activate that oxygen atom to form a bond (e.g. an ester, carbamate, or ether bond) with another reactive group. Such synthetic activating groups are known. Examples of synthetic activating groups that can be attached to an oxygen atom include, but are not limited to, acetate, succinate, triflate, and mesylate. When the synthetic activating group is attached to an oxygen atom of a carboxylic acid, the synthetic activating group can be a group that is derivable from a known coupling reagent (e.g. a known amide coupling reagent). Such coupling reagents are known. Examples of such coupling reagents include, but are not limited to, N,N’-Dicyclohexylcarbodimide (DCC), hydroxybenzotriazole (HOBt), N-(3-Dimethylaminopropyl)-N’ -ethylcarbonate (EDC), (Benzotriazol- 1- yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP), benzotriazol-l-yl- oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) or O-benzotriazol-l-yl- N,N,N’,N’-tetramethyluronium hexafluorophosphate (HBTU).
An “effective amount” or “therapeutically effective amount” of a therapeutic nucleic acid such as siRNA is an amount sufficient to produce the desired effect, e.g., an inhibition of expression of a target sequence in comparison to the normal expression level detected in the absence of a siRNA. In particular embodiments, inhibition of expression of a target gene or target sequence is achieved when the value obtained with a siRNA relative to the control (e.g., buffer only, an siRNA sequence that targets a different gene, a scrambled siRNA sequence, etc. is about 100%, 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 70%, 65%, 60%, 55%,
50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, or 0%. Suitable assays for measuring the expression of a target gene or target sequence include, but are not limited to, examination of protein or mRNA levels using techniques known to those of skill in the art, such as, e.g., dot blots, Northern blots, in situ hybridization, ELISA, immunoprecipitation, enzyme function, as well as phenotypic assays known to those of skill in the art.
The term “nucleic acid” as used herein refers to a polymer containing at least two nucleotides (/.< ., deoxyribonucleotides or ribonucleotides) in either single- or double-stranded form and includes DNA and RNA. “Nucleotides” contain a sugar deoxyribose (DNA) or ribose (RNA), a base, and a phosphate group. Nucleotides are linked together through the phosphate groups. “Bases” include purines and pyrimidines, which further include natural compounds adenine, thymine, guanine, cytosine, uracil, inosine, and natural analogs, and synthetic derivatives of purines and pyrimidines, which include, but are not limited to, modifications which place new reactive groups such as, but not limited to, amines, alcohols, thiols, carboxylates, and alkylhalides. Nucleic acids include nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, and which have similar binding properties as the reference nucleic acid. Examples of such analogs and/or modified residues include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2’-O- methyl ribonucleotides, and peptide-nucleic acids (PNAs). Additionally, nucleic acids can include one or more UNA moieties.
The term “oligonucleotide” includes nucleotides containing up to about 60 nucleotides. A deoxyribooligonucleotide consists of a 5-carbon sugar called deoxyribose joined covalently to phosphate at the 5’ and 3’ carbons of this sugar to form an alternating, unbranched polymer. A ribooligonucleotide consists of a similar repeating structure where the 5-carbon sugar is ribose. RNA may be in the form, for example, of small interfering RNA (siRNA), Dicer-substrate dsRNA, small hairpin RNA (shRNA), small activating RNA (saRNA), asymmetrical interfering RNA (aiRNA), microRNA (miRNA), tRNA, rRNA, tRNA, viral RNA (vRNA). Accordingly, the term “oligonucleotide” refers to a polymer or oligomer of nucleotide or nucleoside monomers consisting of naturally-occurring bases, sugars and intersugar (backbone) linkages. The term “oligonucleotide” also includes polymers or oligomers comprising non-naturally occurring monomers, or portions thereof. Such modified or substituted oligonucleotides may have properties, for example, of enhanced cellular uptake, reduced immunogenicity and/or increased stability in the presence of nucleases.
The term “gene” refers to a nucleic acid e.g., DNA or RNA) sequence that comprises partial length or entire length coding sequences necessary for the production of a polypeptide or precursor polypeptide.
“Gene product,” as used herein, refers to a product of a gene such as an RNA transcript or a polypeptide.
As used herein, the term “label” includes groups that enable the compound to be detected in vitro or in vivo. The term “labelling agent” is used interchangeably with the term label. Without limitation, a label may be selected from the group comprising a fluorophore, a chromophore, and a radionucleotide. In one embodiment, the label can be detected by spectroscopy. In one embodiment, the label can be detected by fluorescence spectroscopy. In one embodiment, the label is a group that is derivable from fluorescein isothiocyanate (FITC) or Cy5. In one embodiment, a label can be detected by an apparatus suitable for detecting any one or more of alpha, beta particles, gamma rays, and x rays.
As used herein, the term "alkyl", by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain hydrocarbon radical, having the number of carbon atoms designated (i.e., Ci-s means one to eight carbons). Examples of alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n-pentyl, n-hexyl, n- heptyl, n-octyl, and the like. The term "alkenyl" refers to an unsaturated alkyl radical having one or more double bonds. Similarly, the term "alkynyl" refers to an unsaturated alkyl radical having one or more triple bonds. Examples of such unsaturated alkyl groups include vinyl, 2- propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(l,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers.
The term "alkylene" by itself or as part of another substituent means a divalent radical derived from an alkane (including straight and branched alkanes), as exemplified by -CH2CH2CH2CH2- and -CH(CH3)CH2CH2-.
The term "cycloalkyl," "carbocyclic," or "carbocycle" refers to hydrocarbon ringsystem having 3 to 20 overall number of ring atoms (e.g., 3-20 membered cycloalkyl is a cycloalkyl with 3 to 20 ring atoms, or C3-20 cycloalkyl is a cycloalkyl with 3-20 carbon ring atoms) and for a 3-5 membered cycloalkyl being fully saturated or having no more than one double bond between ring vertices and for a 6 membered cycloalkyl or larger being fully saturated or having no more than two double bonds between ring vertices. As used herein, "cycloalkyl," "carbocyclic," or "carbocycle" is also meant to refer to bicyclic, polycyclic and spirocyclic hydrocarbon ring systems, such as, for example, bicyclo[2.2.1]heptane, pinane, bicyclo[2.2.2]octane, adamantane, norbornene, spirocyclic C5-12 alkane, etc. As used herein, the
terms, "alkenyl," "alkynyl," "cycloalkyl,", "carbocycle," and "carbocyclic," are meant to include mono and polyhalogenated variants thereof.
The term "heterocycloalkyl," "heterocyclic," or "heterocycle" refers to a saturated or partially unsaturated ring system radical having from 3-20 ring atoms (e.g., 3-20 membered heterocycloalkyl is a heterocycloalkyl radical with 3-20 ring atoms, a C2-19 heterocycloalkyl is a heterocycloalkyl having 3-10 ring atoms with between 2-19 ring atoms being carbon) that contain from one to ten heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, nitrogen atom(s) are optionally quaternized, as ring atoms. Unless otherwise stated, a "heterocycloalkyl," "heterocyclic," or "heterocycle" ring can be a monocyclic, a bicyclic, spirocyclic or a polycylic ring system. Non limiting examples of "heterocycloalkyl," "heterocyclic," or "heterocycle" rings include pyrrolidine, piperidine, N- methylpiperidine, imidazolidine, pyrazolidine, butyrolactam, valerolactam, imidazolidinone, hydantoin, dioxolane, phthalimide, piperidine, pyrimidine-2,4(lH,3H)-dione, 1,4-di oxane, morpholine, thiomorpholine, thiomorpholine-S-oxide, thiomorpholine-S,S-oxide, piperazine, pyran, pyridone, 3 -pyrroline, thiopyran, pyrone, tetrahydrofuran, tetrhydrothiophene, quinuclidine, tropane, 2-azaspiro[3.3]heptane, (lR,5S)-3-azabicyclo[3.2.1]octane, (ls,4s)-2- azabicyclo[2.2.2]octane, (lR,4R)-2-oxa-5-azabicyclo[2.2.2]octane and the like A "heterocycloalkyl," "heterocyclic," or "heterocycle" group can be attached to the remainder of the molecule through one or more ring carbons or heteroatoms. A "heterocycloalkyl," "heterocyclic," or "heterocycle" can include mono- and poly-halogenated variants thereof.
The terms "alkoxy," and “alkylthio”, are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom (“oxy”) or thio grou, and further include mono- and poly -halogenated variants thereof.
The terms "halo" or "halogen," by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. The term “(halo)alkyl” is meant to include both a “alkyl” and “haloalkyl” substituent. Additionally, the term "haloalkyl," is meant to include monohaloalkyl and polyhaloalkyl. For example, the term "Ci-4 haloalkyl" is mean to include trifluoromethyl, 2,2,2-trifluoroethyl, 4 -chlorobutyl, 3 -bromopropyl, difluoromethyl, and the like.
The term "aryl" means a carbocyclic aromatic group having 6-14 carbon atoms, whether or not fused to one or more groups. Examples of aryl groups include phenyl, naphthyl, biphenyl and the like unless otherwise stated.
The term "heteroaryl" refers to aryl ring(s) that contain from one to five heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. A heteroaryl group can be attached to the
remainder of the molecule through a heteroatom. Examples of heteroaryl groups include pyridyl, pyridazinyl, pyrazinyl, pyrimindinyl, triazinyl, quinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalaziniyl, benzotriazinyl, purinyl, benzimidazolyl, benzopyrazolyl, benzotriazolyl, benzisoxazolyl, isobenzofuryl, isoindolyl, indolizinyl, benzotriazinyl, thienopyridinyl, thienopyrimidinyl, pyrazolopyrimidinyl, imidazopyridines, benzothiaxolyl, benzofuranyl, benzothienyl, indolyl, quinolyl, isoquinolyl, isothiazolyl, pyrazolyl, indazolyl, pteridinyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiadiazolyl, pyrrolyl, thiazolyl, furyl, thienyl and the like.
The term “animal” includes mammalian species, such as a human, mouse, rat, dog, cat, hamster, guinea pig, rabbit, livestock, and the like.
The term “alkylamino” includes a group of formula -N(H)R, wherein R is an alkyl as defined herein.
The term “dialkylamino” includes a group of formula -NR2, wherein each R is independently an alkyl as defined herein.
The term “salts” includes any anionic and cationic complex, such as the complex formed between a cationic lipid and one or more anions. Non-limiting examples of anions include inorganic and organic anions, e.g., hydride, fluoride, chloride, bromide, iodide, oxalate (e.g., hemioxalate), phosphate, phosphonate, hydrogen phosphate, dihydrogen phosphate, oxide, carbonate, bicarbonate, nitrate, nitrite, nitride, bisulfite, sulfide, sulfite, bisulfate, sulfate, thiosulfate, hydrogen sulfate, borate, formate, acetate, benzoate, citrate, tartrate, lactate, acrylate, polyacrylate, fumarate, maleate, itaconate, glycolate, gluconate, malate, mandelate, tiglate, ascorbate, salicylate, polymethacrylate, perchlorate, chlorate, chlorite, hypochlorite, bromate, hypobromite, iodate, an alkyl sulfonate, an aryl sulfonate, arsenate, arsenite, chromate, dichromate, cyanide, cyanate, thiocyanate, hydroxide, peroxide, permanganate, and mixtures thereof. In particular embodiments, the salts of the cationic lipids disclosed herein are crystalline salts.
The term “acyl” includes any alkyl, alkenyl, or alkynyl wherein the carbon at the point of attachment is substituted with an oxo group, as defined below. The following are non-limiting examples of acyl groups: -C(=O)alkyl, -C(=O)alkenyl, and -C(=O)alkynyl.
It will be appreciated by those skilled in the art that compounds of the invention having a chiral center may exist in and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of
the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase.
When a bond in a compound formula herein is drawn in a non-stereochemical manner (e.g. flat), the atom to which the bond is attached includes all stereochemical possibilities. Unless otherwise specifically noted, when a bond in a compound formula herein is drawn in a defined stereochemical manner (e.g. bold, bold-wedge, dashed or dashed-wedge), it is to be understood that the atom to which the stereochemical bond is attached is enriched in the absolute stereoisomer depicted. In one embodiment, the compound may be at least 51% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 60% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 80% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 90% the absolute stereoisomer depicted. In another embodiment, the compound may be at least 95 the absolute stereoisomer depicted. In another embodiment, the compound may be at least 99% the absolute stereoisomer depicted.
The term "peptide" as used herein comprises oligo- and polypeptides and refers to substances comprising two or more, preferably 3 or more, preferably 4 or more, preferably 6 or more, such as 8 or more amino acids joined covalently by peptide bonds. A peptide may include natural amino acids and non-natural amino acids, such as D-amino acids. In one embodiment, a peptide merely includes natural amino acids. In one embodiment, all amino acids in a peptide are L-amino acids. A peptide consisting of amino acids may also be referred to as “polypeptide”, e.g. a polypeptide having 6 to 10 amino acid residues, such as 7 to 9 amino acid residues, and preferably about 8 amino acid residues,
As used herein, a "cyclic peptide" or “cyclized peptide” refers to a peptide or polypeptide chain which forms a ring, preferably to a peptide or polypeptide having an intramolecular bond between two non-adjacent amino acids within a peptide. The intramolecular bond may be selected without limitation from the group consisting of (i) backbone to backbone (i.e. peptide bond), (ii) side-chain to backbone and (iii) side-chain to side-chain cycle formation. A cyclic peptide of the invention may comprise a linking group resulting from any of the foregoing, such as e.g. a peptide bond in case of backbone to backbone cyclization and e.g. disulfide bonds resulting from two residues containing thiol groups, such as cysteines which can form intramolecular disulfide bridges giving cyclic peptides.
As used herein, the term "percentage identity" refers to a percentage of amino acid residues which are identical between the two sequences to be compared, obtained after the best alignment of two sequences over their entire length. Sequence comparisons, for purposes of determining the percentage of sequence identity, between two amino acid sequences are
typically carried out by comparing these sequences after having aligned them optimally, said comparison being carried out by segment or by "window of comparison" in order to identify and compare local regions of sequence similarity. The optimal alignment of the sequences for comparison may be produced by means of the local homology algorithm of Smith and Waterman, 1981, Ads App. Math. 2, 482, by means of the local homology algorithm of Needleman and Wunsch, 1970, J. Mol. Biol. 48, 443, by means of the similarity search method of Pearson and Lipman, 1988, Proc. Natl Acad. Sci. USA 85. 2444, or by means of computer programs which use these algorithms (GAP. BESTFIT, FASTA. BLAST P, BLAST N and TFASTA in Wisconsin Genetics Software Package, Genetics Computer Group. 575 Science Drive, Madison, Wis.). Alternatively, two sequences may be aligned manually; this is convenient e.g. for short polypeptide sequences of e.g. 10 amino acid residues or less. The "percentage identity" is calculated as follows: number of identical positions between the two sequences being aligned and compared, divided by the number of positions compared, multiplied the result obtained by 100, thereby obtaining the percentage identity between these two sequences.
Unless stated otherwise herein, the term “about”, when used in connection with a value or range of values, means plus or minus 5% of the stated value or range of values.
Generating siRNA Molecules siRNA can be provided in several forms including, e.g., as one or more isolated smallinterfering RNA (siRNA) duplexes, as longer double-stranded RNA (dsRNA), or as siRNA or dsRNA transcribed from a transcriptional cassette in a DNA plasmid. In some embodiments, siRNA may be produced enzymatically or by partial/total organic synthesis, and modified ribonucleotides can be introduced by in vitro enzymatic or organic synthesis. In certain instances, each strand is prepared chemically. Methods of synthesizing RNA molecules are known in the art, e.g., the chemical synthesis methods as described in Verma and Eckstein (1998) or as described herein.
Methods for isolating RNA, synthesizing RNA, hybridizing nucleic acids, making and screening cDNA libraries, and performing PCR are well known in the art (see, e.g., Gubler and Hoffman, Gene, 25:263-269 (1983); Sambrook et al., supra, Ausubel et al., supra), as are PCR methods (see, U.S. Patent Nos. 4,683,195 and 4,683,202; PCR Protocols: A Guide to Methods and Applications (Innis et al., eds, 1990)). Expression libraries are also well known to those of skill in the art. Additional basic texts disclosing the general methods of use in this invention include Sambrook et al., Molecular Cloning, A Laboratory Manual (2nd ed. 1989); Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); and Current Protocols in
Molecular Biology (Ausubel el al., eds., 1994). The disclosures of these references are herein incorporated by reference in their entirety for all purposes.
Typically, siRNAs are chemically synthesized. The oligonucleotides that comprise the siRNA molecules of the invention can be synthesized using any of a variety of techniques known in the art, such as those described in Usman et al., J. Am. Chem. Soc., 109:7845 (1987); Scaringe et al., Nucl. Acids Res., 18:5433 (1990); Wincott et al., Nucl. Acids Res., 23:2677-2684 (1995); and Wincott et al., Methods Mol. Bio., 74:59 (1997). The synthesis of oligonucleotides makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5 ’-end and phosphoramidites at the 3 ’-end. As a non-limiting example, small scale syntheses can be conducted on an Applied Biosystems synthesizer using a 0.2 pmol scale protocol. Alternatively, syntheses at the 0.2 pmol scale can be performed on a 96-well plate synthesizer from Protogene (Palo Alto, CA). However, a larger or smaller scale of synthesis is also within the scope of this invention. Suitable reagents for oligonucleotide synthesis, methods for RNA deprotection, and methods for RNA purification are known to those of skill in the art. siRNA molecules can be assembled from two distinct oligonucleotides, wherein one oligonucleotide comprises the sense strand and the other comprises the antisense strand of the siRNA. For example, each strand can be synthesized separately and joined together by hybridization or ligation following synthesis and/or deprotection.
Linking Group (L, Li or L2).
The linking group can be variable provided the targeting conjugate functions as described herein. The linking group can vary in length and atom composition and for example can be branched or non-branched or cyclic or a combination thereof. The linking group may also modulate the properties of the targeted conjugate such as but not limited to solubility, stability and aggregation.
In one embodiment the linker comprises about 3-5000 atoms. In one embodiment the linker comprises about 3-4000 atoms. In one embodiment the linker comprises about 3-2000 atoms. In one embodiment the linker comprises about 3-1000 atoms. In one embodiment the linker comprises about 3-750 atoms. In one embodiment the linker comprises about 3-500 atoms. In one embodiment the linker comprises about 3-250 atoms. In one embodiment the linker comprises about 3-100 atoms. In one embodiment the linker comprises about 3-50 atoms. In one embodiment the linker comprises about 3-25 atoms.
In one embodiment the linker comprises about 10-5000 atoms. In one embodiment the linker comprises about 10-4000 atoms. In one embodiment the linker comprises about 10-2000 atoms. In one embodiment the linker comprises about 10-1000 atoms. In one embodiment the
linker comprises about 10-750 atoms. In one embodiment the linker comprises about 10-500 atoms. In one embodiment the linker comprises about 10-250 atoms. In one embodiment the linker comprises about 10-100 atoms. In one embodiment the linker comprises about 10-50 atoms. In one embodiment the linker comprises about 10-25 atoms.
In one embodiment the linker L comprises atoms selected from H, C, N, S and O.
In one embodiment the linker L comprises atoms selected from H, C, N, S, P and O.
In one embodiment the linker L comprises a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to 1000 (or 1-750, 1-500, 1-250, 1-100, 1- 50, 1-25, 1-10, 1-5, 5-1000, 5-750, 5-500, 5-250, 5-100, 5-50, 5-25, 5-10 or 2-5 carbon atoms) wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(Ra)-, 3-7 membered heterocycle, 5-6-membered heteroaryl or carbocycle and wherein each chain, 3-7 membered heterocycle, 5-6-membered heteroaryl or carbocycle is optionally and independently substituted with one or more (e.g. 1, 2, 3, 4, 5 or more) substituents selected from (Ci-Ce)alkyl, (Ci-Ce)alkoxy, (C3-Ce)cycloalkyl, (Ci-Ce)alkanoyl, (Ci- Ce)alkanoyloxy, (Ci-Ce)alkoxycarbonyl, (Ci-Ce)alkylthio, azido, cyano, nitro, halo, -N(Ra)2, hydroxy, oxo (=0), carboxy, aryl, aryloxy, heteroaryl, and heteroaryloxy, wherein each Rais independently H or (Ci-Ce)alkyl. In one embodiment the linker comprises a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to 1000 (or 1- 750, 1-500, 1-250, 1-100, 1-50, 1-25, 1-10, 1-5, 5-1000, 5-750, 5-500, 5-250, 5-100, 5-50, 5-25, 5-10 or 2-5 carbon atoms) wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(Ra)-, wherein each Rais independently H or (Ci-Ce)alkyl.
In one embodiment the linker L comprises a polyethylene glycol. In one embodiment the linker comprises a polyethylene glycol linked to the remainder of the targeted conjugate by a carbonyl group. In one embodiment the polyethylene glycol comprises about 1 to about 500 or about 5 to about 500 or about 3 to about 100 repeat (e.g., -CH2CH2O-) units (Greenwald, R.B., et al., Poly (ethylene glycol) Prodrugs: Altered Pharmacokinetics and Pharmacodynamics, Chapter, 2.3.1., 283-338; Filpula, D., et al., Releasable PEGylation of proteins with customized linkers, Advanced Drug Delivery, 60, 2008, 29-49; Zhao, H., et al., Drug Conjugates with Poly(Ethylene Glycol), Drug Delivery in Oncology, 2012, 627-656).
In one embodiment the linker L is -NH(CH2CH2O)4CH2CH2C(=O)-. In one embodiment the linker L is -NH(CH2CH2O)nCH2CH2C(=O)- wherein n is 1-500, 5-500, 3-100, 5-50, 1-50, 1-20, 1-10, 1-5, 2-50, 2-20, 2-10, 2-5, 3-50, 3-20, 3-10, 3-5, 4-50, 4-20, 4-10, 4-5 .
In one embodiment the linker L is -(CEbCEEO^CEECEbC^O)-.
In one embodiment the linker L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 500 carbon atoms, wherein one or more of the
carbon atoms is optionally replaced independently by -O-, -S, -N(Ra)-, 3-20 membered heterocycle, 3-20 membered heteroaryl or 3-20 membered carbocycle and wherein each chain, 3-20 membered heterocycle, 3-20 membered heteroaryl and 3-20 membered carbocycle is optionally and independently substituted with one or more (e.g. 1, 2, 3, 4, 5 or more) substituents independently selected from the group consisting of (Ci-Ce)alkyl, (Ci-Ce)alkoxy, (C3-Ce)cycloalkyl, (Ci-Ce)alkanoyl, (Ci-Ce)alkanoyloxy, (Ci-Ce)alkoxycarbonyl, azido, cyano, nitro, halo, -N(Ra)2, hydroxy, oxo (=0), and carboxy, wherein each Rais independently H or (Ci- Ce)alkyl.
In one embodiment the linker L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 100 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(Ra)-, 3-20 membered heterocycle, 3-20 membered heteroaryl or 3-20 membered carbocycle and wherein each chain, 3-20 membered heterocycle, 3-20 membered heteroaryl and 3-20 membered carbocycle is optionally and independently substituted with one or more (e.g. 1, 2, 3, 4, 5 or more) substituents independently selected from the group consisting of (Ci-Ce)alkyl, (Ci-Ce)alkoxy, (C3-Ce)cycloalkyl, (Ci-Ce)alkanoyl, (Ci-Ce)alkanoyloxy, (Ci-Ce)alkoxycarbonyl, azido, cyano, nitro, halo, -N(Ra)2, hydroxy, oxo (=0), and carboxy, wherein each Rais independently H or (Ci- Ce)alkyl.
In one embodiment the linker L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 100 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(Ra)-, 3-20 membered heterocycle, 3-20 membered heteroaryl or 3-20 membered carbocycle and wherein each chain, 3-20 membered heterocycle, 3-20 membered heteroaryl and 3-20 membered carbocycle is optionally and independently substituted with one or more (e.g. 1, 2, 3, 4, 5 or more) substituents independently selected from the group consisting of azido, halo, and oxo (=0), and carboxy, wherein each Rais independently H or (Ci-Ce)alkyl.
In one embodiment the linker L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 50 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(Ra)-, 3-20 membered heterocycle, 3-20 membered heteroaryl or 3-20 membered carbocycle and wherein each chain, 3-20 membered heterocycle, 3-20 membered heteroaryl and 3-20 membered carbocycle is optionally and independently substituted with one or more (e.g. 1, 2, 3, 4, 5 or more) substituents independently selected from the group consisting of azido, halo, and oxo (=0), and carboxy, wherein each Rais independently H or (Ci-Ce)alkyl.
In one embodiment the linker L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 50 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(Ra)-, or Rb, wherein each chain and Rb is optionally and independently substituted with one or more (e.g. 1, 2, 3, 4, 5 or more) substituents independently selected from the group consisting of azido, halo, and oxo (=0), and carboxy, wherein each Rb is independently H or (Ci-Ce)alkyl; and each Rb is independently selected from the group consisting of:
In one embodiment the linker L comprises: -C(=O)(CH2)aN(H)C(=O)-; wherein a is 3, 4, 5, 6, 7, or 8.
In one embodiment the linker L comprises -(CH2CH2O)bCH2CH2C(=O)- or -(CH2CH2O)bCH2CH2N(H)C(=O)-, wherein b is 2-50.
In one embodiment the linker L comprises phen-l,3-diyl or phenl-l,3,5-triyl.
In one embodiment each R1 is linked to L through a carbonyl group of L. In one embodiment each R2 is linked to L through a carbon-carbon bond. In one embodiment the linker L is selected from the group consisting of:
In one embodiment, the linker is comprised of a moiety of formula L2-Y’Z’-LI, wherein each of L2, Y’Z’, and Li are as defined herein. Optionally, Y and Z are selected such that Y’Z’ together comprise an oxime functionality. Alternatively, Y and Z are selected such that Y’Z’ together comprise a triazole ring.
Embodiments of the Invention
One aspect of the invention is a compound of formula I, as set forth about in the Summary of the Invention, or a salt thereof.
In a first embodiment (Embodiment 1; abbreviated as “El”) the invention provides a compound of formula (I)
(R1)x— L— (R2)y
(I) or a salt thereof, wherein: x is 2, 3, 4 or 5; each R1 is independently a targeting ligand, which is selected from: a) a cyclic polypeptide depicted by SEQ ID NO: 1 :C*SRNLIDC* (SEQ ID NO: 1), wherein * denotes a disulfide bond linking the two C residues to thereby form the cyclic polypeptide, and b) any cyclic polypeptide having at least 80 % sequence identity (e.g., at least 85%; e.g., at least 87.5%; e.g., at least 90%; e.g., at least 95%; e.g., at least 99% sequence identity) with the polypeptide depicted by SEQ ID NO: 1, under the proviso that both C* residues are present, and wherein * denotes a disulfide bond linking the two C residues to thereby form the cyclic polypeptide;
L is a linking group; y is 1, 2, 3, 4 or 5; and each R2 is independently an oligonucleotide, a label (e.g., a label derivable from fluorescein isothiocyanate (FITC) or Cy5), a phenyl group that is substituted with a formyl (-CHO) group, or a group of formula:
In one embodiment, Ri is a polypeptide, preferably a cyclic polypeptide, having 6 to 10 amino acid residues, such as 7 to 9 amino acid residues, and preferably about 8 amino acid residues.
In one embodiment, the polypeptide defined in b) is identical to the polypeptide defined in a), except that exactly one of the eight amino acid residues is being exchanged for another amino acid, and thus nonidentical. In that case, the sequence identity of the polypeptide defined in b) is determined as 7 (identical amino acids)/8 (total positions)* 100 = 87.5 %. Thus, in a preferred embodiment, the polypeptide of b), as described herein, has 87.5 % sequence identity
with the polypeptide defined in a). In one embodiment, the polypeptide has 7 to 10 amino acid residues, and preferably about 8 or 9 amino acid residues, most preferably 8 amino acid residues.
Alternatively, in one embodiment, Ri can be described as a polypeptide having 7 to 10 amino acid residues, and preferably about 8 or 9 amino acid residues, most preferably 8 amino acid residues, wherein the polypeptide has an amino acid sequence as defined by SEQ ID NO: 1, except that one or more amino acid residues are inserted, deleted or exchanged. Preferably, one to three amino acid residues are inserted, deleted or exchanged, more preferably two or less amino acid residues are inserted, deleted or exchanged, and most preferably one amino acid residue is inserted, deleted or exchanged. Said polypeptide has at least two functional groups capable of forming a bond with each other, such as thiol groups of e.g. cysteine residues, which are capable of forming a disulfide bond, thereby forming a cyclic polypeptide. The functional groups capable of forming a bond with each other are preferably located at or near the N- terminus and C-terminus, respectively.
In one embodiment, Ri is a polypeptide having a core as defined in a) or b) above, and in addition to that an extension of the polypeptide sequence at either the N-terminus and/or the C- terminus of the polypeptide defined above, such that Ri overall is a longer polypeptide which comprises Ri but which is not limited to Ri.
In the cyclic polypeptide as described above, typically, cyclization results from the formation of disulfide bridges between cysteine residues of the peptide such as between the amino acids at positions 1 and 8 of the amino acid sequences described herein, particularly in a) and b) above. Alternatively, an intramolecular bond may be formed in a peptide described herein by a cyclization which is different from a Cys-Cys cyclization. Thus, in an alternative embodiment, the present invention also contemplates peptides, wherein one or both of the Cysteine moieties in the peptide described herein are replaced by a moiety other than Cys. In that embodiment, one or both of the Cys residues at the first and last position (such as positions 1 and 8) of the amino acid sequences described herein may be replaced by (an) amino acid(s) which is (are) able to form an intramolecular bond in the peptide. Preferably, said bond is formed between the amino acids at the first and last position (such as positions 1 and 8) of the amino acid sequences described herein.
Further embodiments (E2-E68) are described below.
E2. The compound or salt of El, wherein x is 2 or 3. Such compound, e.g. when R2 is a oligonucleotide, such as an siRNA, is particularly advantageous (for a non-limiting and illustrative embodiment, see e.g. Example 12)
E3 The compound or salt of El, wherein x is 3.
E4. The compound or salt of any one of E1-E3, wherein each R1 is covalently bound to L (i) through the N terminus of the polypeptide or (ii) through the C terminus of the polypeptide or (iii) through the side chain of an amino acid of the polypeptide.
E5. The compound or salt of any one of E1-E3, wherein each R1 is covalently bound to L through the N terminus of the polypeptide.
E6. The compound or salt of any one of E1-E3, wherein each R1 is independently a targeting ligand of formula:
E7. The compound or salt of any one of E1-E6, wherein each R2 is independently an oligonucleotide.
E8. The compound or salt of any one of E1-E6, wherein each R2 is independently an siRNA. Such compound is particularly advantageous (for a non-limiting and illustrative embodiment, see e.g. Example 12)
E9. The compound or salt of any one of E7-E8, wherein each oligonucleotide or each siRNA is attached to L through a phosphate P(=0)(0H)2-0- of each oligonucleotide or each siRNA.
El l. The compound or salt of any one of E1-E6, wherein each R2 is independently 3- formylphenyl or 4-formylphenyl.
El 2. The compound or salt of any one of El -El 1, wherein L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 500 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently
by -0-, -S, -N(Ra)-, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, or 3-20 membered carbocycle and wherein each chain, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, and 3-20 membered carbocycle is optionally and independently substituted with one or more (e.g. 1, 2, 3, 4, 5 or more) substituents independently selected from the group consisting of (Ci-Ce)alkyl, (Ci-Ce)alkoxy, (C3-Ce)cycloalkyl, (Ci- Ce)alkanoyl, (Ci-Ce)alkanoyloxy, (Ci-Ce)alkoxycarbonyl, azido, cyano, nitro, halo, -N(Ra)2, hydroxy, oxo (=0), and carboxy, wherein each Rais independently H or (Ci-Ce)alkyl.
El 3. The compound or salt of any one of El -El 1, wherein L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 100 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(Ra)-, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, or 3-20 membered carbocycle and wherein each chain, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, and 3-20 membered carbocycle is optionally and independently substituted with one or more (e.g. 1, 2, 3, 4, 5 or more) substituents independently selected from the group consisting of (Ci-Ce)alkyl, (Ci-Ce)alkoxy, (C3-Ce)cycloalkyl, (Ci- Ce)alkanoyl, (Ci-Ce)alkanoyloxy, (Ci-Ce)alkoxycarbonyl, azido, cyano, nitro, halo, -N(Ra)2, hydroxy, oxo (=0), and carboxy, wherein each Rais independently H or (Ci-Ce)alkyl.
El 4. The compound or salt of any one of El -El 1, wherein L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 100 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(Ra)-, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, or 3-20 membered carbocycle and wherein each chain, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, and 3-20 membered carbocycle is optionally and independently substituted with one or more (e.g. 1, 2, 3, 4, 5 or more) substituents independently selected from the group consisting of azido, halo, and oxo (=0), and carboxy, wherein each Rais independently H or (Ci-Ce)alkyl.
El 5. The compound or salt of any one of El -El 1, wherein L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 50 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(Ra)-, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, or 3-20 membered carbocycle and wherein each chain, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, and 3-20 membered carbocycle is optionally and independently substituted with one or more (e.g. 1, 2, 3, 4, 5 or more) substituents independently selected from the group consisting of azido, halo, and oxo (=0), and carboxy, wherein each Rais independently H or (Ci-Ce)alkyl.
El 6. The compound or salt of any one of El -El 1, wherein L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 50 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(Ra)-, or Rb, wherein each chain and Rb is optionally and independently substituted with one or more (e.g. 1, 2, 3, 4, 5 or more) substituents independently selected from the group consisting of azido, halo, =N(0H), -0(NH2) and oxo (=0), and carboxy, wherein each Rb is independently H or (Ci-Ce)alkyl; and each Rb is independently selected from the group consisting of:
El 7. The compound or salt of any one of El -El 1, wherein L comprises: -C(=0)(CH2)aN(H) C(=O)-; wherein a is 3, 4, 5, 6, 7, or 8.
El 8. The compound or salt of any one of El -El 1, wherein L comprises -(CH2CH2O)bCH2CH2C(=O)- or -(CH2CH2O)bCH2CH2N(H)C(=O)-, wherein b is 2- 50.
E19. The compound or salt of any one of El-El 1, wherein L comprises phen-l,3-diyl or phenl-l,3,5-triyl.
E20. The compound or salt of any one of El -El 1, wherein L comprises:
E21. The compound or salt of any one of E1-E20, wherein each R1 is linked to L through a carbonyl group of L.
E22. The compound or salt of any one of E1-E20, wherein each R2 is linked to L through a carbon-carbon bond. E23. The compound or salt of any one of El -El 1, wherein L is selected from the group consisting of:
E24. A compound essentially as defined in El, wherein x is 1, 2 or 3 , wherein the compound is selected from the group consisting of
For clarity, in embodiment E24 compounds wherein x = 1 are also contemplated. All definitions and moi eties are as defined in El, with the exception of x, which may be in embodiment E24 be selected to be 1. These embodiments, i.e. wherein x is optionally 1 are particularly applicable for the case that R2 is independently a label (e.g., a label derivable from fluorescein isothiocyanate (FITC) or Cy5), a phenyl group that is substituted with a formyl (-CHO) group, or a group of formula:
In other words, embodiments, i.e. wherein x is optionally 1 apply with particular preference in case R2 is not an oligonucleotide. In preferred embodiments of E24, R2 is not an oligonucleotide. In preferred embodiments of E24, is selected to be 1.
In a twenty -fifth embodiment (Embodiment 25; abbreviated as “E25”) the invention provides a process for preparation of a diblock polymer of the following formula (X): [Block A] - [Block B]
(X) comprising: a) contacting a compound of structure Va, Vb, Vc, or Vd
wherein R27 is (Ci-Ci2)alkyl,
wherein R28 is (Ci-Ci2)alkyl,
wherein R25 and R26 are independently H, (Ci-Ci2)alkyl, aryl, or heteroaryl,
with one or more A monomers selected from the group consisting of: i) a polyethyleneglycol methacrylate with 2-20 ethylene glycol units
(PEGMA); and ii) M2, wherein M2 is a methacrylate, which is optionally selected among a (C4-Cis)alkyl-methacrylate; a (C4-Cis)branched alkyl-methacrylate; a cholesteryl methacrylate; a (C4-Cis)alkyl-methacrylate substituted with one or more fluorine atoms; and
a (C4-Cis)branched alkyl-methacrylate substituted with one or more fluorine atoms; in the presence of a free radical to provide a first product; b) contacting the first product with one or more B mon omers of formulae B 1, B2 and B3
^Y°H
O (B2)
in the presence of a free radical to provide a second product, and c) optionally contacting the second product with a free radical source (e.g., AIBN) to remove the chain transfer agent and provide the diblock polymer of formula (X); wherein:
Block A comprises one or more residues of A monomers and has a molecular weight of from about 1 kDa to about 25 kDa;
Block B comprises one or more residues of monomers Bl, B2, and B3 and has a molecular weight of from about 1 kDa to about 25 kDa.
Li is a linking moiety;
Z is a functional group that is optionally protected with a protecting group and is capable of reacting with Y of a compound of formula (XII):
T-L2-Y (XII) to form a conjugate wherein:
T is a ligand (optionally targeting ligand);
Y is a functional group that is capable of reacting with Z to form a conjugate; and
L2 is absent or is a linking moiety.
A “free radical source” as used herein is not particularly limited. Suitable free radical sources include without limitation Azobisisobutyronitrile (AIBN), 1,1- Azobis(cyanocyclohexane) (ACHN/VAZO-88), 4,4'-azobis(4-cyanovaleric acid) (ACVA), Potassium persulfate (K2S2O8).
The term “chain transfer agent” (CTA), as used herein, refers to a molecular entity suitable to afford control over the generated molecular weight and poly dispersity during a free- radical polymerization. Typical CTAs suitable in the present invention are, in non-limiting examples, thiocarb onylthio compounds (or similar.. A CTA is also sometimes referred to as “RAFT agent” in the art.- Compounds Va, Vb, Vc and Vd, as introduced above, are non-liming examples of CTA suitable in the process according to the present invention.
While step c) is optional, it is preferred that the process of the present invention actually comprises step c) as well. The result of a process comprising step c) is the compound of formula (I), which is devoid of a CTA moiety. In the alternative embodiment that step c) is not present, the resulting polymer still comprises a moiety derived from the CTA, while otherwise identical to the compound of formula (I).
The product of this process, whether or not comprising step c), is useful for coupling with a T moiety, as described herein below. Typically, the T moiety is conjugated to the polymer obtained by the above process in a step of post-polymerization conjugation:
This process and all its embodiments is particularly helpful for the preparation of a polymer with a T moiety that is not susceptible to RAFT polymerization as described e.g. in WO 2015/017519 Al. This is the case for example when T is selected to be an oligonucleotide or a peptide, such as the cyclic peptide as described herein. In particular, the process according to the present invention is characterized in that T is conjugated to the polymer after the polymerization reaction (also referred to as RAFT polymerization). Thus, the process according to the present invention can also be referred to as post-polymerization conjugation. The inventors made endosome release polymer (ERP) characterized by such T moieties available through the present invention. Thus, the present invention provides a process for making endosome release polymer (ERP), wherein the ERP obtainable by such process is characterized in comprising a ligand which is optionally an oligonucleotide or a peptide. Even though oligonucleotides and peptides, among other ligands, are not susceptible to RAFT polymerization, the present invention makes ERP with such ligands available. The process of the present invention is also an economic process for making ERP comprising a relatively expensive or valuable ligand, optionally selected among an oligonucleotide and a peptide. Conjugation of such expensive or valuable ligand at the final step of synthesis as opposed to the beginning of RAFT polymerization process
significantly reduces the overall production cost because the yield of RAFT polymerization does not affect the amount of ligand required to make the final product.
While the second product, i.e. the product resulting from step b) has a moiety of a radical starter, originating from a compound of structure Va, Vb, Vc, or Vd attached to it, the contacting of the second product with one or more free radicals provides the diblock polymer of formula (X). Thus addition of the free radical removes this group and changes the terminal group of the polymer to a proton. Preferably, the contacting of the second product with one or more free radicals occurs under protic conditions. This is advantageous for changing polymer end group, to substitute the RAFT agent by a proton.
The process of making the diblock polymer of formula (X), as described in E25 and any of its embodiments as described herein can be referred to as “Reversible Addition- Fragmentation chain Transfer” (or RAFT) polymerization. According to the present invention, RAFT is used in synthesizing ethylenic backbone polymers of this invention. RAFT is a living polymerization process. RAFT comprises a free radical degenerative chain transfer process. In some embodiments, RAFT procedures for preparing a polymer described herein employs thiocarbonylthio compounds such as, without limitation, dithioesters, dithiocarbamates, trithiocarbonates and xanthates to mediate polymerization by a reversible chain transfer mechanism. In certain instances, reaction of a polymeric radical with the C=S group of any of the preceding compounds leads to the formation of stabilized radical intermediates. Typically, these stabilized radical intermediates do not undergo the termination reactions typical of standard radical polymerization but, rather, reintroduce a radical capable of re-initiation or propagation with monomer, reforming the C=S bond in the process. In most instances, this cycle of addition to the C=S bond followed by fragmentation of the ensuing radical continues until all monomer has been consumed or the reaction is quenched. Generally, the low concentration of active radicals at any particular time limits normal termination reactions.
In some embodiments, polymers of the present invention have a low poly dispersity index (PDI or DI) or differences in chain length. Poly dispersity index can be determined in any suitable manner, e.g., by dividing the weight average molecular weight of the polymer chains by their number average molecular weight. The number average molecule weight is sum of individual chain molecular weights divided by the number of chains. The weight average molecular weight is proportional to the square of the molecular weight divided by the number of molecules of that molecular weight. Since the weight average molecular weight is always greater than the number average molecular weight, poly dispersity is always greater than or equal to one. As the numbers come closer and closer to being the same, i.e., as the poly dispersity approaches a value of one, the polymer becomes closer to being monodisperse in which every chain has
exactly the same number of constitutional units. Poly dispersity values approaching one are achievable using radical living polymerization. Methods of determining poly dispersity, such as, but not limited to, size exclusion chromatography, dynamic light scattering, matrix-assisted laser desorption/ionization chromatography and electrospray mass chromatography are well known in the art. In some embodiments, the polymers (e.g., membrane destabilizing polymers) provided herein have a poly dispersity index (PDI) of less than 2.0, or less than 1.8, or less than 1.6, or less than 1.5, or less than 1.4, or less than 1.3, or less than 1.2. In some embodiments, the polymer is a block copolymer (e.g., endosome release copolymer) comprising a hydrophilic block and a hydrophobic block and having a poly dispersity index (PDI) of less than 2.0, or less than 1.8, or less than 1.6, or less than 1.5, or less than 1.4, or less than 1.3, or less than 1.2.
Polymerization processes described herein optionally occur in any suitable solvent or mixture thereof. Suitable solvents include water, alcohol (e.g., methanol, ethanol, n-propanol, isopropanol, butanol), tetrahydrofuran (THF) dimethyl] sulfoxide (DMSO), dimethylformamide (DMF), acetone, acetonitrile, hexamethylphosphoramide, acetic acid, formic acid, hexane, cyclohexane, benzene, toluene, dioxane, methylene chloride, ether (e.g., diethyl ether), chloroform, and ethyl acetate. In one aspect, the solvent includes water, and mixtures of water and water-miscible organic solvents such as DMF.
In other words, in this embodiment, the A monomers are selected from the group consisting of monomers of formulae Al and A2.
(XI).
Rounded brackets denote the monomer moieties. Squared brackets denote Blocks A and B, respectively, of the diblock polymer. Stoichiometry (m and n; q, r and s) and molecular weights (v and w) are as defined in E25. E27. The process of E25 or E26 wherein Z is a functional group that is protected with a protecting group, wherein the process further comprises removing the protecting group from Z.
E28. The process of E25 or E26 wherein Z is a functional group that is not protected with a protecting group.
E29. The process of E27 or E28 further comprising reacting the diblock polymer of formula (XI) with a compound of formula (XII):
T-L2-Y (XII) under conditions where Z reacts with Y to form a group Y’Z’ and yield a conjugate of formula:
T - L2 — Y'Z1 - L1 - [Block A] - [Block B]
In one embodiment, this process yields the endosome release polymer described in E49 and any of its embodiments.
In one embodiment, the conjugate is a conjugate of formula (XIII):
(XIII).
Rounded brackets denote the monomer moieties. Squared brackets denote Blocks A and B, respectively, of the diblock polymer.
E30. The process of E29, wherein Block A has a molecular weight of from about 1 kDa to about 25 kDa; and Block B has a molecular weight of from about 1 kDa to about 25 kDa.
E31. The process of E29, wherein Block A has formula:
-[PEGMAm-M2n]v- wherein:
PEGMA is polyethyleneglycol methacrylate residue with 2-20 ethylene glycol units; M2 is a methacrylate residue selected from the group consisting of a (C4-Cis)alkyl-methacrylate residue; a (C4-Cis)branched alkyl- methacrylate residue; a cholesteryl methacrylate residue; a (C4-Cis)alkyl-methacrylate residue substituted with one or more fluorine atoms; and a (C4-Cis)branched alkyl-methacrylate residue substituted with one or more fluorine atoms; and v is 1 to 25 kDa; and wherein Block B has formula:
-[DMAEMAq-PAAr-BMAs]w
wherein:
BMA is butyl methacrylate residue;
PAA is propyl acrylic acid residue;
DMAEMA is dimethylaminoethyl methacrylate residue; m and n are each a mole fraction greater than 0, wherein m is greater than n and m + n = 1 ; q is a mole fraction of 0.2 to 0.75; r is a mole fraction of 0.05 to 0.6; s is a mole fraction of 0.2 to 0.75; q + r + s = 1 ; and w is 1 to 25 kDa.
Rounded brackets denote the monomer moieties. Squared brackets denote Blocks A and B, respectively, of the diblock polymer.
E32. The process of any one of E25-E31, wherein Z and Y are selected so that Y’Z’ comprises an oxime functionality.
E33. The process of any one of E25-E31, wherein Z and Y are selected so that Y’Z’ comprises a triazole ring.
E34. The process of any one of E25-E27 and E29-E32, wherein Z comprises an aminooxy group that is protected, and the protecting group is on the nitrogen of the aminooxy group.
E35. The process of any one of E29-E32, wherein Z comprises an aminooxy group, Y comprises a ketone group or an aldehyde group, and Y’Z’ comprises an oxime functional group.
E36. The process of any one of E29-E32, wherein Z comprises a ketone group or an aldehyde group, Y comprises an aminooxy group, and Y’Z’ comprises an oxime functional group.
E37. The process of E29 or E33, wherein Z comprises an alkyne group, Y comprises an azide group, and Y’Z’ comprises a triazole ring.
E38. The process of E29 or E33, wherein Z comprises an azide group, Y comprises an alkyne group, and Y’Z’ comprises a triazole ring.
E39. The process of any one of any one of E29-E38, wherein T is a targeting ligand or a labeling agent.
E40. The process of any one of E29-E38, wherein the targeting ligand is selected from the group of an oligonucleotide, a peptide, a saccharide, and a small molecule.
E41. The process of any one of E29-E38, wherein the targeting ligand comprises a cyclic peptide.
E42. The process of any one of E29-E38, wherein the targeting ligand comprises a cyclic peptide as described in El.
E43. The process of any one of E29-E38, wherein the targeting ligand comprises a cyclic peptide as described in E6.
E44. The process of any one of E29-E38, wherein the labeling agent is selected from the group consisting of a fluorophore, a chromophore, and a radionucleotide.
E45. The process of any one of E29-E38, wherein the labeling agent is derivable from fluorescein isothiocyanate (FITC) or Cy5.
E46. A product prepared by the process of any one of E25-E45.
E47. A conjugate prepared by the process of any one of E29-E45.
E48. A composition comprising a plurality of conjugates as defined in any one of E29- E45.
E49. The composition of E48, wherein at least one of the conjugates comprises a labelling agent.
In a fiftieth embodiment (Embodiment 50; abbreviated as “E50”) the invention provides a compound of formula (I)
(R1)x— L— (R2)y
(I) or a salt thereof, wherein: x is 1, 2, 3, 4 or 5; each R1 is independently a targeting ligand, which is selected from a) a cyclic polypeptide depicted by SEQ ID NO: 1 :C*SRNLIDC* (SEQ ID NO: 1), wherein * denotes a disulfide bond linking the two C residues to thereby form the cyclic polypeptide, b) any cyclic polypeptide having at least 80 % sequence identity (e.g., at least 85%; e.g., at least 87.5%; e.g., at least 90%; e.g., at least 95%; e.g., at least 99% sequence identity) with the polypeptide depicted by SEQ ID NO: 1, under the proviso that both C* residues are present, and
wherein * denotes a disulfide bond linking the two C residues to thereby form the cyclic polypeptide;
L is a linking group; and y is 1, 2, 3, 4 or 5; and each R2 is independently an endosomal release polymer.
Preferably, the compound or salt of E50 is available by the process of E29 and any of its embodiments.
E51. The compound or salt of E50, wherein the endosomal release polymer comprises a diblock polymer comprising Block A and Block B having the following formula:
[Block A]-[Block B] wherein:
Block A comprises one or more residues of monomers Al and A2 as described in E25 and has a molecular weight of from about 1 kDa to about 25 kDa; and
Block B comprises one or more residues of monomers Bl, B2, and B3 as described in E25 and has a molecular weight of from about 1 kDa to about 25 kDa.
In one embodiment, said compound of Formula (I) is obtainable by a process as described herein.
E52. The compound or salt of E50, wherein the endosomal release polymer has formula XX:
-[PEGMAm-M2n]v-[DMAEMAq-PAAr-BMAs]w (XX) wherein:
PEGMA is polyethyleneglycol methacrylate residue with 2-20 ethylene glycol units; M2 is a methacrylate residue selected from the group consisting of a (C4-Cis)alkyl-methacrylate residue; a (C4-Cis)branched alkyl- methacrylate residue; a cholesteryl methacrylate residue; a (C4-Cis)alkyl-methacrylate residue substituted with one or more fluorine atoms; and a (C4-Cis)branched alkyl-methacrylate residue substituted with one or more fluorine atoms;
BMA is butyl methacrylate residue;
PAA is propyl acrylic acid residue;
DMAEMA is dimethylaminoethyl methacrylate residue;
m and n are each a mole fraction greater than 0, wherein m is greater than n and m + n = 1 ; q is a mole fraction of 0.2 to 0.75; r is a mole fraction of 0.05 to 0.6; s is a mole fraction of 0.2 to 0.75; q + r + s = 1; v is 1 to 25 kDa; and w is 1 to 25 kDa
E53. The compound or salt of E51, wherein Block A comprises one or more residues of monomers of formulae Al and A2 as described in E26.
E54. A pharmaceutical composition comprising a compound as described in any one of E1-E24 and E50-E53 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
E55. A pharmaceutical composition comprising a first compound as described in any one of E1-E24 or a pharmaceutically acceptable salt thereof, wherein each R2 is independently an oligonucleotide and a second compound as described in any one of E50-E53 or a pharmaceutically acceptable salt thereof.
E56. A method to deliver an oligonucleotide to an animal comprising administering a compound as described in any one of E1-E24 or a pharmaceutically acceptable salt thereof, to the animal.
E57. A method to deliver an oligonucleotide to cells that express platelet-derived growth factor receptor (PDGFR) in an animal comprising administering a compound as described in any one of E1-E24 or a pharmaceutically acceptable salt thereof, to the animal.
E58. The method of E57, wherein the platelet-derived growth factor receptor (PDGFR) is platelet-derived growth factor receptor alpha (PDGFRa).
E59. The method of E57, wherein the platelet-derived growth factor receptor (PDGFR) is platelet-derived growth factor receptor beta (PDGFRP).
E60. The method of E57, wherein the cells that express PDGFR are hepatic stellate cells (HSC), endothelial cells, fibroblasts or tumor cells.
E61. A method to treat a disease involving PDGFR expressing cells (e.g., liver fibrosis, non-alcoholic steatohepatitis (NASH), clear cell renal cell carcinoma, kidney fibrosis, or alcoholic steatohepatitis (ASH)) comprising administering a compound as described in any one of E1-E24 or a pharmaceutically acceptable salt thereof, to the animal.
E62. A compound as described in any one of E1-E24 or a pharmaceutically acceptable salt thereof for delivering an oligonucleotide to an animal.
E63. A compound as described in any one of E1-E24 or a pharmaceutically acceptable salt thereof for delivering an oligonucleotide to cells that express platelet-derived growth factor receptor (PDGFR).
E64. A compound as described in any one of E1-E24 or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a disease involving PDGFR expressing cells (e.g., liver fibrosis, non-alcoholic steatohepatitis (NASH), clear cell renal cell carcinoma, kidney fibrosis, or alcoholic steatohepatitis (ASH)).
E65. The use of a compound as described in any one of E1-E24 or a pharmaceutically acceptable salt thereof to prepare a medicament for delivering an oligonucleotide to an animal.
E66. The use of a compound as described in any one of E1-E24 or a pharmaceutically acceptable salt thereof to prepare a medicament for delivering an oligonucleotide to cells that express platelet-derived growth factor receptor (PDGFR).
E67. The use of a compound as described in any one of E1-E24 or a pharmaceutically acceptable salt thereof to prepare a medicament for treating a disease involving PDGFR expressing cells (e.g., liver fibrosis, non-alcoholic steatohepatitis (NASH), clear cell renal cell carcinoma, kidney fibrosis, or alcoholic steatohepatitis (ASH)).
E68. The method, compound of use of any one of E56-E67, which comprises the combined use of a first compound as described in any one of E1-E24, wherein each R2 is independently an oligonucleotide, with a second compound as described in any one of E50-E53.
In another embodiment (Embodiment 101; abbreviated as “El 01”) the invention provides a compound of formula (I)
(R1)x - L— (R2)y
(I) wherein: x is 1, 2, 3, 4 or 5; each R1 is independently a targeting ligand of formula:
L is a linking group; and y is 1, 2, 3, 4 or 5; and each R2 is independently an oligonucleotide, a label (e.g., a label derivable from fluorescein isothiocyanate (FITC) or Cy5), a phenyl group that is substituted with a formyl (-CHO) group, or a group of formula:
or y is 1, 2, 3, 4, or 5 and R2 is an endosomal release agent including polymers and peptides or a salt thereof.
Further embodiments (E102-E122) are described below. El 02. The compound or salt of E101, wherein each R1 is independently a targeting ligand of formula:
El 03. The compound or salt of El 01 or El 02, wherein each R2 is independently an oligonucleotide.
El 04. The compound or salt of El 01 or El 02, wherein each R2 is independently an siRNA.
E105. The compound of E103 or E104, wherein each oligonucleotide or each siRNA is attached to L through a phosphate P(=O)(OH)2-O- of each oligonucleotide or each siRNA.
El 07. The compound or salt of El 01 or El 02, wherein each R2 is independently 3- formylphenyl or 4-formylphenyl.
E108. The compound or salt of any one of E101-E107, wherein L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 500 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(Ra)-, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, or 3-20 membered carbocycle and wherein each chain, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, and 3-20 membered carbocycle is optionally and independently substituted with one or more (e.g. 1, 2, 3, 4, 5 or more) substituents independently selected from the group consisting of (Ci-Ce)alkyl, (Ci-Ce)alkoxy, (C3-Ce)cycloalkyl, (Ci- Ce)alkanoyl, (Ci-Ce)alkanoyloxy, (Ci-Ce)alkoxycarbonyl, azido, cyano, nitro, halo, -N(Ra)2, hydroxy, oxo (=0), and carboxy, wherein each Rais independently H or (Ci-Ce)alkyl.
El 09. The compound or salt of any one of El 01 -El 07, wherein L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 100 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(Ra)-, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, or 3-20 membered carbocycle and wherein each chain, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, and 3-20 membered carbocycle is optionally and independently substituted with one or more (e.g. 1, 2, 3, 4, 5 or more) substituents independently selected from the group consisting of (Ci-Ce)alkyl, (Ci-Ce)alkoxy, (C3-Ce)cycloalkyl, (Ci- Ce)alkanoyl, (Ci-Ce)alkanoyloxy, (Ci-Ce)alkoxycarbonyl, azido, cyano, nitro, halo, -N(Ra)2, hydroxy, oxo (=0), and carboxy, wherein each Rais independently H or (Ci-Ce)alkyl.
E110. The compound or salt of any one of El 01 -El 07, wherein L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 100
carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(Ra)-, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, or 3-20 membered carbocycle and wherein each chain, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, and 3-20 membered carbocycle is optionally and independently substituted with one or more (e.g. 1, 2, 3, 4, 5 or more) substituents independently selected from the group consisting of azido, halo, and oxo (=0), and carboxy, wherein each Rais independently H or (Ci-Ce)alkyl.
El 11. The compound or salt of any one of El 01 -El 07, wherein L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 50 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(Ra)-, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, or 3-20 membered carbocycle and wherein each chain, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, and 3-20 membered carbocycle is optionally and independently substituted with one or more (e.g. 1, 2, 3, 4, 5 or more) substituents independently selected from the group consisting of azido, halo, and oxo (=0), and carboxy, wherein each Rais independently H or (Ci-Ce)alkyl.
El 12. The compound or salt of any one of El 01 -El 07, wherein L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 50 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(Ra)-, or Rb, wherein each chain and Rb is optionally and independently substituted with one or more (e.g. 1, 2, 3, 4, 5 or more) substituents independently selected from the group consisting of azido, halo, =N(0H), -0(NH2) and oxo (=0), and carboxy, wherein each Rb is independently H or (Ci-Ce)alkyl; and each Rb is independently selected from the group consisting of:
El 13. The compound or salt of any one of El 01 -El 12, wherein L comprises: -C(=O)(CH2)aN(H) C(=O)-; wherein a is 3, 4, 5, 6, 7, or 8.
El 14. The compound or salt of any one of E101-E113, wherein L comprises -(CH2CH2O)bCH2CH2C(=O)- or -(CH2CH2O)bCH2CH2N(H)C(=O)-, wherein b is 2- 50.
El 15. The compound or salt of any one of E101-E114, wherein L comprises phen-1,3- diyl or phen 1 - 1 , 3 , 5 -triyl .
El 17. The compound or salt of any one of El 01 -El 16, wherein each R1 is linked to L through a carbonyl group of L.
El 18. The compound or salt of any one of El 01 -El 17, wherein each R2 is linked to L through a carbon-carbon bond.
El 19. The compound or salt of any one of El 01 -El 18, wherein L is selected from the group consisting of:
E121. The compound or salt of E101, wherein y is 1 and R2 is an endosomal release polymer of formula XX:
-[PEGMAm-M2n]v-[DMAEMAq-PAAr-BMAs]w (XX) wherein:
PEGMA is polyethyleneglycol methacrylate residue with 2-20 ethylene glycol units; M2 is a methacrylate residue selected from the group consisting of a (C4-Cis)alkyl-methacrylate residue; a (C4-Cis)branched alkyl- methacrylate residue; a cholesteryl methacrylate residue; a (C4-Cis)alkyl-methacrylate residue substituted with one or more fluorine atoms; and a (C4-Cis)branched alkyl-methacrylate residue substituted with one or more fluorine atoms;
BMA is butyl methacrylate residue;
PAA is propyl acrylic acid residue;
DMAEMA is dimethylaminoethyl methacrylate residue; m and n are each a mole fraction greater than 0, wherein m is greater than n and m + n = 1 ; q is a mole fraction of 0.2 to 0.75; r is a mole fraction of 0.05 to 0.6; s is a mole fraction of 0.2 to 0.75; q + r + s = 1; v is 1 to 25 kDa; and w is 1 to 25 kDa.
E122. The compound or salt of E121, which is a compound of the following formula:
or a salt thereof. Stoichiometry (m and n; q, r and s) and molecular weights (v and w) are as defined in E121.
Processes of the Invention
In one embodiment, the invention provides a process for preparing a diblock polymer of formula (X):
-L! - [Block A] - [Block B]
Z (X)
Prieve et al (Mol Ther 2018) describe the synthesis of di -block polymers using RAFT polymerisation techniques, wherein the alpha end of the polymer features either a mannose or GalNac monosaccharide ligand. Details were limited, input and output amounts were not recorded, and no yields were given. When preparing analogous GalNAc polymers, the synthesis can require significant amounts of input starting material chain transfer agent (CTA) relative to the amount of output polymer. For example, in a synthesis using GalNAc CTA, 180g of input CTA was utilised to produce approximately 50 g of final polymer. This ratio of starting material to product seems to be consistent irrespective of the scale of the synthesis. In cases where ligands are relatively cheap and accessible, this material requirement is not necessarily an obstacle. However, in cases where the ligand may be significantly more expensive, this high input material requirement becomes prohibitive.
In addition, although RAFT polymerisation methodology is reported to be tolerant of a range of functional groups, it does not necessarily extend to all possible functional groups, including the functionality that may be present in a peptide where each amino acid residue may have a different potentially reactive group in its side chain. Incorporating protection group strategies to address the attendant complications would add significant technical complexity to the synthesis and likely further increase the material requirement and cost associated with trying to execute RAFT polymerisation on ligands more complicated than monosaccharides.
One possible solution to address these shortcomings would be to couple the ligand after polymerisation has been conducted. This would simultaneously reduce the amount of required ligand significantly (as the MW of the ligand is usually approximately 10% of the polymer MW) and it would also mitigate or eliminate the need for protection group strategies for complex ligands. The choice for conjugation strategy is not straightforward. The chemistry must be mild, and easy to execute, essentially quantitative, and the resultant functionality must be relatively biologically inert (not subject to in-vivo metabolism, or reactive with proteins and genetic material). It is also necessary to avoid pronounced sizes and structures that may deleteriously
affect polymeric hydrophilic/hydrophobic balance and consequent micelle formation. These criteria significantly limit the available choices.
Conjunction via oxime formation is one possible choice. Indeed, oxime formation proceeded to an appreciable degree particularly in the presence of an acid catalyst, (e.g trifluoroacetic acid (TFA)) Thus, oxime chemistry is particularly suitable for ligands (functional and protecting groups) that are not acid sensitive.
For example, while GalNAc, is conjugatable to polymer via processes known in the art, and would be less suitable to be conjugated in the new process according to the present invention because it might undergo acid catalyzed hydrolysis at the glycometric centre resulting in ligand elimination, there are a number of ligands such as those described herein including the peptides described herein, which are particularly suitable to be conjugated by the process according to the present invention, but cannot be conjugated to a satisfying degree by the processes previously known in the art.
Further to this, polymer synthesis is complicated by the lack of useful, non destructive, diagnostic techniques for reaction monitoring and determination of reaction completion. The processes of the invention enable accurate determination of reaction endpoint, confirmation of ligand attachment, and they provide an approach to reaction clean up that removes unwanted reagents from the reaction without the need for additional precipitation or dialysis that can significantly impact recovered yield of the final polymer.
As used herein, the term “block copolymer” refers to two or more homopolymer or copolymer subunits linked by covalent bonds. Block copolymers with two or three distinct blocks are called diblock copolymers and triblock copolymers, respectively. A schematic generalization of a diblock copolymer is represented by the formula [F;G,Hh. . ,]g - [JjKxLi ...]:, wherein each letter stands for a constitutional unit derived from polymerization of a corresponding monomer and wherein each subscript to a constitutional unit represents the mole fraction of that unit in the particular block, the three dots indicate that there may be more (there may also be fewer) constitutional units in each block and q and r indicate the molecular weight of each block in the diblock copolymer. As suggested by the schematic, in some instances, the number and the nature of each constitutional unit is separately controlled for each block. The schematic is not meant and should not be construed to infer any relationship whatsoever between the number of constitutional units and the number of different types of constitutional units in each of the blocks. Nor is the schematic meant to describe any particular number or arrangement of the constitutional units within a particular block. In each block the constitutional units may be disposed in a purely random, an alternating random, a regular alternating, a regular block or a random block configuration unless expressly stated to be otherwise. A purely random
configuration, for example, may have the non -limiting form: f-f-g-h-f-g-g-h-g-h-h-h.... An exemplary alternating random configuration may have the non-limiting form: f-g-f-h-g-f-g-h-g- f-h...., and an exemplary regular alternating configuration may have the non-limiting form: f-g- h-fg- h-f-g-h....An exemplary regular block configuration may have the following non-limiting configuration: ...f-f-f-g-g-g-h-h-h-f-f. while an exemplary random block configuration may have the non-limiting configuration: f-f-f-h-h-f-f-g-g-g-h-h-h-f-f-h-h-h.... In a gradient polymer, the content of one or more monomeric units increases or decreases in a gradient manner from the a-end of the polymer to the w-end. In none of the preceding generic examples is the particular juxtaposition of individual constitutional units or blocks or the number of constitutional units in a block or the number of blocks meant nor should they be construed as in any manner bearing on or limiting the actual structure of block copolymers described herein. As used herein, the brackets enclosing the constitutional units are not meant and are not to be construed to mean that the constitutional units themselves form blocks. That is, the constitutional units within the square brackets may combine in any manner with the other constitutional units within the block, i.e., purely random, alternating random, regular alternating, regular block or random block configurations. The block copolymers described herein are, optionally, alternate, gradient or random block copolymers. Block copolymers and methods for their preparation are described in International Patent Application Publication Number W02015/017519, which is hereby incorporated herein by reference in its entirety.
However, according to the present invention, the ligand (such as e.g. targeting ligand), is not incorporated during polymerization such as contemplated in W02015/017519, e.g. by incorporating monomer A4 (comprising a targeting moiety T2) into block A of the polymer, but rather, according to the present invention, the ligand T (e.g. targeting ligand) is incorporated post polymerization. This allows, among other aspects, to control for stoichiometry of ligand incorporated per co-polymer, and also allows to incorporate ligands which are not susceptible to RAFT polymerization, such as in a non-limiting example oligonucleotides and peptides, such as the pPB peptide. In typical embodiments, one ligand (T), or one moiety bearing a natural number of targeting ligands (T) is being incorporated into every one polymer, i.e. according to the present invention a typical stoichiometry is 1, or a multiplicity thereof. The process of the present invention is thus differentiated over W02015/017519 at least in higher specificity of ligand incorporation and in allowing incorporating certain ligands that the process of W02015/017519 does not allow for. A further advantage of the present invention results from the fact that the ligand T is always placed on the hydrophilic end of the polymer, as opposed to incorporation at a random position as taught in W02015/017519. In other words, the ligand endosome release polymer (ERT) of the present invention, which can be visualized by Formula (I}:
(R1)x— L— (R2)y (I) wherein R1 and R2 and L are defined as specified herein, and wherein x is selected from an integer among 1, 2, 3, 4 or 5, and y is selected from an integer among 1, 2, 3, 4 or 5, provides for a defined stoichiometry between R1 and R2.
Examples of block copolymers according to the present invention include those where Block A is a first block that is a random copolymer formed from monomers of formulae Al, A2 and A3 as described herein. Additional examples of block copolymers include those where Block A is a first block that is a random copolymer formed from monomers comprising formulae Al and A2 as described above. Additional examples of block copolymers include those where A is a first block that is a polymer formed from monomer A2 as described above. Additional examples of block copolymers include those where Block A is a first block that is a random copolymer comprising residues of monomers of formula Al. Additional examples of block copolymers include those where Block A is a first block that is a random copolymer comprising residues of monomers of formula A2. Additional examples of block copolymers include those where Block A is a first block that is a random copolymer comprising residues of monomers of formula A3.
Examples of block copolymers include those where Block B is a second block that is a random copolymer formed from monomers of formulae Bl, B2 and B3 as described herein. Additional examples of block copolymers include those where Block B is a second block that is a random copolymer comprising residues of monomers of formula Bl. Additional examples of block copolymers include those where Block B is a second block that is a random copolymer comprising residues of monomers of formula B2. Additional examples of block copolymers include those where Block B is a second block that is a random copolymer comprising residues of monomers of formula B3.
In the diblock polymer of formula (X and XI), Block A comprises residues derived from the polymerization of monomers of formulae Al and A2. As used herein, the term “residue” means the portion of the monomer that remains in the polymer following polymerization. In one embodiment, Block A comprises one or more residues of monomers Al and A2 and has a molecular weight of from about 1 kDa to about 25 kDa. In another embodiment, Block A comprises one or more residues of monomers Al and A2 and has a molecular weight of from about 2 kDa to about 20 kDa. In another embodiment, Block A comprises one or more residues of monomers Al and A2 and has a molecular weight of from about 2 kDa to about 15 kDa. In another embodiment, Block A comprises one or more residues of monomers Al and A2 and has a molecular weight of from about 2 kDa to about 10 kDa. In another embodiment, Block A
comprises one or more residues of monomers Al and A2 and has a molecular weight of from about 2 kDa to about 5 kDa. In another embodiment, Block A comprises one or more residues of monomers Al and A2 and has a molecular weight of from about 5 kDa to about 20 kDa. In another embodiment, Block A comprises one or more residues of monomers Al and A2 and has a molecular weight of from about 5 kDa to about 15 kDa. In another embodiment, Block A comprises one or more residues of monomers Al and A2 and has a molecular weight of from about 5 kDa to about 10 kDa. In another embodiment, Block A comprises one or more residues of monomers Al and A2 and has a molecular weight of from about 10 kDa to about 25 kDa. In another embodiment, Block A comprises one or more residues of monomers Al and A2 and has a molecular weight of from about 10 kDa to about 20 kDa. In another embodiment, Block A comprises one or more residues of monomers Al and A2 and has a molecular weight of from about 10 kDa to about 15 kDa.
In the diblock polymer of formula (X and XI), Block B comprises residues derived from the polymerization of monomers of formulae B 1, B2 and B3. As used herein, the term “residue” means the portion of the monomer that remains in the polymer following polymerization. In one embodiment, Block B comprises one or more residues of monomers Bl, B2 and B3 and has a molecular weight of from about 1 kDa to about 25 kDa. In another embodiment, Block B comprises one or more residues of monomers Bl, B2 and B3 and has a molecular weight of from about 2 kDa to about 20 kDa. In another embodiment, Block B comprises one or more residues of monomers B 1 , B2 and B3 and has a molecular weight of from about 2 kDa to about 15 kDa. In another embodiment, Block B comprises one or more residues of monomers Bl, B2 and B3 and has a molecular weight of from about 2 kDa to about 10 kDa. In another embodiment, Block B comprises one or more residues of monomers Bl, B2 and B3 and has a molecular weight of from about 2 kDa to about 5 kDa. In another embodiment, Block B comprises one or more residues of monomers B 1, B2 and B3 and has a molecular weight of from about 5 kDa to about 20 kDa. In another embodiment, Block B comprises one or more residues of monomers Bl, B2 and B3 and has a molecular weight of from about 5 kDa to about 15 kDa. In another embodiment, Block B comprises one or more residues of monomers B 1, B2 and B3 and has a molecular weight of from about 5 kDa to about 10 kDa. In another embodiment, Block B comprises one or more residues of monomers Bl, B2 and B3 and has a molecular weight of from about 10 kDa to about 25 kDa. In another embodiment, Block B comprises one or more residues of monomers Bl, B2 and B3 and has a molecular weight of from about 10 kDa to about 20 kDa. In another embodiment, Block B comprises one or more residues of monomers Bl, B2 and B3 and has a molecular weight of from about 10 kDa to about 15 kDa.
According to the processes of the invention, Z and Y are selected so that Z in the diblock polymer of formula (X and XI) will react with Y in a compound of formula (XII):
T-L2-Y (XII) to form a group Y’Z’ and yield a conjugate of formula:
T - L2 — Y'Z1 - L1 - [Block A] - [Block B]
Suitable non-limiting examples of Z and Y as well as the corresponding groups Y’Z’ that remain in the conjugate of formula (XIII) after the reaction of Y and Z are illustrated in the following table A
Table A: Embodiments for X and Y, and the resulting conjugation product X’-Y’ according to certain exemplified embodiments of the invention.
In the first row of the table, the aminoxy of Z can react with an aldehyde (R”’is H) or with a ketone (R”’is C) of Y to provide the corresponding Z’Y’ oxime. In the second row of the table, the aminoxy of Y can react with an aldehyde (R”is H) or with a ketone (R”is C) of Z to provide the corresponding Z’Y’ oxime.
It may be desirable to prepare a compound of formula (X) wherein Z is protected with a protecting group. In such a case, the protecting group may be removed from Z prior to reaction with the compound of formula (XII). It may also be desirable to prepare a compound of formula (XII) wherein Y is protected with a protecting group. In such a case, the protecting group may be removed from Y prior to reaction with the compound of formula (X). A compound of formula (X) wherein Z is protected with a protecting group is a useful intermediate for preparing a conjugate of the invention (e.g., a conjugate of formula (XIII)). Such a protected compound of formula (X) is an embodiment of the invention. A compound of formula (XII) wherein Y is protected with a protecting group is a useful intermediate for preparing a conjugate of the invention (e.g., a conjugate of formula (XIII)). Such a protected compound of formula
(XII) is an embodiment of the invention.
EXAMPLES
The present invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes and are not intended to limit the invention in any manner. Those of skill in the will readily recognize a variety of noncritical parameters which can be changed or modified to yield essentially the same result.
Nomenclature pPB = (N- to C- terminus) H2N-CSNLIDC-C00H (disulphide between two Cys).
Scrambled pPB = (N- to C- terminus) H2N-CIDNLSRC-C00H) (disulphide between two Cys). Used as a control for the pPB active ligand.
Example 1: Biotinylated ligands
Biotinylated versions of ligands were prepared for in vitro binding experiments, to gauge relative binding efficiencies (see Example 6, 7 and 8). The following biotinylated ligands were prepared using standard solid phase peptide synthesis (SPPS). Biotin was coupled using standard organic chemistry amide coupling techniques and the final ligands were purified with reverse phase HPLC. Product confirmation was achieved with mass spectrometry and product purity determined by RPLC techniques.
pPB monovalent Biotin (Compound 1). MW: Calc 1260.56. Found 1260.2. Purity (HPLC) >90%
Scrambled pPB monovalent Biotin. (Compound 2). MW: Calc 1260.56. found 1260.2. Purity (HPLC) >90%
pPB Trivalent Biotin (Compound 3). MW: Calc. 3437.97. Found 3438.89. Purity (HPLC) >90%
Scrambled pPB Trivalent Biotin (Compound 4). MW: Calc. 3438.97. Found 3438.39. Purity
(HPLC) >90%
pPB Divalent Biotin “1A” (Compound 5). MW: Calc.2462.87. found 2463.37. Purity (HPLC >90%)
Example 2: Synthesis of peptide conjugated PEG 12 benzaldehydes The following pPB benzaldehyde ligands (18a and 18b) were synthesized to allow for conjugation to the endosome release polymer (27) once RAFT polymerization was completed.
18a+b
R = pPB, Scrambled pBB a. Step 1 Synthesis of perfluorophenyl 3-(l,3-dioxolan-2-yl)benzoate (13) 3-(l,3-Dioxolan-2-yl)benzoic acid (11) (7.9 g, 41 mmol) and (TEA 11.4 mL, 81 mmol) were stirred in DCM at 0°C. 2,3,4,5,6-Pentafluorophenyl 2,2,2-trifluoroacetate (12) (7.0 mL, 41 mmol) was added dropwise and the reaction allowed to warm to RT over 2 hr. The reaction was concentrated in-vacuo. taken up in EtOAc (200 mL) and washed with NaHCOs (2 x 100 mL) and brine (1 x lOOmL), dried (MgSCU), filtered and concentrated in-vacuo to give perfluorophenyl 3-(l,3-dioxolan-2-yl)benzoate (13) (13.6 g, 92.8 %) which was used without purification.
b. Step 2 Synthesis of l-{[3-(l,3-dioxolan-2-yl)phenyl]formamido}-
3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39-oic acid (15) l-Amino-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39-oic acid (14) (7 g, 11.3 mmol), 2,3,4,5,6-pentafluorophenyl 3-(l,3-dioxolan-2-yl)benzoate (13) (4.5 g, 12.5 mmol), and DMAP (69 mg, 0.6 mmol) were stirred at in DCM (200 ml) at RT for 16 hr. The reaction was concentrated in-vacuo and purified by automated flash chromatography (0-10% MeOH/DCM) to give l-{[3-(l,3-dioxolan-2-yl)phenyl]formamido}-
3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39-oic acid (15) (5.1 g, 56.7 %). c. Step 3 Synthesis of 4-nitrophenyl l-{[3-(l,3-dioxolan-2-yl)phenyl]formamido}- 3,6,9,12,15, 18,21,24,27, 30,33,36-dodecaoxanonatriacontan-39-oate (17) l-{[3-(l,3-dioxolan-2-yl)phenyl]formamido}-3,6,9,12,15,18,21,24,27,30,33,36- dodecaoxanonatriacontan -39-oic acid (15) (5.1 g, 6.4 mmol), TEA (1.4 mL, 9.6 mmol) and bis(4-nitrophenyl) carbonate (16) (2.15 g, 7.1 mmol) were stirred in DCM (100 mL) at RT for 16 hr. The reaction was diluted with DCM (100 mL), washed with saturated NaHCOs (5 x 75 mL), concentrated in-vacuo and the residue purified by automated flash chromatography (0 - 10% MeOH/DCM) to give 4-nitrophenyl l-{[3-(l,3-dioxolan-2-yl)phenyl]formamido}-
3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxanonatriacontan-39-oate (17) (5.1 g, 86.8 %). d. Step 4 Synthesis of pPB PEG 12 benzaldehydes (18 a + b) pPB and scrambled pPB peptides were prepared using standard solid phase peptide synthesis techniques. The peptides were globally deprotected followed by amide conjugation with activated carboxylic acid (n). deprotection of the dioxalan, purification by reverse phase RPLC and subsequent lyophilization gave peptide conjugated PEG 12 benzaldehydes (18 a + b).
Monovalent pPB PEG12 benzaldehyde (18a). MW: Calc.1652.92 Found 1653.92. Purity (RP-
Scrambled monovalent pPB PEG12 benzaldehyde (18b). MW: Calc.1652.92 Found 1653.85.
Purity (RP-HPLC) >95% Example 3: Synthesis of Endosomal release polymer
The endosome release polymer was synthesized using RAFT polymerization and terminated with a protected aminooxy functional group to allow for subsequent oxime conjugation to benzaldehyde peptide ligands (18a and 18b). Part 1) Synthesis of chain transfer agent tert-butyl ((6-cyano-6-methyl-9,15-dioxo-4-thioxo-
3,5-dithia-10,14-diazahexadecan-16-yl)oxy)carbamate (compound 24)
a. Step 1 Synthesis of perfluorophenyl 4-cyano-4-(((ethylthio)carbonothioyl)thio)- pentanoate (20).
4-Cyano-4-{[(ethylsulfanyl)methanethioyl]sulfanyl}-4-methylbutanoic acid (19) (26 g, 99 mmol) and triethylamine (12 g, 118 mmol) were stirred at 0°C in anhydrous DCM (500 mL).
2.3.4.5.6-Pentafluorophenyl 2,2,2-trifluoroacetate (12) (33 g, 118.5 mmol) was added slowly over 15 mins. The solution was stirred at 0°C until complete. The reaction was washed with saturated NaHCOs (3 x 250 mL), dried (MgSOQ, filtered and concentrated in-vacuo to give perfluorophenyl 4-cyano-4-(((ethylthio)carbonothioyl)thio)pentanoate (20) (Quant) which was used without further purification. b. Step 2 Synthesis of tert-butyl (2-((3-(((benzyloxy)carbonyl)amino)propyl)amino)-2- oxoethoxy)carbamate (22)
{[(tert-butoxycarbonyl)amino]oxy}acetic acid (21) (20 g, 105 mmol), DIPEA (55 mL, 314 mmol), HATU (40 g, 105 mmol) and benzyl N-3-[ amino]propylcarbamate HC1 salt (26 g, 105 mmol) were stirred in DCM (350 mL) at RT for 16 h. DCM (150 mL) was added and the reaction washed with saturated NaHCOs and brine, dried (MgSOQ, concentrated in-vacuo and purified by automated flash chromatography (0-5% MeOH in DCM) to give tert-butyl N-{[(3- {[(benzyloxy)carbonyl]amino}propyl) carbarn oyl]methoxy} carbamate (22)(31 g, 78.2 %). c. Step 3 Synthesis of tert-butyl (2-((3-aminopropyl)amino)-2-oxoethoxy)- carbamate (23)
/c/V-Butyl N-{ [(3-{ [(benzyloxy)carbonyl]amino}propyl)carbamoyl]methoxy } -carbamate (22) (31 g, 81 mmol) was subjected to catalytic hydrogenation in MeOH (200 mL) over 10% palladium on carbon (cat) at RT for 16 hr. Upon completion the solution was filtered through celite and concentrated to dryness to give tert-butyl (2-((3-aminopropyl)amino)-2- oxoethoxy)carbamate (23) (19.4 g, 91.5%) which was used without further purification. d. Step 4 Synthesis of tert-butyl ((6-cyano-6-methyl-9,15-dioxo-4-thioxo-3,5-dithia- 10,14-diazahexadecan-16-yl)oxy)carbamate (24)
/c/V-Butyl N-{ [(3 -aminopropyl)carbamoyl]methoxy} carbamate (23) (18 g, 73 mmol),
2.3.4.5.6-pentafluorophenyl 4-cyano-4-{[(ethylsulfanyl)methanethioyl]sulfanyl}-4- methylbutanoate (20) (31 g, 73 mmol) and DMAP (178 mg, 1.5 mmol) were stirred in DCM (100 mL) at RT until complete. The reaction was concentrated in-vacuo, taken up in EtOAc (250 mL), washed with sat'd NaHCOs (2 x lOOmL), dried (MgSOQ, filtered and concentrated in- vacuo. The residue was purified by automated flash chromatography (0-5% MeOH/DCM) to
give tert-butyl ((6-cyano-6-methyl-9,15-dioxo-4-thioxo-3,5-dithia-10,14-diazahexadecan-16- yl)oxy)carbamate (24) (28 g, 78.1%). ’H NMR (400 MHz, CDCh) 6 8.29 (bs, Ih), 7.79 (s, 1H), 6.62 (m, IH), 5.29 (s, 2H), 4.32 (s, 2H), 3.27-3.39 (m, 6H), 2.40-2.50 (m, 4H), 1.88 (s, 3H), 1.72-1.85 (m, 3 H), 1.48 (s, 9H), (1.34 (t, 3H).
Part 2) synthesis of “BOC-gly” Endosomal release polymer (compound 25)
“BOC-Gly” endosomal release polymer (25) was prepared using RAFT polymerisation techniques from chain transfer agent (24) as with analogous synthetic techniques as described in Prieve, M.G., Harvie, P., Monahan, S.D., Roy, D., Li, A.G., Blevins, T.L., Paschal, A.E., Waldheim, M., Bell, E.C., Galperin, A., Ella-Menye, J.R., et al. (2018). Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency. Mol Ther 26, 801-813. 10.1016/j.ymthe.2017.12.024. The final released material had the following observed monomeric composition and average molecular weight.
2’-O-Methyl nucleotides are depicted as “m” + UPPER CASE; 2’ -Fluoro nucleotides are depicted as “f” + UPPER CASE; Phosphorothioate linkers are depicted as “s” Part 3) Synthesis of oxime conjugated ligand functionalized endosomal release polymers exemplified by the following general reaction protocol.
a. Step 1. Removal of BOC from endosomal release polymer 25 1 ,044g of polymer was taken up in DCM (4 ml) and TF A (3 ,3ml) was added. The reaction was stirred at RT for 2 hr. The reaction was concentrated in-vacuo for 60 mins. The residual TFA salt was used in the subsequent conjugation step without additional processing. b. Step 2. Oxime conjugation. The residual material from the previous step was taken up in DCM (5 mL), 0.55 stoichiometric equivalents of the appropriate peptide benzaldehyde (18 a or b) added and the reaction stirred at RT for 72 hrs. An additional 0.55 stoichiometric equivalents of the appropriate peptide benzaldehyde was added and stirring continued for a further 72 hrs. Resin bound sequestration agent PS-TsNHNH2 (PS-tosylhydrazide) resin (3 equivalents) were added and the reaction left to stand for 24 hrs. The resin was removed by filtration washing with additional
DCM. The solvent was removed in-vacuo drying to a constant weight. The residual material was taken up in acetone and dialysed against methanol for 2 days followed by water for 2 days. Lyophilising give the peptide oxime conjugated endosomal release polymers 28 a or b.
Example 4: Ligands and chemistry used to form siRNA-ligand conjugates
The following ligands and corresponding siRNA conjugates were synthesized to assess in vitro (Example 10) and in vivo activity (Example 11) in conjunction with a targeting endosome release polymer (Example 3). Peptide ligands were first synthesized using standard solid phase peptide synthesis protocols, then functionalized with an appropriate conjugation motif (e.g mal eimide or DBCO) to facilitate coupling to the 3’ end of the sense strand of an siRNA molecule. The phosphate at the 3’ end of the siRNA was also accordingly modified for coupling to the ligand (e.g 3’ C6 amino or 3’ C6 sulfhydryl).
Scrambled monovalent pPB (compound 30)
MsCI/TEA/DCM
divalent pPB Maleimide (compound 42) a. Step 1: Synthesis of tert-butyl 3-(2-(2-(2-((methylsulfonyl)oxy)ethoxy)ethoxy)- ethoxy)propanoate tert-Butyl-3-{2-[2-(2-hydroxyethoxy)ethoxy]ethoxy}propanoate (25 g, 90 mmol) and TEA (16.0 mL, 113 mmol were stirred in DCM at 0°C. Methanesulfonyl chloride (11.3 g, 99 mmol) in DCM was added dropwise and the reaction stirred at RT for 1.5 hr. The organics were washed with saturated NaHCOs, water and brine, dried (MgSOQ and concentrated in- vacuo to give tert-butyl 3-(2-{2-[2-(methanesulfonyloxy)ethoxy]ethoxy}ethoxy)propanoate (32.1 g, Quant) which was used without purification.
b. Step 2: Synthesis of tert-butyl 3-(2-(2-(2-bromoethoxy)ethoxy)ethoxy)propanoate tert-Butyl 3-(2-{2-[2-(methanesulfonyloxy)ethoxy]ethoxy}ethoxy)propanoate (33 g,
92 mmol) and TBAB (39 g, 120 mmol) were heated at reflux for 2 hr. The reaction was cooled, washed with water and the aqueous back extracted with hexane. The combined organics were washed with brine, dried (Na2SO4), concentrated in-vacuo and the residue purified by automated flash chromatography (35% EtOAc/hex) to give tert-butyl 3-{2-[2-(2- bromoethoxy)ethoxy] ethoxy } propanoat e (27.4 g, 87.1%) c. Step 3: Synthesis of 2-(3,5-dimethoxybenzyl)isoindoline-l, 3-dione
(3,5-Dimethoxyphenyl)methanamine and isobenzofuran-1, 3-dione were heated in AcOH at reflux for 16 h. The reaction was concentrated in-vacuo, the residue taken up in DCM, washed with IM HC1, NaHCOs, water and brine, dried (Na2SO4) and concentrated in-vacuo. The residue was purified bu automated flash chromatography (35% EtOAc/Hex) to give 2-[(3,5- dimethoxyphenyl)methyl]isoindole-l, 3-dione (9.03 g, 45.6 %). d. Step 4 : Synthesis of 2-(3,5-dihydroxybenzyl)isoindoline-l, 3-dione
2-[(3,5-Dimethoxyphenyl)methyl]isoindole-l, 3-dione (9 g, 30 mmol) was stirred in DCM at 0°C. BBn (11.7 mL, 121 mmol) was added dropwise and the reaction stirred for 16 hr allowing to warm to RT. The reaction was cooled to 0°C, quenched with MeOH and concentrated in-vacuo. The residue was taken up in EtOAc, washed sequentially with IM HC1, saturated NaHCOs, water and brine, dried (MgSCU) and concentrated in-vacuo to give 2-[(3,5- dihydroxyphenyl)methyl]isoindole-l, 3-dione (7.8 g 95.7 %) which was used without further purification. e. Step 5: Synthesis of tert-butyl 3-{2-[2-(2-{3-[2-(2-{2-[3-(tert-butoxy)-3-oxopropoxy]- ethoxy}ethoxy)ethoxy]-5-[(l,3-dioxoisoindol-2-yl)methyl]phenoxy}ethoxy)ethoxy]ethoxy}- propanoate
2-[(3,5-dihydroxyphenyl)methyl]isoindole-l, 3-dione (10 g, 37 mmol), tert-butyl 3-{2- [2-(2-bromoethoxy)ethoxy] ethoxy } propanoat e (30.4 g, 89 mmol) and K2CO3 were heated at reflux in MeCN for 16 hr. The reaction was cooled to RT, filtered, washed with additional MeCN and concentrated in-vacuo. The residue was by automated flash chromatography (60% EtOAc/hex) to give tert-butyl 3-{2-[2-(2-{3-[2-(2-{2-[3-(tert-butoxy)-3- oxopropoxy]ethoxy}ethoxy)ethoxy]-5-[(l,3-dioxoisoindol-2- yl)methyl]phenoxy}ethoxy)ethoxy]ethoxy}propanoate (14 g, 47.7 %)
/ /
f. Step 6: Synthesis of tert-butyl 3-[2-(2-{2-[3-(aminomethyl)-5-[2-(2-{2-[3-(tert- butoxy)-3-oxopropoxy] ethoxy} ethoxy)ethoxy] phenoxy] ethoxy} ethoxy)ethoxy] propanoate . tert-Butyl 3-{2-[2-(2-{3-[2-(2-{2-[3-(tert-butoxy)-3-oxopropoxy]ethoxy}ethoxy)- ethoxy]-5-[(l,3-dioxo-3a,7a-dihydroisoindol-2-yl)methyl]phenoxy}ethoxy)ethoxy]- ethoxy} propanoate (14 g, 17.7 mmol) and hydrazine hydrate (4.3 ml, 88 mmol) were stirred in MeOH at 50°C for 16 hr. The resultant precipitate was removed by filtration and the filtrate concentrated in-vacuo. The residue was purified by automated flash chromatography (10% MeOH/DCM) to give tert-butyl 3-[2-(2-{2-[3-(aminomethyl)-5-[2-(2-{2-[3-(tert-butoxy)-3- oxopropoxy] ethoxy} ethoxy)ethoxy]phenoxy] ethoxy} ethoxy)ethoxy]propanoate (7.71 g, 66.1 %). g. Step 7: Synthesis of tert-butyl 3-{2-[2-(2-{3-[2-(2-{2-[3-(tert-butoxy)-3- oxopropoxy]ethoxy}ethoxy)ethoxy]-5-{[3-(2,5-dioxopyrrol-l- yl)propanamido]methyl}phenoxy} ethoxy)ethoxy]ethoxy}propanoate tert-Butyl-3-[2-(2-{2-[3-(aminomethyl)-5-[2-(2-{2-[3-(tert-butoxy)-3- oxopropoxy] ethoxy} ethoxy)ethoxy]phenoxy] ethoxy} ethoxy)ethoxy]propanoate (7.71 g, 11.7 mmol), 2,5-dioxopyrrolidin-l-yl 3-(2,5-dioxopyrrol-l-yl)propanoate (3.1 g, 11.7 mmol) and NMM (1.41 ml, 12.9 mmol) were stirred in DCM at RT for 36 ht. The reaction was concentrated in-vacuo and the residue purified by automated flash chromatography (2.5% MeOH/DCM) to give tert-butyl 3-{2-[2-(2-{3-[2-(2-{2-[3-(tert-butoxy)-3-oxopropoxy]ethoxy}ethoxy)ethoxy]-5- {[3-(2,5-dioxopyrrol-l-yl)propanamido]methyl}phenoxy} ethoxy)ethoxy] ethoxy (propanoate (9.0 g, 95.1 %) h. Step 8: Synthesis of 3-[2-(2-{2-[3-(2-{2-[2-(2-carboxyethoxy)ethoxy]ethoxy}ethoxy)- 5-{[3-(2,5-dioxopyrrolidin-l- yl)propanamido] methyl} phenoxy] ethoxy} ethoxy)ethoxy] propanoic acid tert-butyl 3-{2-[2-(2-{3-[2-(2-{2-[3-(tert-butoxy)-3-oxopropoxy]ethoxy(ethoxy)ethoxy]- 5-{[3-(2,5-dioxopyrrolidin-l-yl)propanamido]methyl(phenoxy(ethoxy)ethoxy]- ethoxy} propanoate (9.0 g, 11.1 mmol) was stirred in formic acid at RT for 16 hr. The reaction was concentrated in-vacuo azeotroping with toluene twice and drying under high vacuum to give 3-[2-(2-{2-[3-(2-{2-[2-(2-carboxyethoxy)ethoxy]ethoxy(ethoxy)-5-{[3-(2,5-dioxopyrrolidin-l- yl)propanamido]methyl}phenoxy]ethoxy}ethoxy)ethoxy]propanoic acid quantitatively which was used with purification.
Step 9: Synthesis of 2,5-dioxopyrrolidin-l-yl 3-(2-{2-[2-(3-{[3-(2,5-dioxopyrrol-l- yl)propanamido] methyl}-5- {2- [2- (2- {3- [(2,5-dioxopyrrohdin- l-yl)oxy] -3- oxopr opoxy} ethoxy)ethoxy] ethoxy} phenoxy)ethoxy] ethoxy} ethoxy)propanoate
3-[2-(2-{2-[3-(2-{2-[2-(2-carboxyethoxy)ethoxy]ethoxy}ethoxy)-5-{[3-(2,5- dioxopyrrol-l-yl)propanamido]methyl}phenoxy]ethoxy}ethoxy)ethoxy]propanoic acid (8g, 11.5 mmol), N-hydroxysuccinimde (3.6 g, 31. 4 mmol) and DMAP were stirred in DCM at RT for 5 hr. The reaction was concentrated in-vacuo and purified by automated flash chromatography (10 % MeOH/DCM) to give 2,5-dioxopyrrolidin-l-yl 3-(2-{2-[2-(3-{[3-(2,5-dioxopyrrol-l- yl)propanamido]methyl}-5-{2-[2-(2-{3-[(2,5-dioxopyrrolidin-l-yl)oxy]-3- oxopropoxy}ethoxy)ethoxy]ethoxy}phenoxy)ethoxy]-ethoxy}ethoxy)propanoate (42) (3.7 g, 36.2%) pPB conjugation and siRNA synthesis were conducted as described elsewhere to give aromatic dimeric pPB (compound 43) and aromatic dimeric scrambled pPB (compound 44)
Trimeric pPB (compound 58)
Trimeric pPB (compound 58) can be prepared according to the procedure described in the scheme above.
Trimeric scrambled pPB (compound 59)
Trimeric scrambled pPB (compound 59) can be prepared using an analogous procedure to that described for compound 58.
5 Trimeric C6 pPB (compound 63)
Trimeric C6 pPB (compound 63) can be prepared according to the procedure described in the scheme above.
Trimeric C6 scrambled pPB (compound 64) Trimeric C6 scrambled pPB (compound 64) can be prepared using an analogous procedure to that described for compound 63 pPB conjugation and siRNA synthesis were conducted as described elsewhere to give trimeric pPB (compound 58), trimeric scrambled pPB (compound 59), trimeric C6 pPB (compound 63) and trimeric C6 scrambled pPB (compound 64)
Example 5: ligand siRNA conjugates
The following siRNA-ligand conjugates, as illustrated in Example 3, were prepared using automated oligonucleotide synthesis using standard procedures. Nucleotide deprotection and cleavage from the solid support, afforded the 3’ modified sense strand and the corresponding and complementary anti-sense strand. After purification by dual HPLC, the ligand conjugated siRNA duplex was formed by annealing. Table 1 lists siRNA sequences, ID’s and mass analysis.
A = adenine; G = guanine; U = uracil; C = cytosine; mN = 2’0Me ribose modification; fN = 2’fluoro ribose modification; s = phosphorothioate (PS) modification.
Example 6. Uptake of monovalent and trivalent pPB ligand by HSC-T6 and NIH3T3 Cells in vitro.
HSC-T6 is an immortalized rat hepatic stellate cell line and NIH3T3 is a murine embryonic fibroblast cell line. Both cell lines express the pPB target receptor PDGFRB with NIH3T3 cells exhibiting higher expression (Fig 1). Preparation of biotin-pPB/AF488-streptavidin complex
Biotinylated monovalent or trivalent pPB ligand were reconstituted in DMSO and functionalized by incubating with Alexa Fluor 488-labelled streptavidin in Tyrode buffer (containing 10 mM HEPES, 5.6 mM glucose, 10 mM KC1, 35 mM NaCl, 0.4 mM MgCl, 1.0 mM CaC12 and 0.1% BSA, pH 7.3) at 4°C overnight at a molar ratio of 4.5:1 of biotinylated ligands to biotin binding sites.
Cell culture
HSC-T6 cells were cultured in rat HSC medium (DMEM-High Glucose without Sodium Pyrvate containing 10% FBS and 2.5 mM L-Glutamine). NIH3T3 cells were cultured in MEM containing 10% FBS and 2.5 mM L-Glutamine.
Western blot analysis of PDGFRB expression
Cultured HSC-T6 cells and NIH3T3 cells were lysed with RIPA buffer. Cell lysates were cleared by centrifugation at 13000*g for 15 min and separated with SDS PAGE, transferred to PVDF membrane, and probed using anti-PDGFRB (cell signaling) and anti-beta-actin antibodies (Cell Signaling) in 5% BSA Tris-buffered saline and Tween-20 buffer.
Uptake of biotin-pPB/AF488-streptavidin complex
HSC-T6 or NIH3T3 cells were seeded into sterile 96 wells plates (20000/well) and cultured for 48 h at 37 °C. The previous prepared biotin-pPB/AF488-streptavidin complex was diluted to 2.22, 0.556, 0.136, 0.035 and 0.009 pM (based on streptavidin molar concentration) in Tyrode buffer and was kept on ice. Prior to complex incubation, the cells were washed three times with ice cold Tyrode buffer and functionalized streptavidin was added to each well which was incubated at 4 °C for 1.5 h. After incubation, the cells were washed three times with ice-cold Tyrode buffer to remove any unbound ligand complex, before adding 37 °C preheated complete media and immediately incubating the cells in 37 °C for 1 h to allow endocytosis of receptor bound ligand-complexes. After incubation, the cells were washed once with DPBS and 50 pL of 0.25% Trypsin-EDTA was added to each well. After incubation at 37 °C for 3-4min, 100 pL of media was added to each well to inactivate the trypsin, and detachment of cells was accomplished with vigorous mixing. The cells were transferred to a V-bottom 96-well plate, spun at 1200 RPM for 5 min, and washed twice with DPBS before resuspension in DPBS containing Live/Dead Red stain. After 30 min at 4 °C, the cells were centrifuged, and the pellet resuspended in stain buffer prior to flow cytometry analysis.
Flow cytometry analysis
Analyses were performed on a FACS-Canto II using the software FACS Diva. As a marker for viability, cells were stained with Live/Dead Red. The forward scatter and side scatter gate were set to include all viable cells.
Approximately 10000-15000 cells were counted for each sample and binding/uptake was determined as increased intensity in green fluorescence at 488 nm detected in the FL1 channel. The mean fluorescence intensity (MFI) of cells incubated with functionalized streptavidin minus
the MFI of cells incubated without functionalized streptavidin (free fluorophore only) was used to determine binding/uptake.
Results
Uptake of monovalent and trivalent pPB ligand complexes was observed in both HSC-T6 cells and NIH3T3 cells as evidenced by the dose dependent increase of AF488 fluorescence in the treated cells (Fig 2). Trivalent pPB ligands showed ~60-fold higher binding affinity than monovalent pPB ligands. Ligand complex with scrambled monovalent pPB peptide showed ~4-fold lower potency than monovalent pPB ligand complex. This potency difference increased to ~60 fold in the trivalent ligands. The mean fluorescence intensity (MFI) from the ligand was higher in NIH3T3 cells than HSC-T6 cells, correlated to the PDGFRB receptor expression level in these two cell lines. These results demonstrated the effective uptake of pPB ligands in PDGFRB expressing cells.
Example 7. Uptake of divalent and trivalent pPB ligands by primary human hepatic stellate cells in vitro.
Materials and Methods
Preparation of biotin-pPB/AF488-streptavidin complex
Biotinylated divalent, trivalent pPB or scrambled trivalent pPB ligands were reconstituted in DMSO and functionalized by incubating with Alexa Fluor 488-labelled streptavidin in Tyrode buffer (containing 10 mM HEPES, 5.6 mM glucose, 10 mM KC1, 35 mM NaCl, 0.4 mM MgCl, 1.0 mM CaC12 and 0.1% BSA, pH 7.3) at 4°C overnight at a molar ratio of 4.5: 1 of biotinylated ligands to biotin binding sites.
Cell culture pHHSC were cultured using a human hepatic stellate cell culture kit from ScienCell.
Uptake of biotin-pPB/AF488-streptavidin complex pHHSCs were seeded into sterile 96 wells plates (6000 cells/well) and cultured for 48 h at 37 °C. The previous prepared biotin-pPB/AF488-streptavidin complex was diluted to 3, 1, 0.3 and 0.1 pM (based on streptavidin molar concentration) in Tyrode buffer and was kept on ice. Prior to complex incubation, the cells were washed three times with ice cold Tyrode buffer and functionalized streptavidin was added to each well which was incubated at 4 °C for 1.5 h. After
incubation, the cells were washed three times with ice-cold Tyrode buffer to remove any unbound ligand complex, before adding 37 °C preheated complete media and immediately incubating the cells in 37 °C for 1 h to allow endocytosis of receptor bound ligand-complexes. After incubation, the cells were washed once with DPBS and 50 pL of 0.025% Trypsin-EDTA was added to each well. After incubation at 37 °C for 3-4min, 100 pL of Trypsin Neutralization Solution (TNS) was added to each well to inactivate the trypsin, and detachment of cells was accomplished with vigorous mixing. The cells were transferred to a V-bottom 96-well plate, spun at 1200 RPM for 5 min, and washed twice with stain buffer before resuspension in stain buffer containing DAPI (4’,6-diamidino-2-phenylindole) prior to flow cytometry analysis.
Flow cytometry analysis
Analyses were performed on a FACS-Canto II using the software FACS Diva. As a marker for viability, cells were stained with DAPI. The forward scatter and side scatter gate were set to include all viable cells. Approximately 10000-15000 cells were counted for each sample and binding/uptake was determined as increased intensity in green fluorescence at 488 nm detected in the FL1 channel. The mean fluorescence intensity (MFI) of cells incubated with functionalized streptavidin minus the MFI of cells incubated without functionalized streptavidin (free fluorophore only) was used to determine binding/uptake.
Results
Uptake of divalent and trivalent pPB ligand complexes was observed in pHHSCs as evidenced by the dose dependent increase of AF488 fluorescence in the treated cells (Fig 3) Divalent pPB ligands showed slightly lower binding activity than trivalent pPB ligands but were much more potent than the scrambled trivalent pPB ligand. These results demonstrates that pPB ligand valency affects binding affinity.
Example 8. Uptake of Trivalent pPB ligand by NIH3T3, LX-2 and Primary Human HSC in vitro.
LX-2 is an immortalized human hepatic stellate cell line and NIH3T3 is a murine embryonic fibroblast cell line. All 3 cell lines express the pPB target receptor PDGFRB with NH43T3 cells exhibited highest expression (Fig 4).
Materials and Methods
Preparation of biotin-pPB/AF488-streptavidin complex
Biotinylated trivalent pPB ligand was reconstituted in DMSO and functionalized by incubating with Alex Fluor 488-labelled streptavidin in Tyrode buffer (containing 10 mM HEPES, 5.6 mM glucose, 10 mM KC1, 35 mM NaCl, 0.4 mM MgCl, 1.0 mM CaC12 and 0.1% BSA, pH 7.3) at 4°C overnight at a molar ratio of 4.5: 1 of biotinylated ligands to biotin binding sites.
Cell culture
LX-2 cells were cultured in DMEM-High Glucose containing 10% FBS and 2.5 mM L- Glutamine. NIH3T3 cells were cultured in MEM with containing 10% FBS and 2.5 mM L- Glutamine. pHHSC were cultured using the human hepatic stellate cell culture kit from ScienCell.
Western blot analysis of PDGFRB expression
Cultured LX-2, NIH3T3 and pHHSC cells were lysed with RIP A buffer. Cell lysates were cleared by centrifugation at 13000* for 15 min and separated with SDS PAGE, transferred to PVDF membrane, and probed using anti-PDGFRB (cell signaling) and anti -beta- actin antibodies (Cell Signaling) in 5% BSA Tris-buffered saline and Tween-20 buffer.
Uptake of biotin-pPB/AF488-streptavidin complex
LX-2, NIH3T3 or pHHSC cells were seeded into sterile 96 wells plates (20000/well) and cultured for 48 h at 37 °C. The previous prepared biotin-pPB/AF488-streptavidin complex was diluted to 3, 1, 0.3, and 0.1 pM (based on streptavidin molar concentration) in Tyrode buffer and was kept on ice. Prior to complex incubation, the cells were washed three times with ice cold Tyrode buffer and functionalized streptavidin was added to each well which was incubated at 4 °C for 1.5 h. After incubation, the cells were washed three times with ice-cold Tyrode buffer to remove any unbound ligand complex, before adding 37 °C preheated complete media and immediately incubating the cells in 37 °C for 1 h to allow endocytosis of receptor bound ligandcomplexes. After incubation, the cells were washed once with DPBS and 50 pL of 0.25% Trypsin-EDTA was added to each well. After incubation at 37 °C for 3-4min, 100 pL of media was added to each well to inactivate the trypsin, and detachment of cells was accomplished with vigorous mixing. The cells were transferred to a V-bottom 96-well plate, spun at 1200 RPM for
5 min, and washed twice with stain buffer before resuspension in stain buffer containing DAPI prior to flow cytometry analysis.
Flow cytometry analysis
Analyses were performed on a FACS-Canto II using the software FACS Diva. As a marker for viability, cells were stained with DAPI. The forward scatter and side scatter gate were set to include all viable cells. Approximately 10000-15000 cells were counted for each sample and binding/uptake was determined as increased intensity in green fluorescence at 488 nm detected in the FL1 channel. The mean fluorescence intensity (MFI) of cells incubated with functionalized streptavidin minus the MFI of cells incubated without functionalized streptavidin (free fluorophore only) was used to determine binding/uptake.
Results
Uptake of trivalent pPB ligand complexes was observed in HSC-T6, LX-2 and pHHSC as evidenced by the dose dependent increase of fluorescence intensity in the treated cells (Fig 5). The mean fluorescence intensity (MFI) in the 3 cell types correlated with the target receptor (PDGFBR) expression levels. These results demonstrate effective uptake of pPB ligands in PDGFRB expressing cells including human hepatic stellate cells.
Example 9. Trivalent pPB Conjugate siRNA Enabled Gene Silencing in NIH3T3 Cells in Vitro when Treated Together with Chloroquine.
PPIB is a widely expressed protein coding gene and was used as a surrogate siRNA target in this study. NIH3T3 cells express high levels of PDGFRB and exhibited the best pPB ligand uptake efficiency in the previous experiments. To address limited endosome release in siRNA conjugate delivery, we stimulated the cells with chloroquine after siRNA conjugate treatment.
Materials and Methods
Cell culture
NH43T3 cells were cultured in MEM with containing 10% FBS and 2.5 mM L- Glutamine.
Treatment of siRNAs in NIH3T3 cells
NIH3T3 cells were seeded into sterile 96 wells plates (10000/well) and cultured for 24 h at 37 °C. Cells were then washed with 100 pL OptiMEM and then incubated with 0.4, 0.1 or 0.025 pM of TripPB-siPPIB, Tri-Scr-pPB-siPPIB, unconjugated siPPIB or siLuc2 in OptiMEM for 4 h. The siRNAs or conjugates were then removed, and the cells were treated with 50 pM of chloroquine in complete culture medium for another 20 h. Culture medium were removed after treatment completion and the cells were lysed with QuantiGene Lysis Mixture for next step gene expression quantification.
QuantiGene branched DNA assay
To evaluate gene silencing activity, cell lysates collected after siRNA treatment were subject to QuantiGene branched DNA assay according to the manufacturer’s protocol. In brief, cell lysates were incubated with capture probes targeting mPpib (target gene) and mGapdh (endogenous control) at 55 °C for 18-20 h. After washing, the plates were incubated with preamplification probes and amplification probes to amplify the signal. The excess probes were washed off and assay substrates added to allow quantifying luminescence using a plate reader. Ppib signal was normalized to the signal from Gapdh.
Results
Dose dependent target gene (Ppib) silencing was observed in TripPB-siPPIB, Tri- Scr-pPB-siPPIB and unconjugated PPIB treated cells but not in the siLuc2 treated cells, demonstrating targeted gene silencing mediated by siPPIB (Fig 6). Importantly, TripPB conjugated siRNA conferred the highest activity as compared to Tri-Scr-pPB-siPPIB and unconjugated PPIB, suggesting that TripPB ligand enables more efficient delivery of siRNA. Consistent with the ligand binding results, Tri-Scr-pPB ligand conjugation moderately improved RNAi activity as compared to unconjugated siRNA. Unconjugated siRNA was only active at the highest tested dose (0.40 pM), potentially through a passive uptake delivery mechanism. These results demonstrated that trivalent pPB ligand conjugation could enhance delivery of siRNA to NIH3T3 cells.
Example 10. Trivalent pPB Conjugate siRNA with pPB Functionalized Endosome Release Polymer Enabled Gene Silencing in pHHSC Cells in Vitro.
Materials and Methods
The polymer was dissolved in 10 mM phosphate/200mM sucrose PBS (pH 7), up to 40 mg/mL followed by successive filtration (3-4 times) through a 0.2-micron sterile filter.
Cell culture pHHSC were cultured using the human hepatic stellate cell culture kit from ScienCell.
Treatment of siRNAs in pHHSC cells pHHSC cells were seeded into sterile 96 wells plates (5000/well) and cultured for 24 h at 37 °C. Cells were then washed with 100 pL OptiMEM and then treated with 0.3 or 0.1 pM of TripPB-siPPIB or unconjugated siPPIB in OptiMEM for 4 h. GalNAc or pPB functionalized ERP were then added to the culture at the concentration of 30 ug/mL. At 24 h post siRNA treatment, cells were supplemented with 10% FBS. Culture medium were removed at 72 h post siRNA treatment and the cells were lysed with QuantiGene Lysis Mixture for next step gene expression quantification.
QuantiGene branched DNA assay
To evaluate gene silencing activity, cell lysates collected after siRNA treatment were subject to QuantiGene branched DNA assay according to manufacturer’s protocol. In brief, cell lysates were incubated with capture probes targeting human PPIB (target gene) and GAPDH (endogenous control) at 55 °C for 18-20 h. After washing, the plates were incubated with preamplification probes and amplification probes to amplify the signal. The excessive probes were then washed off and assay substrates were added to allow quantifying luminescence using a plate reader. The signal from PPIB was normalized to the signal from GAPDH.
Results
When combined with 30 pg/mL of pPB-ERP, TripPB-siPPIB enabled 79% and 65% target gene KD when treated at 0.3 and 0.1 pM, respectively (Fig 7). In contrast, unconjugated siPPIB showed low gene silencing activity (<40%) when treated in combination with 30 pg/mL pPB-ERP and the dose response effect was not appreciable. RNAi activity was also observed in the TripPB-siPPIB + GalNAc-ERP combo treatment group but the GalNAc-ERP was less effective as compared to pPB-ERP. siRNA alone, either unconjugated or conjugated with
TripPB, or pPB-ERP alone showed no effect on target gene silencing. These results suggested that pPB ligand could improve both siRNA and ERP delivery to pHHSC in vitro.
Example 11. pPB-ERP Improves in vivo Gene Silencing by TripPB siRNA Conjugate in Mouse Liver Fibrosis Model.
HSC specific gene Hsp47 was selected as the siRNA target to allow evaluation of RNAi activity in the targeted cell population.
Materials and Methods
Assessment of TripPB siRNA conjugate and pPB-ERP in mouse liver fibrosis model
Balb/c female mice aged 6-8 weeks (n=4-5 per group) were injected intraperitoneally with 2.5 mL/kg of 20% CC14 in corn oil twice a week for two weeks to induce HSC activation. One day post the last dose of CC14, animals were injected subcutaneously (SQ) in the scapular region with a single dose of vehicle control (saline), pPB-ERP alone (40 mg/kg), TripPB- siHsp47 (10 mg/kg) with pPB-ERP (40 mg/kg), unconjugated siHsp47 (10 mg/kg) with pPB- ERP (40 mg/kg), using a volume of 5 mL/kg body weight. Single intravenous (IV) dosing of TripPB-siHsp47 (10 mg/kg) with pPB-ERP (40 mg/kg) was also tested in one group of the animals. The livers of treated animals were collected two days post siRNA and ERP treatment and fixed with RNAlater for a minimum of 16 h at 4 °C. RNAi activity of siRNA conjugates was assessed by quantifying target gene expression using Quantigene assay.
QuantiGene branched DNA assay
Between 20 and 25 mg of RNAlater fixed liver tissue was homogenized in Epicentre lysis buffer containing 1% proteinase K using the FastPrep®-24 homogenization instrument (4.0 m/s, 3 x 15 second bursts, MP Biomedicals). Samples were kept on ice both before and after the homogenization to prevent degradation. The lysates were cleared by centrifugation at 16,000 x at 16°C for 5 min and diluted in lysis working buffer to ensure all values would be in the assay linear range of detection before being subjected to bDNA assay using the Affymetrix QuantiGene 2.0 assay kit, according to the manufacturer’s protocol. The bDNA probes were specifically designed to target mouse Hsp47 and mouse Gapdh. The signal from Hsp47 was normalized to the signal from Gapdh.
Results
Combination treatment of TripPB-siHsp47 with pPB-ERP in the tested dosing regimen resulted in 47% target gene KD when dosed subcutaneously (Fig 8) and 68% gene suppression when dosed intravenously. The improvement of RNAi activity with IV dosing is likely associated with high bioavailability with this dosing method. In contrast, minimal (25%) gene silencing was observed in animals treated with unconjugated siHsp47 and pPB- ERP. pPB-ERP treatment alone did not induce any reduction in target gene expression. Of note, Hsp47 is an HSC specific gene. Together, these data demonstrated that trivalent pPB ligand conjugated siRNA in combination with pPB-ERP could enable target gene silencing in HSC in liver fibrosis model.
Example 12. Dose Response of pPB-ERP in HSC Targeted RNAi in Mouse Liver Fibrosis Model.
HSC specific gene Hsp47 was selected as the siRNA target to allow evaluation of RNAi activity in the targeted cell population.
Materials and Methods
Assessment of pPB- ERP dose response in mouse liver fibrosis model
Balb/c female mice aged 6-8 weeks (n=4-5 per group) were injected intraperitoneally with 2.5 mL/kg of 20% CC14 in corn oil twice a week for two weeks to induce HSC activation. One day post the last dose of CC14, animals were injected subcutaneously in the scapular region with a single dose of vehicle control (saline), TripPB-siHsp47 (3 mg/kg), pPB-ERP alone (40 mg/kg) or TripPB-siHsp47 (3 mg/kg) with pPB-ERP at 12, 20 or 40 mg/kg, using a volume of 5 mL/kg body weight. The livers of treated animals were collected two days post siRNA and ERP treatment and fixed with RNAlater for a minimum of 16 h at 4 °C. RNAi activity of siRNA conjugates was assessed by quantifying target gene expression using Quantigene assay.
QuantiGene branched DNA assay
Between 20 and 25 mg of RNAlater fixed liver tissue was homogenized in Epicentre lysis buffer containing 1% proteinase K using the FastPrep®-24 homogenization instrument (4.0 m/s, 3 x 15 second bursts, MP Biomedicals). Samples were kept on ice both before and after the homogenization to prevent degradation. The lysates were cleared by centrifugation at 16,000*g at 16°C for 5 min and diluted in lysis working buffer to ensure all values would be in the assay linear range of detection before being subjected to bDNA assay using the Affymetrix
QuantiGene 2.0 assay kit, according to the manufacturer’s protocol. The bDNA probes were specifically designed to target mouse Hsp47 and mouse Gapdh. The signal from Hsp47 was normalized to the signal from Gapdh.
Results
No gene silencing was observed in the TripPB-siHsp47 or pPB-ERP single treatment groups (Fig 9) which is consistent with results in other examples reported in this patent. Dose response effect in pPB-ERP treatment was evident in the TripPB-siHsp47 combination treatment groups, with 12, 20, and 40 mg/kg of pPB-ERP resulted in 15%, 30% and 53% decline in the gene expression of HSC target Hsp47. These data demonstrated the importance of including an endosome release element.
Example 13. Divalent pPB-siRNA Conjugates Showed Comparable Activity to TripPB siRNA Conjugate in Mouse Liver Fibrosis Model.
This example illustrates the in vivo gene silencing mediated by divalent and trivalent pPB conjugate siRNA together with pPB-ERP in a CC14 induced mouse liver fibrosis model. HSC specific gene Hsp47 was selected as the siRNA target to allow evaluation of RNAi activity in the targeted cell population.
Materials and Methods
Assessment of DipPB and TripPB siRNA conjugate and pPB-ERP in mouse liver fibrosis model
Balb/c female mice aged 6-8 weeks (n=4-5 per group) were injected intraperitoneally with 2.5 mL/kg of 20% CC14 in corn oil twice a week for two weeks to induce HSC activation. One day post the last dose of CC14, animals were injected subcutaneously (SQ) in the scapular region with a single dose of vehicle control (saline), DipPB-siHsp47 (3 mg/kg) with pPB-ERP (40 mg/kg), or TripPB -siHsp47 (3 mg/kg) with pPB-ERP (40 mg/kg), using a volume of 5 mL/kg body weight. The livers of treated animals were collected two days post siRNA and ERP treatment and fixed with RNAlater for a minimum of 16 h at 4 °C. RNAi activity of siRNA conjugates was assessed by quantifying target gene expression using Quantigene assay.
QuantiGene branched DNA assay
Between 20 and 25 mg of RNAlater fixed liver tissue was homogenized in Epicentre lysis buffer containing 1% proteinase K using the FastPrep®-24 homogenization instrument (4.0
m/s, 3 x 15 second bursts, MP Biomedicals). Samples were kept on ice both before and after the homogenization to prevent degradation. The lysates were cleared by centrifugation at 16,000 xg at 16°C for 5 min and diluted in lysis working buffer to ensure all values would be in the assay linear range of detection before being subjected to bDNA assay using the Affymetrix QuantiGene 2.0 assay kit, according to the manufacturer’s protocol. The bDNA probes were specifically designed to target mouse Hsp47 and mouse Gapdh. The signal from Hsp47 was normalized to the signal from Gapdh.
Results
Combination treatment of TripPB-siHsp47 with pPB-ERP in the tested dosing regimen showed 46% target gene KD. Replacing TripPB-siHsp47 with DipPB-siHsp47 resulted in 58% gene silencing but there were no statistical differences to the TripPB-siHsp47 group. Overall, the trivalent and divalent pPB-siRNA conjugates showed comparable activity in this study.
Synthesis of endosome release polymer
Endosome release polymers (Mannose-ERP 40 and GalNAc-ERP 41) were synthesized by Syngene International LTD using synthetic methodology analogous to that described in Prieve, M.G., Harvie, P., Monahan, S.D., Roy, D., Li, A.G., Blevins, T.L., Paschal, A.E., Waldheim, M., Bell, E.C., Galperin, A., Ella-Menye, J.R., et al. (2018). Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency. Mol Ther 26, 801-813.
10.1016/j.ymthe.2017.12.024. The structures of Mannose-ERP 40 and GalNAc-ERP 41 are presented below.
PEGMA HMA DMAEMA BMA PAA
GalNAc ERP 41
• Block 1 MW 5.7 KDa ± 15% of Target value (4.85 - 6.56 KDa)
• Block 2 MW 7.9 kDa ± 15% of target value (9.11 - 6.73 kDa)
• Block 1 Monomer Incorporation • PEGMA 75% (71-79%)
• HMA 25% (21-29%)
• Block 2 Monomer Incorporation
• BMA 54% (47-57%)
• DMAEMA 35% (30-40%) • PAA 12% (9-16%)
Claims
1. A compound of formula (I)
(R1)x - L— (R2)y
(I) or a salt thereof, wherein: x is 2, 3, 4 or 5; each R1 is independently a targeting ligand, which is selected from: a) a cyclic polypeptide depicted by SEQ ID NO: 1 :C*SRNLIDC* (SEQ ID NO: 1), wherein * denotes a disulfide bond linking the two C residues to thereby form the cyclic polypeptide, and b) any cyclic polypeptide having at least 80 % sequence identity with the polypeptide depicted by SEQ ID NO: 1, under the proviso that both C* residues are present, and wherein * denotes a disulfide bond linking the two C residues to thereby form the cyclic polypeptide;
2. The compound or salt of claim 1, wherein x is 2 or 3.
3. The compound or salt of claim 1, wherein x is 3.
4. The compound or salt of any one of claims 1-3, wherein each R1 is covalently bound to L
(i) through the N terminus of the polypeptide or (ii) through the C terminus of the polypeptide or (iii) through the side chain of an amino acid of the polypeptide.
5. The compound or salt of any one of claims 1-3, wherein each R1 is covalently bound to L through the N terminus of the polypeptide.
7. The compound or salt of any one of claims 1-6, wherein each R2 is independently an oligonucleotide.
8. The compound or salt of any one of claims 1-6, wherein each R2 is independently an siRNA.
9. The compound or salt of any one of claims 7-8, wherein each oligonucleotide or each siRNA is attached to L through a phosphate P(=0)(0H)2-0- of each oligonucleotide or each siRNA.
11. The compound or salt of any one of claims 1-6, wherein each R2 is independently 3- formylphenyl or 4-formylphenyl.
12. The compound or salt of any one of claims 1-11, wherein L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 500 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(Ra)-, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, or 3-20 membered carbocycle and wherein each chain, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, and 3-20 membered carbocycle is optionally and independently substituted with one or more (e.g. 1, 2, 3, 4, 5 or more) substituents independently selected from the group consisting of (Ci-Ce)alkyl, (Ci-Ce)alkoxy, (C3-Ce)cycloalkyl, (Ci- Ce)alkanoyl, (Ci-Ce)alkanoyloxy, (Ci-Ce)alkoxycarbonyl, azido, cyano, nitro, halo, -N(Ra)2, hydroxy, oxo (=0), and carboxy, wherein each Rais independently H or (Ci-Ce)alkyl.
13. The compound or salt of any one of claims 1-11, wherein L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 100 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(Ra)-, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, or 3-20 membered carbocycle and wherein each chain, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, and 3-20 membered carbocycle is optionally and independently substituted with one or more (e.g. 1, 2, 3, 4, 5 or more) substituents independently selected from the group consisting of (Ci-Ce)alkyl, (Ci-Ce)alkoxy, (C3-Ce)cycloalkyl, (Ci- Ce)alkanoyl, (Ci-Ce)alkanoyloxy, (Ci-Ce)alkoxycarbonyl, azido, cyano, nitro, halo, -N(Ra)2, hydroxy, oxo (=0), and carboxy, wherein each Rais independently H or (Ci-Ce)alkyl.
14. The compound or salt of any one of claims 1-11, wherein L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 100 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(Ra)-, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, or 3-20 membered carbocycle and wherein each chain, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, and 3-20 membered carbocycle is optionally and independently substituted with one or more (e.g. 1, 2, 3, 4, 5 or more) substituents independently selected from the group consisting of azido, halo, and oxo (=0), and carboxy, wherein each Rais independently H or (Ci-Ce)alkyl.
15. The compound or salt of any one of claims 1-11, wherein L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 50 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently
by -O-, -S, -N(Ra)-, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, or 3-20 membered carbocycle and wherein each chain, 3-20 membered heterocycle, 3-20 membered heteroaryl, 6-14 membered aryl, and 3-20 membered carbocycle is optionally and independently substituted with one or more (e.g. 1, 2, 3, 4, 5 or more) substituents independently selected from the group consisting of azido, halo, and oxo (=0), and carboxy, wherein each Rais independently H or (Ci-Ce)alkyl.
16. The compound or salt of any one of claims 1-11, wherein L is a branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from about 1 to about 50 carbon atoms, wherein one or more of the carbon atoms is optionally replaced independently by -O-, -S, -N(Ra)-, or Rb, wherein each chain and Rb is optionally and independently substituted with one or more (e.g. 1, 2, 3, 4, 5 or more) substituents independently selected from the group consisting of azido, halo, =N(0H), -0(NH2) and oxo (=0), and carboxy, wherein each Rb is independently H or (Ci-Ce)alkyl; and each Rb is independently selected from the group consisting of:
17. The compound or salt of any one of claims 1-11, wherein L comprises: -C(=O)(CH2)aN(H) C(=O)-; wherein a is 3, 4, 5, 6, 7, or 8.
18. The compound or salt of any one of claims 1-11, wherein L comprises -(CH2CH2O)bCH2CH2C(=O)- or -(CH2CH2O)bCH2CH2N(H)C(=O)-, wherein b is 2- 50.
19. The compound or salt of any one of claims 1-11, wherein L comprises phen-l,3-diyl or phenl-l,3,5-triyl.
21. The compound or salt of any one of claims 1-20, wherein each R1 is linked to L through a carbonyl group of L.
22. The compound or salt of any one of claims 1-20, wherein each R2 is linked to L through a carbon-carbon bond.
25. A process for preparation of a diblock polymer of the following formula (X): [Block A] - [Block B]
(X) comprising: a) contacting a compound of structure Va, Vb, Vc, or Vd
wherein R27 is (Ci-Ci2)alkyl,
wherein R28 is (Ci-Ci2)alkyl,
wherein R25 and R26 are independently H, (Ci-Ci2)alkyl, aryl, or heteroaryl,
with one or more A monomers selected from the group consisting of: iii) a polyethyleneglycol methacrylate with 2-20 ethylene glycol units (PEGMA); and iv) M2, wherein M2 is a methacrylate, which is optionally selected among a (C4-Cis)alkyl-methacrylate; a (C4-Cis)branched alkyl-methacrylate; a cholesteryl methacrylate; a (C4-Cis)alkyl-methacrylate substituted with one or more fluorine atoms; and a (C4-Cis)branched alkyl-methacrylate substituted with one or more fluorine atoms;
in the presence of a free radical to provide a first product; b) contacting the first product with one or more B monomers of formulae B 1, B2 and B3
in the presence of a free radical to provide a second product, and c) optionally contacting the second product with a free radical source (e.g., AIBN) to remove the chain transfer agent and provide the diblock polymer of formula (X); wherein:
Block A comprises one or more residues of A monomers and has a molecular weight of from about 1 kDa to about 25 kDa;
Block B comprises one or more residues of monomers Bl, B2, and B3 and has a molecular weight of from about 1 kDa to about 25 kDa.
Li is a linking moiety;
Z is a functional group that is optionally protected with a protecting group and is capable of reacting with Y of a compound of formula (XII):
T-L2-Y (XII) to form a conjugate wherein:
T is a ligand (optionally targeting ligand);
Y is a functional group that is capable of reacting with Z to form a conjugate; and
L2 is absent or is a linking moiety.
27. The process of claim 25 or 26 wherein Z is a functional group that is protected with a protecting group, wherein the process further comprises removing the protecting group from Z.
28. The process of claim 25 or 26 wherein Z is a functional group that is not protected with a protecting group.
29. The process of claim 27 or 28 further comprising reacting the diblock polymer of formula (X) with a compound of formula (XII):
T-L2-Y (XII) under conditions where Z reacts with Y to form a group Y’Z’ and yield a conjugate of formula:
T - L2 — Y'Z1 - L1 - [Block A] - [Block B]
30. The process of claim 29, wherein Block A has a molecular weight of from about 1 kDa to about 25 kDa; and Block B has a molecular weight of from about 1 kDa to about 25 kDa.
31. The process of claim 29, wherein Block A has formula:
-[PEGMAm-M2n]v- wherein:
PEGMA is polyethyleneglycol methacrylate residue with 2-20 ethylene glycol units; M2 is a methacrylate residue selected from the group consisting of a (C4-Cis)alkyl-methacrylate residue; a (C4-Cis)branched alkyl- methacrylate residue;
a cholesteryl methacrylate residue; a (C4-Cis)alkyl-methacrylate residue substituted with one or more fluorine atoms; and a (C4-Cis)branched alkyl-methacrylate residue substituted with one or more fluorine atoms; and v is 1 to 25 kDa; and wherein block B has formula:
-[DMAEMAq-PAAr-BMAs]w wherein:
BMA is butyl methacrylate residue;
PAA is propyl acrylic acid residue;
DMAEMA is dimethylaminoethyl methacrylate residue; m and n are each a mole fraction greater than 0, wherein m is greater than n and m + n = 1 ; q is a mole fraction of 0.2 to 0.75; r is a mole fraction of 0.05 to 0.6; s is a mole fraction of 0.2 to 0.75; q + r + s = 1 ; and w is 1 to 25 kDa;
32. The process of any one of claims 25-31, wherein Z and Y are selected so that Y’Z’ comprises an oxime functionality.
33. The process of any one of claims 25-31, wherein Z and Y are selected so that Y’Z’ comprises a triazole ring.
34. The process of any one of claims 25-27 and 29-32, wherein Z comprises an aminooxy group that is protected and the protecting group is on the nitrogen of the aminooxy group.
35. The process of any one of claims 29-32, wherein Z comprises an aminooxy group, Y comprises a ketone group or an aldehyde group, and Y’Z’ comprises an oxime functional group.
36. The process of any one of claims 29-32, wherein Z comprises a ketone group or an aldehyde group, Y comprises an aminooxy group, and Y’Z’ comprises an oxime functional group.
I l l
37. The process of claim 29 or 33, wherein Z comprises an alkyne group, Y comprises an azide group, and Y’Z’ comprises a triazole ring.
38. The process of claim 29 or 33, wherein Z comprises an azide group, Y comprises an alkyne group, and Y’Z’ comprises a triazole ring.
39. The process of any one of claims 29-38 wherein T is a targeting ligand or a labeling agent.
40. The process of any one of claims 29-38, wherein the targeting ligand is selected from the group of an oligonucleotide, a peptide, a saccharide, and a small molecule.
41. The process of any one of claims 29-38, wherein the targeting ligand comprises a cyclic peptide.
42. The process of any one of claims 29-38, wherein the targeting ligand comprises a cyclic peptide as described in claim 1.
43. The process of any one of claims 29-38, wherein the targeting ligand comprises a cyclic peptide as described in claim 6.
44. The process of any one of claims 29-38, wherein the labeling agent is selected from the group consisting of a fluorophore, a chromophore, and a radionucleotide.
45. The process of any one of claims 29-38, wherein the labeling agent is derivable from fluorescein isothiocyanate (FITC) or Cy5.
46. A product prepared by the process of any one of claims 25-45.
47. A conjugate prepared by the process of any one of claims 29-45.
48. A composition comprising a plurality of conjugates as defined in any one of claims 29-45.
49. The composition of claim 48, wherein at least one of the conjugates comprises a labelling agent.
50. A compound of formula (I)
(R1)x - L— (R2)y
(I) or a salt thereof, wherein: x is 1, 2, 3, 4 or 5; each R1 is independently a targeting ligand, which is selected from a) a cyclic polypeptide depicted by SEQ ID NO: 1 :C*SRNLIDC* (SEQ ID NO: 1), wherein * denotes a disulfide bond linking the two C residues to thereby form the cyclic polypeptide, b) any cyclic polypeptide having at least 80 % sequence identity with the polypeptide depicted by SEQ ID NO: 1, under the proviso that both C* residues are present, and wherein * denotes a disulfide bond linking the two C residues to thereby form the cyclic polypeptide;
L is a linking group; and y is 1, 2, 3, 4 or 5; and each R2 is independently an endosomal release polymer.
51. The compound or salt of claim 50, wherein the endosomal release polymer comprises a diblock polymer comprising Block A and Block B having the following formula:
[Block A]-[Block B] wherein:
Block A comprises one or more residues of the A monomers described in claim 25 and has a molecular weight of from about 1 kDa to about 25 kDa; and
Block B comprises one or more residues of monomers Bl, B2, and B3 as described in claim 25 and has a molecular weight of from about 1 kDa to about 25 kDa.
52. The compound or salt of claim 50, wherein the endosomal release polymer has formula (XX):
-[PEGMAm-M2n]v-[DMAEMAq-PAAr-BMAs]w (XX) wherein:
PEGMA is polyethyleneglycol methacrylate residue with 2-20 ethylene glycol units; M2 is a methacrylate residue selected from the group consisting of a (C4-Cis)alkyl-methacrylate residue; a (C4-Cis)branched alkyl- methacrylate residue; a cholesteryl methacrylate residue; a (C4-Cis)alkyl-methacrylate residue substituted with one or more fluorine atoms; and a (C4-Cis)branched alkyl-methacrylate residue substituted with one or more fluorine atoms;
BMA is butyl methacrylate residue;
PAA is propyl acrylic acid residue;
DMAEMA is dimethylaminoethyl methacrylate residue; m and n are each a mole fraction greater than 0, wherein m is greater than n and m + n = 1 ; q is a mole fraction of 0.2 to 0.75; r is a mole fraction of 0.05 to 0.6; s is a mole fraction of 0.2 to 0.75; q + r + s = 1; v is 1 to 25 kDa; and w is 1 to 25 kDa.
53. The compound or salt of claim 51, wherein Block A comprises one or more residues of monomers of formulae Al and A2 as described in claim 26.
54. A pharmaceutical composition comprising a compound as described in any one of claims 1-24 and 50-53 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
55. A pharmaceutical composition comprising a first compound as described in any one of claims 1-24 or a pharmaceutically acceptable salt thereof, wherein each R2 is independently an oligonucleotide and a second compound as described in any one of claims 50-53 or a pharmaceutically acceptable salt thereof.
56. A method to deliver an oligonucleotide to an animal comprising administering a compound as described in any one of claims 1-24 or a pharmaceutically acceptable salt thereof, to the animal.
57. A method to deliver an oligonucleotide to cells that express platelet-derived growth factor receptor (PDGFR) in an animal comprising administering a compound as described in any one of claims 1-24 or a pharmaceutically acceptable salt thereof, to the animal.
58. The method of claim 57, wherein the platelet-derived growth factor receptor (PDGFR) is platelet-derived growth factor receptor alpha (PDGFRa).
59. The method of claim 57, wherein the platelet-derived growth factor receptor (PDGFR) is platelet-derived growth factor receptor beta (PDGFRP).
60. The method of claim 57, wherein the cells that express PDGFR are hepatic stellate cells (HSC), endothelial cells, fibroblasts or tumor cells.
61. A method to treat a disease involving PDGFR expressing cells (e.g., liver fibrosis, nonalcoholic steatohepatitis (NASH), clear cell renal cell carcinoma, kidney fibrosis, or alcoholic steatohepatitis (ASH)) comprising administering a compound as described in any one of claims 1-24 or a pharmaceutically acceptable salt thereof, to the animal.
62. A compound as described in any one of claims 1-24 or a pharmaceutically acceptable salt thereof for delivering an oligonucleotide to an animal.
63. A compound as described in any one of claims 1-24 or a pharmaceutically acceptable salt thereof for delivering an oligonucleotide to cells that express platelet-derived growth factor receptor (PDGFR).
64. A compound as described in any one of claims 1-24 or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a disease involving PDGFR expressing cells (e.g., liver fibrosis, non-alcoholic steatohepatitis (NASH), clear cell renal cell carcinoma, kidney fibrosis, or alcoholic steatohepatitis (ASH)).
65. The use of a compound as described in any one of claims 1-24 or a pharmaceutically acceptable salt thereof to prepare a medicament for delivering an oligonucleotide to an animal.
66. The use of a compound as described in any one of claims 1-24 or a pharmaceutically acceptable salt thereof to prepare a medicament for delivering an oligonucleotide to cells that express platelet-derived growth factor receptor (PDGFR).
67. The use of a compound as described in any one of claims 1-24 or a pharmaceutically acceptable salt thereof to prepare a medicament for treating a disease involving PDGFR expressing cells (e.g., liver fibrosis, non-alcoholic steatohepatitis (NASH), clear cell renal cell carcinoma, kidney fibrosis, or alcoholic steatohepatitis (ASH)).
68. The method, compound of use of any one of claims 56-67, which comprises the combined use of a first compound as described in any one of claims 1-24, wherein each R2 is independently an oligonucleotide, with a second compound as described in any one of claims 50-53.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263405697P | 2022-09-12 | 2022-09-12 | |
US63/405,697 | 2022-09-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024057190A2 true WO2024057190A2 (en) | 2024-03-21 |
Family
ID=88147297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2023/059008 WO2024057190A2 (en) | 2022-09-12 | 2023-09-11 | Targeted compositions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024057190A2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
WO2015017519A1 (en) | 2013-07-30 | 2015-02-05 | Phaserx, Inc. | Block copolymers and their conjugates or complexes with oligonucleotides |
-
2023
- 2023-09-11 WO PCT/IB2023/059008 patent/WO2024057190A2/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683202B1 (en) | 1985-03-28 | 1990-11-27 | Cetus Corp | |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683195B1 (en) | 1986-01-30 | 1990-11-27 | Cetus Corp | |
WO2015017519A1 (en) | 2013-07-30 | 2015-02-05 | Phaserx, Inc. | Block copolymers and their conjugates or complexes with oligonucleotides |
Non-Patent Citations (24)
Title |
---|
"Current Protocols in Molecular Biology", 1994 |
BYROM ET AL., AMBION TECHNOTES, vol. 10, no. 1, 2003, pages 4 - 6 |
CALEGARI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 99, 2002, pages 14236 - 9947 |
CHEN ET AL., JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 370, no. 3, 2019, pages 695 - 702 |
CLIN LIVER DIS., vol. 12, no. 4, November 2008 (2008-11-01), pages 733 - 46 |
FILPULA, D. ET AL.: "Releasable PEGylation of proteins with customized linkers", ADVANCED DRUG DELIVERY, vol. 60, 2008, pages 29 - 49, XP022370570, DOI: 10.1016/j.addr.2007.02.001 |
GREENWALD, R.B. ET AL., POLY (ETHYLENE GLYCOL) PRODRUGS: ALTERED PHARMACOKINETICS AND PHARMACODYNAMICS, pages 283 - 338 |
GUBLERHOFFMAN, GENE, vol. 25, 1983, pages 263 - 269 |
J HEPATOL., vol. 67, no. 6, December 2017 (2017-12-01), pages 1265 - 127 |
KAWASAKI ET AL., NUCLEIC ACIDS RES., vol. 31, 2003, pages 981 - 987 |
KNIGHT ET AL., SCIENCE, vol. 293, 2001, pages 2269 - 2271 |
KRIEGLER, GENE TRANSFER AND EXPRESSION: A LABORATORY MANUAL, 1990 |
N ENGL J MED., vol. 377, no. 21, 23 November 2017 (2017-11-23), pages 2063 - 2072 |
NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 |
PEARSONLIPMAN, PROC. NATL ACAD. SCI. USA, vol. 85, 1988, pages 2444 |
PRIEVE, M.G.HARVIE, P.MONAHAN, S.D.ROY, D.LI, A.G.BLEVINS, T.L.PASCHAL, A.E.WALDHEIM, M.BELL, E.C.GALPERIN, A.: "Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency", MOL THER, vol. 26, 2018, pages 801 - 813, XP055568760, DOI: 10.1016/j.ymthe.2017.12.024 |
ROBERTSON ET AL., J. BIOL. CHEM., vol. 243, 1968, pages 82 |
SAMBROOK ET AL., MOLECULAR CLONING, A LABORATORY MANUAL, 1989 |
SCARINGE ET AL., NUCL. ACIDS RES., vol. 18, 1990, pages 5433 |
SMITHWATERMAN, ADS APP. MATH., vol. 2, 1981, pages 482 |
USMAN ET AL., J. AM. CHEM. SOC., vol. 109, 1987, pages 7845 |
WINCOTT ET AL., METHODS MOL. BIO., vol. 74, 1997, pages 59 |
WINCOTT ET AL., NUCL. ACIDS RES., vol. 23, 1995, pages 2677 - 2684 |
ZHAO, H. ET AL.: "Drug Conjugates with Poly(Ethylene Glycol", DRUG DELIVERY IN ONCOLOGY, 2012, pages 627 - 656 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10316316B2 (en) | Compositions for targeted delivery of siRNA | |
AU2012300476B2 (en) | Poly(vinyl ester) polymers for in vivo nucleic acid delivery | |
US8933047B2 (en) | Poly(acrylate) polymers for in vivo nucleic acid delivery | |
US11840688B2 (en) | Compositions and methods for inhibiting gene expression of Hif2alpha | |
AU2011352204B2 (en) | In vivo polynucleotide delivery conjugates having enzyme sensitive linkages | |
KR20110033124A (en) | Diblock copolymers and polynucleotide complexes thereof for delivery into cells | |
US20080064863A1 (en) | Conjugate of Peo and Double Stranded Nucleic Acid | |
CN117858948A (en) | Novel therapeutic agent delivery moieties and uses thereof | |
WO2024057190A2 (en) | Targeted compositions | |
WO2023187760A1 (en) | Mannose-targeted compositions | |
WO2023045995A1 (en) | Multivalent Ligand Clusters with Diamine Scaffold for Targeted Delivery of Therapeutic Agents | |
EP2807216A1 (en) | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23776101 Country of ref document: EP Kind code of ref document: A2 |